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Rheumatoid arthritis (RA) is a chronic inflammatory disorder with features of autoimmunity 
whose exact aetiology remains unknown although interactions between genetic factors, sex 
hormones and environmental factors are thought to play a role. Recent data support the view 
that RA is a disease characterised by aberrant adaptive immune responses, imposed in part via 
defective pathways of T cell activation. SKG mice carry a mutation in the protein tyrosine kinase 
ZAP-70, leading to attenuated TCR signalling and activation, and develop an autoimmune 
inflammatory arthritis resembling human RA, mediated by T cells. 
 
The hypothesis behind this project is that reconstitution of TCR signalling in mature, peripheral 
arthritogenic SKG T cells can restore immune homeostasis, which in turn suppresses the disease 
process. Firstly, it was demonstrated that naïve Balb/c and ZAP-70 mutant SKG CD4+ T cells 
expressing a TCR transgene differentiate into distinct subsets of effector Th cells following 
stimulation with specific antigen in the absence of a polarising cytokine environment.  
Significantly, SKG effector T cells are deficient in IL-2, IL-4 and IFN-γ production during 
differentiation and become IL-17 high-producers, when compared to wild type Balb/c T cells.  
 
The mechanism through which defective TCR signalling in SKG T cells favours the generation of 
arthritogenic IL-17 expressing T cells was then investigated, using two complimentary 
approaches. The first approach sought to establish virus-mediated gene transfer protocols to 
compare the effects of reconstituting SKG T cells with wild type or mutant ZAP-70 on the 
development of arthritis in a T cell-mediated adoptive transfer model. Despite trying both 
lentiviral and retroviral vector approaches, the efficiency of gene transduction into target murine 
primary T cells was insufficient for further in vitro functional analysis or for testing the 
arthritogenicity of transduced T cells in adoptive transfer experiments.    
 
Using a second approach, I tested the effects of reconstituting in vitro the defects in cytokine 
expression observed during differentiation of SKG T cells. Notably, supplementation of 
differentiating SKG T cells with exogenous recombinant IL-2 inhibited the differentiation to IL-17 
producing T cells. This effect was associated with repression of induction of RORc, the master 
transcriptional regulator of IL-17 gene expression. The effects of IL-2 supplementation were also 
tested in vivo in the adoptive transfer model and found to have a suppressive effects on disease 
severity and incidence.    
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1.1. Overview of the immune system 
 
The immune system is composed of specialised molecules, cells and organs which work together to 
initiate, regulate and coordinate complex responses to protect individuals mainly against the threat of 
disease caused by infectious organisms.  
 
Several physical barriers, such as skin and mucosa, prevent pathogens from entering the body. Breach 
of these barriers by micro-organisms, such as bacteria and viruses for instance, triggers two different 
types of responses which both rely on the immune system’s ability to distinguish between self and 
non-self molecules. 
 
First, the innate response generates an immediate and powerful response to invading pathogens, 
which does not require prior recognition to initiate its engagement. It achieves clearance of 
pathogens from the host through the recognition of a broad spectrum of molecules found on the 
different classes of pathogen. The innate response is also responsible for the priming of the adaptive 
response, a process which requires a longer period of time to initiate fully through cellular and 
molecular mediators. Whereas innate responses do not change according to the number of times the 
infectious agent is encountered, adaptive responses improve on repeated exposure to a given 
infection and develop immunological memory (Sprent and Tough 1994; Delves and Roitt 2000).  
 
1.1.1. Innate immunity 
Innate responses are mounted mainly by phagocytic cells (neutrophils, monocytes, and 
macrophages), cells that release inflammatory mediators (basophils, mast cells, and eosinophils), and 
natural killer (NK) cells. Those cells, called leukocytes (or white blood cells), and which also participate 
in adaptive immunity, develop from pluripotent hematopoietic stem cells in the bone marrow and the 
fetal liver (Abdou, Alavi et al. 1976; Phillips and Melchers 1976), and collectively perform two 
important immunological functions: recognise the presence of foreign pathogens, and provide an 
immediate cellular response to remove them.  
 
Innate immune recognition is mediated by germ-line–encoded receptors whose specificity is 
genetically pre-determined (Medzhitov and Janeway 2000). Those receptors, called pattern-
recognition receptors (PRRs) have evolved to recognise a few highly conserved structures, called 
pathogen-associated molecular pattern (PAMP), and present in large groups of microbes such as for 
instance lipopolysaccharides which are exclusively synthesised by gram-negative bacteria (Janeway 
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and Medzhitov 2002). Endocytic PRRs, such as the macrophage mannose receptor, bind to 
components of microbial cell walls and mediate the uptake and phagocytosis of pathogens by 
antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages (Fraser, Koziel et al. 
1998). Recognition of pathogenic elements by Toll-like receptors (TLRs), another form of PRRs found 
on leukocytes, leads to the activation of signalling pathways that induce the production and secretion 
of cytokines as well as the up-regulation of co-stimulatory molecules on the cell-surface (Medzhitov, 
Preston-Hurlburt et al. 1997; Rock, Hardiman et al. 1998).  
 
Innate responses also frequently involve molecular components such as complement, acute-phase 
proteins and cytokines. The complement system is composed of a set of serum proteins that initiate 
biochemical cascades to help destroy infectious pathogens by producing peptides that attract 
immune cells, increase vascular permeability and opsonise the surface of a pathogen marking it for 
destruction (Roozendaal and Carroll 2007).  Acute-phase proteins can also act as opsonins to help 
phagocytosis as well as promote the repair of damaged tissue (Gabay and Kushner 1999). Common 
cytokines produced during inflammation include interleukins (IL) and interferons (IFN), and serve a 
hormone-like function to enable cells to communicate with each other usually in a paracrine or 
autocrine manner. Consequently cytokines act as messengers both within the immune system and 
between the immune system and other systems of the body and are intimately involved in the 
regulation of immune responses (Delves and Roitt 2000; Wood 2006). Chemokines are also important 
to promote chemotaxis and thereby controlling the migration of cells between and within tissues 
(Sabroe, Lloyd et al. 2002).  
 
Inflammation is one of the first physiological outcomes of the innate immune response to infections. 
Upon recognition of microbial products, tissue macrophages release cytokines and other 
inflammatory mediators that cause vasodilation and increased vascular permeability and have 
chemotactic effects on monocytes and neutrophils. Phagocytes recruited to the site of infection can 
begin the process of clearing the pathogen before it can colonise the body and cause long-term 
damage. Inflammatory mediators can activate mast cells and basophils to release further mediators 
and amplify the response. If the local production of cytokines is high enough, they can function in an 
endocrine fashion and affect other organs. Failure of the immune system to resolve inflammation can 
lead to tissue damage, a characteristic of chronic inflammatory autoimmune diseases such as 
rheumatoid arthritis (RA).  
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1.1.2. Adaptive immunity 
The adaptive immune system mounts a more refined response to infections which is antigen-specific 
and involves the recognition of non-self antigens during a process called antigen presentation. An 
antigen is an entity that leads to the generation of effector cells and antibodies, thus causing an 
immune response. Antigen presentation is mediated by APCs, which, as the inflammation progresses, 
process proteins derived from phagocytosed pathogens to generate antigenic peptides and form a 
complex with major-histocompatibility complex (MHC) molecules on their cell surface (Medzhitov and 
Janeway 2000; Knight, Burke et al. 2002). By doing so, APCs recruit effector cells to eradicate 
pathogens from the system and prime those cells for any future encounter with the same type of 
pathogen, thereby leading to the development of immunological memory (Sprent and Tough 1994; 
Borghans, Noest et al. 1999).  
 
Adaptive responses involve the proliferation of antigen-specific B and T cells, which are special types 
of leukocytes, called lymphocytes. B cells reach maturity within the bone marrow, but T cells must 
travel to the thymus to complete their development (Abdou, Alavi et al. 1976; Rocha and von 
Boehmer 1991). The activation and proliferation of naïve B and T lymphocytes during the first 
encounter with an antigen, the primary immune response, generates effector T cells (cytotoxic or 
helper) and effector B cells (antibody-secreting plasma cells), as well as memory B and T cells (Dutton, 
Bradley et al. 1998). Because memory cells are increased in number relative to naïve cells and 
because they are more easily triggered, the secondary immune response is quicker and larger than 
the primary response (Wood 2006).  
 
Both B and T cells carry receptor molecules that recognise specific target antigens. The T cell receptor 
(TCR) and the B cell receptor (BCR) are generated somatically, during the development of T and B 
cells, in a way that endows each lymphocyte with a structurally unique receptor (Medzhitov and 
Janeway 2000).  
 
T cells, involved in cell-mediated immune responses, require at least two signals to become activated. 
The first signal is antigen-specific and provided by the interaction of the TCR and the peptide-MHC 
(pMHC) complex on the membrane of APCs. The second signal, the co-stimulatory signal, is mediated 
by co-stimulatory molecules expressed on the surface of the APCs (e.g. CD80 and CD86) and the T 
cells (e.g. CD28) (Gross, Callas et al. 1992; Shahinian, Pfeffer et al. 1993). These two signals induce the 
expression of cytokines, such as IL-2, and lead to proliferation and activation of the T cells (Sharpe 
1995). 
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Although traditionally thought as distinct responses, interactions between innate and adaptive 
immunity are essential to ensure appropriate host defences.  Thus recognition of PAMPs by PRRs 
leads to the activation of signalling pathways which induce cytokines secretion and up-regulation of 
co-stimulatory molecules on the cell-surface of APCs (Medzhitov, Preston-Hurlburt et al. 1997), 
thereby ensuring efficient activation of T cells.  
  
There are two major subtypes of T cells characterised by the exclusive expression of either the cell 
surface marker CD4 or CD8.  
 
CD4+ helper T (Th) cells recognise antigens associated with MHC class II molecules whose expression 
is restricted to APCs and, as such, is specific for extra-cellular pathogens. CD4+ T cells orchestrate the 
adaptive response through cell-cell contacts with other effector cells and the secretion of cytokines. 
Th cells also play a role in directing humoral immunity by inducing B cells to produce antibodies. The 
balance of cytokines present during naïve T cell activation results in differentiation of helper T cells 
into distinct Th subsets (Th1, Th2 or Th17) and subsequent polarisation of the adaptive response 
(further details in section 1.3.3.).  T cells can also differentiate, in the thymus or the periphery, into 
regulatory T cells (Treg cells) which help control immune responses and maintain self-tolerance.  
 
CD8+ T cells recognise antigens associated with MHC class I molecules which are ubiquitously 
expressed and specific for the presentation of cytosolic proteins. For instance in the case of intra-
cellular viral infection, MHC class I molecules present the viral proteins expressed by the infected 
cells. Upon recognition of peptide-MHC class I complex, CD8+ T cells adopt a cytotoxic phenotype and 
can kill the infected cells by several mechanisms including secretion of proteins that can lyse the 
target cells, or expression of Fas-ligand (FasL) which can induce apoptosis of the target cells (Borrow 
1997; Refaeli, Van Parijs et al. 1998).  
 
In contrast, the BCR can recognise pathogens without a need for processing. When the BCR binds to 
specific determinants, called epitopes, on the surface of these pathogens (Wang, Lopes et al. 2004), 
they take up the antigen to process it and act as APCs by presenting antigenic peptides on their MHC 
class II. Activated B cells then interact with antigen-specific Th cells via both direct cell-cell contact 
and the production of cytokines (Norvell, Birkeland et al. 1996; Grewal and Flavell 1998). As a 
consequence, the Th and B cells are both stimulated to proliferate. Some B cells differentiate into 
memory cells, others in plasma cells. Therefore B cells play a major role in the humoral immune 
response by secreting immunoglobulins (Ig), the antigen-specific antibodies responsible for 
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eliminating extra-cellular micro-organisms. These antibodies circulate in blood and lymph, bind to 
pathogens expressing the epitope and mark them for destruction by the complement system or for 
uptake by phagocytes. Antibodies can also neutralise threats directly by binding to bacterial toxins or 
by interfering with the receptors that viruses and bacteria use to infect cells (de Haas, Vossebeld et al. 
1995; Wood 2006). Most responses are polyclonal in that they involve different clones activated from 
different epitopes on a same antigen. 
 
Adaptive immune responses are generated in the lymph nodes, spleen, and mucosa-associated 
lymphoid tissues (MALTs), also referred to as the secondary lymphoid tissues. Because only a few 
lymphocytes are specific for a given antigen, T cells and B cells need to migrate throughout the body 
to increase the probability that they will encounter that particular antigen. Immune responses to 
blood-borne antigens are usually initiated in the spleen, and responses to micro-organisms in tissues 
are generated in local lymph nodes, but most pathogens are encountered after they are inhaled or 
ingested. Antigens entering the body through mucosal surfaces activate cells in the MALTs which 
include the tonsils, adenoids, and Peyer’s patches (Pabst, Westermann et al. 1998; Delves and Roitt 
2000).  
 
1.1.3.  Self-tolerance and autoimmunity 
Dysregulation of normal homeostasis of the immune system can lead to various pathologies which 
include immunodeficiencies, immunoproliferative disorders and organ-specific or systemic 
autoimmune and inflammatory diseases. Immunodeficiency diseases arise when the immune system 
becomes less efficient at overcoming diseases than normal, which can result in life-threatening 
infections. Immunodeficiency can either be inherited, such as in individuals with severe combined 
immunodeficiency (SCID), or caused by an infection, such as the acquired immune deficiency 
syndrome (AIDS) due to the human immunodeficiency virus (HIV) (Ioachim 1990). In contrast, 
autoimmune diseases arise from uncontrolled immune responses when self-reactive clones 
accumulate and turn the immune system’s effectors upon normal components of the body (self-
antigens), usually proteins and less often carbohydrates, lipids or DNA (Shlomchik, Craft et al. 2001).  
 
Autoimmune disorders affect approximately 5% of the population and comprise a heterogeneous 
group of diseases whose aetiology is poorly understood (Davidson and Diamond 2001; Marrack, 
Kappler et al. 2001). Common autoimmune diseases include RA, type 1 diabetes and systemic lupus 
erythematosus (SLE). Immune tolerance is normally maintained by a group of central and peripheral 
autoregulatory processes and molecules and the factors that breach self-tolerance and contribute to 
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the development of autoimmune disease are complex and likely to involve both genetic and 
environmental factors. Autoimmune diseases are usually characterised by abnormal lymphocyte 
activities such as the production of high-affinity auto-antibodies or the generation of autoreactive T 
cells (O'Shea, Ma et al. 2002).  The emergence of pathogenic autoimmune Th cells is probably a multi-
stage process that reflects the complex interplay between genes and environmental factors. 
Cytokines which have essential roles in the development, differentiation and regulation of immune 
cells are also thought to play a central part, and dysregulation in the production or action of cytokines 
is the hallmark of many autoimmune and inflammatory diseases (Feldmann, Brennan et al. 1998; 
Wood 2006).  
 
1.2. T cell signalling  
 
T cell activation, survival and death, as well as lineage commitment and differentiation into effector 
or memory T cells result from selection events that are controlled by signals from the TCR following 
recognition of MHC associated with foreign antigens. TCR signal strength, defined by the affinity of 
the TCR for pMHC and by their concentration, largely determines functional outcomes by 
predisposing the T cells to integrate additional fate-directing stimuli that are provided by soluble and 
membrane-bound ligands (Acuto, Di Bartolo et al. 2008).  
 
1.2.1. The T cell receptor 
The TCR is a molecule used by T cells to recognise antigens (Haskins, Kappler et al. 1984). The TCR 
consists of two membrane-bound glycoproteins chains called α and β in 95% of T lymphocytes, or δ 
and γ chains in 5% of T cells.  
 
Both α and β chains show a typical Ig-like domain structure and each chain has a N-terminal variable 
domain facing outward, a constant domain, a trans-membrane region and a short cytoplasmic tail at 
the C-terminal end.  
 
The variable region of the α and β chains contains three hyper-variable or complementarity 
determining regions (CDRs) which fold to provide an antigen-binding site. CDR1 and CDR3 are 
responsible for recognising antigenic peptide. CDR2 is thought to recognise the MHC since, unlike B 
cell-produced antibodies which can recognise free antigens, TCRs can only recognise antigens when 
associated with MHC molecules on the surface of APCs (Chlewicki, Holler et al. 2005). MHC refers to a 
region of DNA containing over 100 genes and which can be found in all species of vertebrates. It is 
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called Human Leukocyte Antigen (HLA) in humans and H-2 in mice (Klein and Shreffler 1971; Thorsby 
1974).  
 
The TCR is non-covalently associated with a group of proteins with signalling functions called CD3. 
There are five CD3 proteins called γ, δ, ε, ζ and η. The ε sub-unit can form heterodimers with γ or δ. 
The ζ chain can form homodimers or heterodimers with a η chain (figure 1.1). All CD3 complexes on T 
cells contain γε and δε dimers, and either ζζ dimers (90% of cases) or ζη dimers (10%). The CD3 
complex is not involved in antigen recognition per se but instead initiates intra-cellular signalling 
pathways upon antigen recognition by TCRs (Saito, Hochstenbach et al. 1988; Jin, Koyasu et al. 1990; 
Ohno and Saito 1990; Wood 2006). 
 
Because the immune system must generate, from a limited amount of genetic material, a huge 
number of T cells with specificities for all the possible antigenic epitopes that an individual may 
encounter, the immune system has developed unique molecular mechanisms involving re-
arrangements of the genes coding for TCRs.  
 
Processes to generate TCR diversity are very similar to those for generating multiple Ig proteins in B 
cells. The genes coding for the TCR chains are made up of highly polymorphic gene-segments. For 
instance the variable region of the TCR α chain is coded by segments V and J, and the variable region 
of the TCR β chain is coded for by segments V, J and D (Davis, Chien et al. 1984; Kavaler, Davis et al. 
1984; Siu, Kronenberg et al. 1984). Both CD4+ and CD8+ T cells use the same genes to produce their 
TCR. During a process called gene re-arrangement, each T cell will randomly select one allele for each 
gene-segment, thereby creating combinatorial diversity. Further mechanisms such as imprecise DNA 
joining will also increase diversity in the re-arranged genes. Consequently, this will ensure that 










    
 
Figure 1.1 – Structure of the T cell receptor. The TCR consists of two membrane-bound glycoproteins, α and β. Each 
chain consists of a variable domain (V) and a constant domain (C). Three hyper-variable regions in Vα and Vβ make up the T 
cell specific antigen-binding domain (not shown). The TCR is non-covalently associated with dimers of CD3 signalling 
proteins γ, ε, δ, and δ.  
 
 
1.2.2. ZAP-70  
ZAP-70 (ζ-associated protein of 70 kDa) is a cytoplasmic protein tyrosine kinase (PTK) initially 
identified as a preferential phosphorylation partner of the ζ chain of the CD3 complex associated to 
the TCR on T cells (Chan, Iwashima et al. 1992; van Oers, Killeen et al. 1994).  
 
ZAP-70 and Syk (spleen tyrosine kinase) are the only two members of the Syk-family of PTKs. Whereas 
Syk is preferentially expressed in B cells, T cells and myeloid cells (Taniguchi, Kobayashi et al. 1991), 
and is mainly concerned with B cell activation (van Oers and Weiss 1995), ZAP-70 appears to be 
exclusively expressed in thymocytes, T cells and NK cells (Chan, van Oers et al. 1994). ZAP-70 has been 
shown to be a crucial molecule for the selective activation of T cells, since in its absence, TCR-
mediated T cell activation fails to occur (Au-Yeung, Deindl et al. 2009).  
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ZAP-70 is a protein of 619 amino acids in length encoded by a single gene located on chromosome 2 
in humans and chromosome 1 in mice (Ku, Malissen et al. 1994). Structurally, ZAP-70 contains two 
tandem N-terminal Src-homology 2 (SH2) domains, that bind to phosphorylated immunoreceptor 
tyrosine-based activation motifs (ITAMs) on TCR sub-units, and a C-terminal catalytic kinase domain, 




Figure 1.2 – Domain structure of ZAP-70. Two tandem N-terminal SH2 domains are linked to the catalytic kinase domain by 
Interdomain B, which contains Y292, Y315 and Y319, three tyrosine residues that get phosphorylated upon binding of ZAP-70 
to phosphorylated ITAMs on CD3-δ and serve as docking sites for downstream signalling molecules. The catalytic domain 
also contains two tyrosine residues known to be phosphorylated and exert a regulatory role for the kinase activity of ZAP-70. 
Adapted from (Au-Yeung, Deindl et al. 2009) 
 
The SH2 domains are structurally conserved domains of about 100 amino acids long, and are 
composed of two α helices and anti-parallel β strands. SH2 domains specifically recognise and bind to 
phosphorylated tyrosine residues (phosphotyrosines) in the context of longer peptide sequences 
present in ITAMs and, via this specific interaction, are responsible for the recruitment of ZAP-70 to 
the CD3 and ζ dimers of the TCR complex (van Oers and Weiss 1995). Both SH2 domains are necessary 
for high avidity binding and for the function of ZAP-70 in signal transduction (Bu, Shaw et al. 1995; 
Ottinger, Botfield et al. 1998). Upon binding to doubly phosphorylated ζ subunit ITAMs of the 
activated TCR, ZAP-70 itself becomes catalytically active through phosphorylation, both by Src-family 
PTKs and via auto-phosphorylation, of tyrosine residues contained in the interdomain B and the 
catalytic site (figure 1.3).  
 





Figure 1.3 – Activation of ZAP-70 in proximal TCR signalling. Upon TCR engagement with pMHC, Lck phosphorylates 
tyrosine residues in ITAMs on the intra-cellular CD3-δ chains. ZAP-70 binds to phosphotyrosine residues in ITAMs through its 
SH2 domains (in purple) and is then phosphorylated by Lck, leading to activation of ZAP-70 kinase activity and auto-
phosphorylation. Catalytically active ZAP-70 phosphorylates its substrates SLP-76 and LAT (not shown), leading to 
stimulation of downstream signals and T cell activation. Red arrows: phosphorylation; Green dots: phosphotyrosine residues. 
Diagram from (Au-Yeung, Deindl et al. 2009), used with permission from the authors. 
 
Active ZAP-70 subsequently phosphorylates at least two critically important substrates, the adaptor 
proteins LAT (linker for the activation of T cells) and SLP-76 (SH2-domain containing leukocyte 
phosphoprotein of 76 kDa) (Bubeck Wardenburg, Fu et al. 1996; Zhang, Sloan-Lancaster et al. 1998) 
which in turn facilitate the assembly of molecular complexes required for downstream signalling, 
further described in section 1.2.3. Three phosphorylated residues (Y292, Y315, Y319) have also been 
implicated in binding other signalling molecules including Vav, Lck (lymphocyte-specific protein 
tyrosine kinase) and PLCγ1 (phospholypase Cγ1) making ZAP-70 an important adaptor protein to 
recruit signalling molecules to the activated TCR complex (Di Bartolo, Mege et al. 1999; Pelosi, Di 
Bartolo et al. 1999; Williams, Irvin et al. 1999; Gong, Jin et al. 2001). In fact, recent studies have 
demonstrated that ZAP-70, in particular through Y315 and Y319, has a kinase-independent scaffolding 
role that promotes integrin activation and cellular adhesion (Au-Yeung, Levin et al. 2010).  
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ZAP-70 tyrosine kinase activity results in the transfer of a phosphate group from adenosine 
triphosphate (ATP) to tyrosine residues which have a free hydroxyl group.  The catalytic region of ZAP-
70 contains two tyrosine residues, located in the protein activation loop, which when phosphorylated 
are thought to regulate the kinase activity of ZAP-70. Mutational analyses have revealed a negative 
regulatory role for Y492 and a positive regulatory role for Y493 (Chan, Dalton et al. 1995; Wange, 
Guitian et al. 1995) as the phosphorylation of these two residues, located within the activation loop, 
is thought to displace the activation loop from the catalytic site of the kinase.  
 
Studies have demonstrated a crucial role of ZAP-70 in TCR signal transduction. In mice, ZAP-70 
expression is required for thymic selection to progress beyond the double-positive stage and ZAP-70-
deficient mice have no single-positive CD4+ or CD8+ thymocytes or peripheral T cells (Negishi, 
Motoyama et al. 1995; Kadlecek, van Oers et al. 1998). In humans, loss of function or expression of 
ZAP-70  leads to severe combined immunodeficiency characterised by a nearly complete absence of 
peripheral CD8+ T cells and normal to elevated numbers of peripheral CD4+ T cells which are 
incompetent at transducing signals downstream of the TCR (Chan, Kadlecek et al. 1994; Elder, Lin et 
al. 1994). In addition to a fundamental role in thymocyte development, ZAP-70 is also important in 
peripheral T cell function and the catalytic activity of ZAP-70 has been shown to be essential and non-
redundant for the TCR-induced activation and proliferation of naïve T cells as well as the effector 
functions and memory responses of conventional CD4+ and CD8+ T cells (Au-Yeung, Levin et al. 2010).  
 
1.2.3. The T cell signalling pathway upon TCR activation 
When a T cell is presented with antigenic peptide by APCs, TCR-induced signals initiate a program of 
actin cytoskeletal modifications that results in polarisation and activation of the T cell and formation 
of an immunological synapse where signalling molecules accumulate and form, via physical 
interactions and activation mechanisms, a large molecular complex called the TCR signalosome. The 
synapse is highly coordinated and integrates cell adhesion, TCR binding of pMHC ligands and a range 
of activating or inhibitory molecules to promote or repress T cell signalling. The reorganisation of 
molecules on the cell membrane form supra-molecular activation clusters (SMACs) with TCRs and 
associated signalling molecules (CD3 complex, CD4, CD28) located in the central region (c-SMAC) and 
integrins in the periphery (p-SMAC) (Fooksman, Vardhana et al. 2010). 
 
1.2.3.1. Formation of the proximal TCR signalosome 
The engagement of the TCR with pMHC initiates a series of biochemical signals to translate the extra-
cellular binding event into an intra-cellular response that results in T cell activation. Since neither TCR 
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nor the non-covalently associated CD3 sub-units have intrinsic enzymatic activity, the TCR-induced 
signalling cascade depends heavily on protein phosphorylation and is dynamically regulated by 
protein tyrosine kinases and phosphatases.  
 
Early signalling events are initiated by two families of PTKs (Iwashima, Irving et al. 1994). First, a CD4- 
or CD8- associated Src-family PTK, such as Lck or more rarely Lyn, phosphorylates two tyrosines in the 
ITAM consensus sequence *(D ⁄ E)xxYxxI ⁄ Lx(6–8)YxxI ⁄ L+ in the cytoplasmic tails of the CD3 and ζ 
subunits of TCR (Barber, Dasgupta et al. 1989). The tyrosine phosphorylation event provides a docking 
site for the recruitment of the Syk family PTK ZAP-70. The binding of ZAP-70 to the dually 
phosphorylated ITAMs serves two purposes: help localize ZAP-70 to a stimulated TCR at the plasma 
membrane, but also relieve an auto-inhibited conformation of the kinase (Brdicka, Kadlecek et al. 
2005). The catalytic activity of ZAP-70 is activated by Lck or by trans-auto-phosphorylation of tyrosine 
residues in the activation loop of the kinase domain. The LAT and SLP-76 proteins are phosphorylated 
by active ZAP-70 and serve to recruit other signalling molecules, thus creating a proximal signalling 
complex responsible for propagating the TCR signal into multiple distal signalling pathways which 
initiate downstream biochemical events and trigger transcriptional events that ultimately lead to T 
cell proliferation, differentiation and cytokine production (Au-Yeung, Deindl et al. 2009). 
 
1.2.3.2. Distal TCR signalling pathways 
The proximal TCR signalling complex results in the activation of PLCγ1-dependent pathways including 
Calcium ions (Ca2+) and DAG (diacylglycerol)-mediated responses, cytoskeletal re-arrangements and 
integrin activation pathways (Smith-Garvin, Koretzky et al. 2009).  
 
PLCγ1 is first recruited by LAT, SLP-76 and Vav1 and activated by Itk (IL-2 inducible T cell kinase) (Liu, 
Bunnell et al. 1998; Reynolds, Smyth et al. 2002). Activated PLCγ1 then hydrolyses the membrane 
lipid PI(4,5)P2 (phosphatidylinositol 4,5 biphosphate) into two second messengers, IP3 (inositol 
triphosphate) and DAG (Berridge and Irvine 1984; Nishizuka 1984).  
 
1.2.3.3. DAG-induced signal transduction 
DAG activates two major signalling pathways (figure 1.4). The first pathway involves Ras, a small 
GTPase which is active only when bound to GTP. Ras activation is positively regulated by proteins 
containing GEF (guanine nucleotide exchange factor) domains and suppressed by GAPs (GTPase 
activating protein). RasGRP (Ras guanyl nucleotide-releasing protein) is a cytosolic GEF protein which 
is recruited to the membrane by DAG and which specifically activates Ras through the exchange of 
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bound GDP for GTP (Dower, Stang et al. 2000; Ebinu, Stang et al. 2000). Active Ras is then required for 
the activation of Raf-1, a serine-threonine kinase that phosphorylates downstream MAPKs (mitogen-
associated protein kinases) such as ERK1 (extra-cellular signal-regulated kinase 1) and ERK2 (Genot 
and Cantrell 2000). This pathway leads to the expression of several proteins, including transcription 
factor Elk-1, but also leads to the serine phosphorylation of STAT3 (signal transducer and activator of 
transcription 3) thereby linking the MAPK and cytokine signalling pathways (Ng and Cantrell 1997).  
 
DAG also triggers the PKCθ (protein kinase C θ) pathway which plays an essential role in NF-κB 
(nuclear factor κB) activation (Bi, Tanaka et al. 2001). NF-κB is a cytosolic protein which is inhibited in 
resting cells through its association with IκB (inhibitor of κB).  Following T cell activation, DAG recruits 
PKCθ to the plasma membrane where it gets activated (Monks, Freiberg et al. 1998; Melowic, Stahelin 
et al. 2007). This results in the activation of IKK (IκB kinase) which phosphorylates IκB. Phosphorylated 
IκB proteins are then targeted for degradation by ubiquitination and NF-κB is free to translocate into 
the nucleus and act as transcription factors, leading to IL-2 transcription in mature T cells (Sun, Arendt 
et al. 2000). 
 
1.2.3.4. Intra-cellular Ca2+ mobilisation 
Cytosolic accumulation of IP3 initiates intra-cellular Ca
2+ mobilisation through two inter-dependent 
processes. First the binding of IP3 to Calcium-permeable IP3 receptors (IP3R) on the membrane of the 
endoplasmic reticulum (ER) leads to the depletion of ER Ca2+ stores into the cytoplasm (Imboden and 
Stobo 1985; Guse, Roth et al. 1993). In turn this triggers a sustained influx of extra-cellular Ca2+ 
through the activation of specialised plasma-membrane Ca2+ channels (Putney 1990; Berridge 1993). 
In lymphocytes, this second mechanism constitutes the major pathway to increase intra-cellular Ca2+ 
concentrations.  
 
Increased intra-cellular Ca2+ levels result in the activation of signalling proteins including the 
phosphatase calcineurin and the CaM (Ca2+-calmodulin-dependent) kinase which activate the 
transcription factor NFAT (nuclear factor of activated T cells) leading to its translocation to the 
nucleus. NFAT can form cooperative transcriptional complexes with a variety of other transcription 
factors thereby resulting in differential, and sometimes contrary, transcriptional patterns. For 
instance NFAT can either promote the expression of many genes associated with T cell activation 
when associated with AP-1 (Rao, Luo et al. 1997), or activate a distinct set of anergy-associated genes 
and promote T cell tolerance in the absence of co-stimulation-induced AP-1 (Macian, Garcia-Cozar et 
al. 2002). Recently NFAT has also been shown to cooperate, in Treg cells, with FoxP3 to repress the 
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expression of IL-2 whilst up-regulating CD25 and CTLA-4 (Cytotoxic T lymphocyte antigen-4) (Wu, 
Borde et al. 2006). Such gene expression is regulated in a highly dynamic manner by intra-cellular Ca2+ 
since a decrease in their levels results in an almost immediate phosphorylation of export of NFAT 
from the nucleus and these events all need sustained Ca2+ influx to keep cytoplasmic Ca2+ 
concentrations at higher than basal levels for several hours (Dolmetsch, Lewis et al. 1997).  
 
1.2.3.5. The role of co-stimulation 
In addition to the antigen-specific signal induced by the interaction between TCR and the pMHC 
complex, full T cell activation also requires a non-specific co-stimulatory signal generated by the 
engagement of CD28 by CD80 (B7.1) and CD86 (B7.2) molecules on the APCs (Kane, Lin et al. 2002; 
Zhang and Zhao 2007) although molecules other than CD28 can also provide the co-stimulation for T 
cells. In the absence of co-stimulation, the TCR signal induces a state of unresponsiveness, known as 
anergy, in T cells and makes them refractory to re-stimulation (Harding, McArthur et al. 1992). This 
process enables T cell tolerance to self-antigens in the periphery (Kamradt and Mitchison 2001).  
 
1.2.3.6. Cytoskeleton re-arrangement and cell adhesion 
Actin re-organisation is essential for the formation of proximal TCR signals (Holsinger, Graef et al. 
1998) and accumulation of F-actin at the interface of T cells and APCs is due to the localised activation 
of several pathways of actin regulation and polymerisation.   
 
The Arp2/3 (actin-related proteins 2/3) complex plays a major role in the regulation of the actin 
cytoskeleton since it simultaneously controls actin nucleation, the first step of actin polymerization, 
and branching of filaments (Suetsugu, Miki et al. 2002). Arp2/3 activity is induced through 
interactions with nucleation-promoting proteins such as WASp (Wiskott-Aldrich syndrome protein) or 
WAVE2 (Wiskott-Aldrich syndrome protein family member 2). WASp is recruited to the TCR 
signalosome via its interaction with the SLP-76 associated adapter protein Nck (non-catalytic region of 
tyrosine kinase) and is activated by Cdc42 (cell-division cycle 42) (Zeng, Cannon et al. 2003). 
 
Integrin activation is also a critical factor for productive communication between T cells and APCs. 
Integrins are heterodimeric cell surface receptors which function to mediate cell-cell and cell-extra-
cellular matrix (ECM) interactions. The major T cell integrins include LFA-1 (leukocyte function-
associated antigen-1) and VLA-4 (very late antigen-4) which bind their respective ligands ICAM-1 
(intercellular adhesion molecule-1) and VCAM (vascular cell adhesion molecule) on other immune 
cells (Smith-Garvin, Koretzky et al. 2009). On resting T cells, integrins are inactive and exhibit low 
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affinity for their ligands. TCR engagement with pMHC results in signalling events that lead to a 
conformational change in integrin structure, which increases the affinity for their ligands. TCR 
stimulation also results in clustering of integrins on the cell surface, thereby leading to increased 
avidity (Menasche, Kliche et al. 2007). 
 
Although the pathway from the TCR to integrin activation has not been fully clarified, several 
molecular components are required including ADAP (adhesion and degranulation promoting adapter 
protein) and SKAP55 (Src kinase-associated phosphoprotein of 55 kDa) which form a complex to 
activate and ensure proper localisation of Rap1 (Ras-proximity 1), a small GTPase critical to mediate 
the TCR-induced adhesion of ICAM-1 (Bos, de Bruyn et al. 2003).  
 
1.2.3.7. Negative regulation of TCR signalling 
As previously described, TCR-induced signalling triggers a range of effector pathways. Regulation of 
these pathways is essential to ensure that T cells respond to appropriate ligands and for the proper 
duration. Negative regulation of T cell signalling is mediated through both TCR-generated signals and 
those emanating from other cell surface receptors and via mechanisms as diverse as de-
phosphorylation to an inactive state, competitive binding, protein degradation or sequestration of 
ligands (Acuto, Di Bartolo et al. 2008; Smith-Garvin, Koretzky et al. 2009).  
 
Proximal TCR signalling events are actively regulated mainly through the multiple proteins that 
control the activity of Lck. Co-receptors CD4/CD8-associated Lck can be found in one of three 
conformations: catalytically inactive, primed or active and the adoption of one of the three isoforms 
is under the control of several proteins. When Lck is phosphorylated on Y505, intra-molecular 
interactions keep it in an inactive conformation.  Upon de-phosphorylation of this residue by the 
membrane-bound protein tyrosine phosphatase CD45, Lck is unlocked into a primed state (Harder 
and Engelhardt 2004). Clustering of co-receptors enables further trans-auto-phosphorylation, and 
phosphorylation of Y394 results in full activation of Lck. Lck is inactivated by de-phosphorylation of 
the active site Y394 by the cytoplasmic phosphatase PTPN22 (protein tyrosine phosphatase, non-
receptor 22) (Hasegawa, Martin et al. 2004) and phosphorylation of its inhibitory Y505 by Csk (C-
terminal Src kinase) (Vang, Abrahamsen et al. 2004). Interestingly, CD45 can also de-phosphorylate 
Y394 to limit Lck activity. Therefore the negative or positive regulation of TCR signalling by CD45 is 
likely to be influenced by its proximity to other effector molecules stimulated by the TCR engagement 
and whether CD45 itself is in a favourable catalytic conformation (Hermiston, Xu et al. 2003; Smith-
Garvin, Koretzky et al. 2009). 
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An additional layer of TCR signalling regulation is provided by adapter proteins. Dok-1 (downstream of 
kinase) and Dok-2 have been shown to be negative regulators of T cell signalling and deletion or 
knock-down of these proteins lead to prolonged phosphorylation of ZAP-70, LAT, SLP-76 and results in 
increased T cell proliferation and cytokine production (Dong, Corre et al. 2006; Yasuda, Bundo et al. 
2007). Although Dok can also associate with negative regulators such as Csk, RasGAP or SHP-1 (SH2 
domain-containing phosphatase-1) the mechanism by which Dok downregulate T cell signalling has 
not been completely elucidated (Dong, Corre et al. 2006; Smith-Garvin, Koretzky et al. 2009). 
However, recent structural and functional in vitro studies suggest that Dok-1 and -2 may, through 
their PTB (phospho-tyrosine binding) domain compete with ZAP-70 for binding to CD3 ITAMs (Yasuda, 
Bundo et al. 2007).  
 
TCR signalling can be further negatively regulated by ubiquitin ligases Cbl-b (Casitas B-lineage 
lymphoma-b) and c-Cbl which are recruited to the proximal signalosome following TCR activation. Cbl 
proteins, which facilitate the ubiquitination of proteins, down-regulate PTKs such as Lck (Rao, Dodge 
et al. 2002), Fyn (Andoniou, Lill et al. 2000) and ZAP-70 (Thien, Bowtell et al. 1999) as well as being 
involved in the degradation of activated signalling molecules such as Vav (Miura-Shimura, Duan et al. 
2003) or LAT (Balagopalan, Barr et al. 2007). Thus, Cbl proteins, by way of their ability to regulate 
protein degradation, provide another means by which TCR signalling is terminated (Bachmaier, 
Krawczyk et al. 2000; Naramura, Jang et al. 2002).  
 
Inhibitory regulatory signals can also be provided by molecules such as CTLA-4 and PD-1 
(programmed death-1) to limit the expansion and activation of TCR-triggered T cells (Waterhouse, 
Penninger et al. 1995; Freeman, Long et al. 2000). These molecules are up-regulated on the surface of 
activated T cells and may use motifs on their intra-cellular tail to provide docking sites for negative 
regulators of TCR signalling. Another mode of function is to bind the same ligand as co-stimulatory 
receptors, thus setting up the potential for sequestration of ligands. For instance CTLA-4 and CD28 
share the ligands CD80 and CD86 and counter each other in the regulation of TCR signalling (Linsley 
1995; van der Merwe, Bodian et al. 1997). 
 




Figure 1.4 – The TCR signalosome. Following TCR agonist stimulation, activation of CD4-associated PTK Lck is de-
phosphorylated by the protein tyrosine phosphatase CD45. Lck activates the signal triggering module by fully phosphorylating 
ITAMs of CD3 δ‑chains. ITAM binding and Lck‑dependent tyrosine phosphorylation recruits and activates ZAP-70, which 
induces the assembly of the signal diversification and regulation module by phosphorylating the scaffold proteins LAT and 
SLP-76. This module also includes regulators of Ca2+ signalling and DAG production (which are PLCγ1 and Itk), actin 
polymerization (Nck and Vav1) and integrin activation (ADAP), all of which are activating signalling pathways that control cell 
adhesion, cytoskeletal re-arrangements and gene expression. Taken and adapted from (Acuto, Di Bartolo et al. 2008). 
 
1.3. T cell development and differentiation 
 
1.3.1. Thymic selection 
The importance of the thymus in the immune system was discovered in 1961 by Jacques Miller, when 
he surgically removed the thymus from three day old mice and observed the subsequent deficiency in 
a lymphocyte population (Miller 2002). The thymus has a two-lobed structure and each lobe is 
composed of numerous lobules separated by connective tissue. Follicles, contained into the lobules, 
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consist of a medullary and a cortical portion. The cortex is composed primarily of thymocytes, with a 
few epithelial whereas the medulla is composed of more epithelial cells but fewer lymphocytes. 
Macrophages and DCs are also found in the thymus (Nishino, Ashiku et al. 2006).   
 
T cells develop from bone-marrow hematopoietic progenitor cells, called pro-thymocytes, which 
reach the thymus through the circulation. Once in the thymus, those cells rapidly divide and give rise 
to large numbers of thymocytes. As the developing thymocytes mature, they stop dividing and move 
deeper into the cortex. Processes of β-selection, positive selection and negative selection shape the 
population of thymocytes into a pool of T cells released in the periphery and which are able to 
recognise foreign pathogens in the context of MHC-restriction and are immunologically tolerant 
towards self antigens (Wood 2006).  
Early thymocytes do not express CD4 or CD8 cell surface markers and are called double-negative. The 
ability of T cells to recognise foreign antigens is mediated by the TCR. To create a functional TCR, the 
maturing thymocytes use a series of enzymes to clip the DNA and re-arrange gene fragments 
together.  The outcome of this process is that each TCR has a different specificity, due to selection of 
gene fragments as well as any errors introduced during the splicing and joining process. Such 
mechanism enables the generation of a huge range of unique TCRs, each capable of recognising a 
different peptide. To pass the first checkpoint, rearranged TCR β-chain must retain the structural 
properties allowing it to be assembled on the surface of the thymocyte with pre-TCR α-chain and 
CD3. Thymocytes that have generated non-functional receptors because of gross defects introduced 
by gene rearrangement die by apoptosis.  
The next major stage of thymocyte development is positive selection for cells with a TCR capable of 
binding pMHC molecules with at least a weak avidity. At this stage, and since the TCR requires CD8 to 
bind to MHC class I and CD4 to bind MHC class II, thymocytes up-regulate both co-receptors and 
become CD4+ CD8+ double-positive cells. Thymocytes with TCRs that can bind self-MHCs expressed on 
the epithelial cells in the cortex receive survival signals and proceed to the next stage of maturation. 
Positively selected thymocytes undergo lineage commitment by maturing into either CD4+ or CD8+ 
single-positive T cell, up-regulate the chemokine receptor CCR7 and consequently migrate from the 
cortex to the medulla. Thymocytes whose TCRs are not capable of binding self-MHC undergo 
apoptosis (Kruisbeek, Mond et al. 1985; McDuffie, Born et al. 1986; Born, McDuffie et al. 1987).  
Negative selection, which occurs at the cortico-medullary junction and in the medulla, is the active 
induction of apoptosis in thymocytes whose TCRs are capable of binding self-peptides presented on 
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MHC class I or MHC class II with a high avidity. This process eliminates strongly autoreactive cells, 
produced from the TCR gene re-arrangement stage, and which would otherwise direct immune 
responses towards self-proteins in the periphery and lead to autoimmunity (Kappler, Roehm et al. 
1987; Kappler, Wade et al. 1987; Kappler, Staerz et al. 1988; Kisielow, Bluthmann et al. 1988; 
MacDonald, Schneider et al. 1988).  
In order to remove thymocytes reactive to peripheral organs, DCs present developing thymocytes 
with peptides derived from self-antigens either expressed in the thymus or travelling to the thymus 
through the bloodstream. In addition the gene AIRE (autoimmune regulator) drives the expression of 
tissue-specific antigens, such as insulin, to allow single-positive thymocytes to be exposed to a more 
complex set of self-antigens than would otherwise be present in the thymus (Liston, Lesage et al. 
2003). 
Thymocytes which do not react with self-pMHC ligands can complete the maturation process and 
emerge from the thymus as mature CD4+ or CD8+ T cells. Since the negative selection is not 100% 
efficient, some autoreactive T cells may escape thymic selection and be released in the periphery. 
Additional mechanisms, such as clonal anergy and regulatory T cells, exist to maintain peripheral 
tolerance and silence these cells. If these peripheral tolerance mechanisms also fail, autoimmunity 
may arise. 
 
1.3.2. T cell homeostasis 
The survival and composition of the mature T cell pool are governed by complex homeostatic signals 
(Surh and Sprent 2005; Surh and Sprent 2008). Recognition of specific and limited self-pMHC ligands 
is required for naïve T cell survival, meaning that post-thymic T cells must in fact retain a low degree 
of self-reactivity. Therefore the TCR responsiveness to self-antigens is tuned so as to allow naïve T 
cells to receive weak signals that are sufficient to promote survival but not induce the cells to divide 
and cause autoimmunity (Krogsgaard, Juang et al. 2007; Surh and Sprent 2008). Survival signals for 
naïve T cells in interphase are dependent on a combination of TCR signalling from interactions with 
self-pMHC ligands and interactions with members of the γc cytokine family, especially IL-7 and to a 
lesser extent IL-15 (Lodolce, Boone et al. 1998; Schluns, Kieper et al. 2000; Vivien, Benoist et al. 2001; 
Berard, Brandt et al. 2003). IL-7 maintains the survival of naïve T cells by signalling through JAK3 
(Janus-associated kinase) and STAT5 and prevent activation of the mitochondrial pathway of 
apoptosis by inducing expression of Bcl-2 and Mcl-1, although the exact intra-cellular pathways 
induced within T cells are not yet completely deciphered (Opferman, Letai et al. 2003; Wojciechowski, 
Tripathi et al. 2007). 
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Upon encounter of foreign antigens, naïve T cells become activated and undergo expansion and cell 
differentiation to acquire the appropriate effector functions required to eliminate the pathogens. A 
large number of effector cells die off within the next few weeks, but a small fraction of those cells 
survive as long-lived memory cells (Sprent and Surh 2002). Most of those memory cells rely heavily on 
contact with a mixture of IL-7 and IL-15 for their survival and intermittent homeostatic proliferation 
but in contrast to naïve T cells they are largely pMHC-independent (Tan, Ernst et al. 2002; Kondrack, 
Harbertson et al. 2003).  
 
1.3.3. CD4+ T cell differentiation 
After selection, single-positive CD4+ T cells that emigrate from the thymus, named naïve T helper 
precursor (Thp), are functionally immature and only capable of secreting IL-2. Upon recognition of 
antigens and contact with APCs, signals generated by the TCR and co-stimulatory molecules initiate 
the process by which naive Thp differentiate into distinct Th cell phenotypes, each characterised by 
subset-specific cytokine profiles and effector function to mediate different types of immune 
responses  (Abehsira-Amar, Gibert et al. 1992; Rocken, Muller et al. 1992; Kamogawa, Minasi et al. 
1993). T cell lineage commitment is also intricately coupled with differential epigenetic changes in 
chromatin structure and the expression of lineage-specific transcription factors (Agarwal and Rao 
1998; Agarwal and Rao 1998) 
 
Differentiation of Th cells is partly based on complex interactions with APCs in a permissive milieu. A 
number of factors can influence lineage commitment including the antigenic type, load and affinity 
(Constant, Pfeiffer et al. 1995; Constant and Bottomly 1997) and the strength of the resulting TCR 
signal is thought to skew the differentiation pathway possibly through controlling the duration or 
magnitude of Ca2+ fluxes (Sloan-Lancaster, Steinberg et al. 1997; Grakoui, Donermeyer et al. 1999). 
Interactions between cell-surface molecules such as co-stimulatory or adhesion molecules have also 
been shown to play a part in T cell differentiation (Rulifson, Sperling et al. 1997; Salomon and 
Bluestone 1998; Luksch, Winqvist et al. 1999). Yet the most potent determinant of Th cell fate is the 
cytokine milieu itself (O'Garra 1998; Glimcher and Murphy 2000). The early cytokine micro-
environment is generated by cells of the innate immune system, including various APC subsets, mast 
cells and NK cells, as well as CD4+ T cells (Miossec, Korn et al. 2009). 
 
Although Th cells were classically considered to belong to either Th1 or Th2 cell subsets (Seder and 
Paul 1994), Th17 cells have recently emerged as an additional lineage of CD4+ T cells (Harrington, 
Hatton et al. 2005; Park, Li et al. 2005). These three effector subsets seem to have evolved to permit 
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host defence against distinct classes of pathogens. Th1 cells typically guard against intra-cellular 
bacteria and viral infections, Th2 cells are associated with immune responses elicited by parasitic 
helminths, whereas Th17 responses are protective against certain extra-cellular bacterial and fungal 
infections (Weaver, Hatton et al. 2007). Dysregulated Th2 responses can promote allergy and asthma 
(Robinson, Hamid et al. 1992) while excessive and uncontrolled Th1 and Th17 responses can lead to 
autoimmune inflammation (O'Garra, Steinman et al. 1997; Langrish, Chen et al. 2005; Park, Li et al. 
2005); therefore, the actions of effector CD4+ T cells need to be tightly regulated. This control is 
partially carried out by Treg cells, a sub-population of CD4+ T cells which preserve peripheral 
tolerance and prevent the development of autoimmunity (Sakaguchi, Fukuma et al. 1985; Sakaguchi, 
Sakaguchi et al. 1995). Although these four phenotypes constitute the main fate choices that naïve 
CD4+ T cells will adhere to when differentiating into effector T cells, the regular emergence of novels T 
cell subsets, such as effector Th9 cells (Dardalhon, Awasthi et al. 2008; Veldhoen, Uyttenhove et al. 
2008) demonstrate the complexity of the Th differentiation process.  
 
1.3.3.1. Th1 and Th2 subsets 
The two critical cytokines that control Th1 and Th2 differentiation are IL-12 and IL-4, respectively. 
These two cytokines enhance the generation of their own effector subset and simultaneously inhibit 
the generation of the opposing phenotype (Scott 1991; Maggi, Parronchi et al. 1992; Parronchi, De 
Carli et al. 1992). Once established, Th1 and Th2 cells are thought to be terminally differentiated and 
unable to revert (Scott 1991; Murphy, Shibuya et al. 1996). 
 
Intra-cellular pathogens promote macrophages and DCs to secrete IL-12 (Macatonia, Hosken et al. 
1995; Scheicher, Mehlig et al. 1995), which in concert with TCR-pMHC engagement, activate STAT4 
and drives naïve CD4+ T cells to express the master transcription factor T-bet and become Th1 cells 
(Murphy, Ouyang et al. 1999). In turn Th1 cells produce their hallmark cytokines IFNγ and 
lymphotoxin, which can activate microbicidal activity as well as cytokine production in macrophages 
(Mosmann and Coffman 1989; Sher and Coffman 1992; Abbas, Murphy et al. 1996). IFNγ further 
amplifies Th1 differentiation in an autocrine loop by activating STAT1 and also promoting the 
expression of T-bet (Murphy, Ouyang et al. 1999; Lighvani, Frucht et al. 2001) 
 
Helminthic pathogens promote the generation of Th2 cells from naive CD4+ T cells by inducing the 
innate immune cells to secrete IL-4 (Swain, Weinberg et al. 1990). IL-4 signals through STAT6 (Hou, 
Schindler et al. 1994) and leads to the expression of the transcription factor GATA3 (Zheng and Flavell 
1997) in turn resulting in the production of IL-4, IL-5 and IL-13 which can activate mast cells and 
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eosinophils to eradicate parasitic pathogens (Mosmann and Coffman 1989; Sher and Coffman 1992; 
Urban, Madden et al. 1992).  
 
GATA3 is an essential transcription factor to regulate Th2 cytokine expression not only at the 
transcription level, by directly binding to the promoters of the IL-5 and IL-13 gene, but also by 
remodelling the chromatin structure and opening the IL-4 locus (Agarwal and Rao 1998; Takemoto, 
Koyano-Nakagawa et al. 1998). Moreover GATA3 further stabilises the Th2 phenotype, first by 
preventing Th1 development through repressing the expression of the IL-12R β2-chain, and second by 
boosting its own expression by a positive feedback regulatory loop (Zhou and Ouyang 2003). c-Maf 
has also been shown to be another important transcription factor to activate the IL-4 promoter and 
enables Th2 differentiation (Ho, Hodge et al. 1996). 
Peripheral T cell differentiation is accompanied by chromatin changes at the signature cytokine loci. 
High levels of histone acetylation at particular loci correlate with transcriptional activity (Hebbes, 
Clayton et al. 1994) and recent work by Fields and colleagues showed that the IFNγ and IL-4 loci saw 
profound increases in histone acetylation during Th1/Th2 differentiation. Initial TCR signals are 
thought to activate chromatin remodelling and locus opening in a cytokine-independent manner, with 
subsequent cytokine signalling reinforcing T cell differentiation by expanding and maintaining the 
accessible state at the relevant cytokine locus. In this model, GATA3 and T-bet serve as transcriptional 
maintenance factors, which keep the locus accessible to the transcriptional machinery (Fields, Kim et 
al. 2002). 
 
1.3.3.2. Th17 subset 
Th17 cells are important for the clearance of specific extra-cellular bacterial and fungal infection that 
require a massive inflammatory response and which are not adequately dealt with by Th1 or Th2 
responses (Korn, Bettelli et al. 2009).  
 
IL-17A, first identified in 1995 (Yao, Painter et al. 1995), is the hallmark cytokine of Th17 cells 
(Langrish, Chen et al. 2005) although they also produce IL-17F, IL-21 and IL-22 (Aggarwal, Ghilardi et 
al. 2003; Liang, Tan et al. 2006; Wei, Laurence et al. 2007) but not IFNγ or IL-4 which both antagonise 
the development and proliferation of Th17 cells (Harrington, Hatton et al. 2005; Park, Li et al. 2005). 
IL-17A will be subsequently referred to as IL-17 in the remainder in this document. Both IL-17 and IL-
17F have pro-inflammatory properties and act on a broad range of cells to induce the expression of 
cytokines (TNFα (tumour necrosis factor α), IL-1β, IL-6, GM-CSF, G-CSF), chemokines and 
metalloproteinases (Fossiez, Djossou et al. 1996; Jovanovic, Di Battista et al. 1998; Awane, Andres et 
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al. 1999; Laan, Cui et al. 1999; Martel-Pelletier, Mineau et al. 1999; Park, Li et al. 2005; Korn, Bettelli 
et al. 2009). They are also key cytokines for the recruitment and activation of neutrophils (Moseley, 
Haudenschild et al. 2003).   
 
Th17 and Th17-associated cytokines have been implicated in the development of various human 
autoimmune diseases such as multiple sclerosis (Matusevicius, Kivisakk et al. 1999), RA (Kirkham, 
Lassere et al. 2006), psoriasis (Krueger, Langley et al. 2007) and inflammatory bowel disease (Duerr, 
Taylor et al. 2006).   
 
In mice, Th17 cells develop from naive CD4+ T cells in response to TGFβ and IL-6 (Bettelli, Carrier et al. 
2006; Mangan, Harrington et al. 2006; Veldhoen, Hocking et al. 2006). TGFβ is indispensable for the 
generation of Th17 cells, although high concentrations of TGFβ may inhibit the production of various 
effector cytokines of Th17 cells and ultimately inhibit the generation of Th17 by inducing FoxP3 
(Chen, Jin et al. 2003; Fantini, Becker et al. 2004). IL-6 induces the expression of IL-21, which amplifies 
Th17 differentiation in an autocrine manner, and also of IL-23R at the cell-surface of differentiating 
CD4+ T cells (Zhou, Ivanov et al. 2007). Although not required for the initial Th17 differentiation from 
naïve precursors, IL-23, which is produced by activated DCs, seems essential to stabilise the Th17 
phenotype (figure 1.5). IL-23 sustains Th17 differentiation possibly by enhancing the expression of IL-
17, but also inducing the expression of IL-22, and suppressing IL-10 and IFNγ (Aggarwal, Ghilardi et al. 
2003; Langrish, Chen et al. 2005; McGeachy, Bak-Jensen et al. 2007). Yet naïve CD4+ T cells cannot 
differentiate into Th17 cells in the presence of IL-23 alone as they do not have IL-23R on their cell-
surface (Mangan, Harrington et al. 2006).  
 
Th17 differentiation is dependent upon signal transduction through STAT3 and can be abrogated by a 
deficiency in STAT3 (Yang, Panopoulos et al. 2007). IL-6, IL-21 and IL-23 activate STAT3 signalling 
pathways which lead to the expression of IL-17 (Chen, Laurence et al. 2006), IL-21 (Wei, Laurence et 
al. 2007) and IL-23R (Zhou, Ivanov et al. 2007). Socs3 (suppressor of cytokine signalling 3) is a negative 
regulator of STAT3 and its deletion is associated with increased STAT3 phosphorylation and IL-17 
production, and subsequent multi-organ inflammation (Wong, Egan et al. 2006).  
 
Both in vitro and in vivo differentiation of the Th17 cell lineage require the STAT3-dependent up-
regulation of RORγt (Ivanov, McKenzie et al. 2006), which in turn promotes the expression of Th17 
signature cytokines (Liang, Tan et al. 2006; Nurieva, Yang et al. 2007; Zheng, Danilenko et al. 2007). 
Although the mechanisms by which RORγt regulate IL-17 have not been fully elucidated, there are 
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multiple functional RORγt binding sites present in the IL-17A promoter and RORγt has been found to 
bind the gene promoter, as demonstrated by chromatin immunoprecipitation (Ichiyama, Yoshida et 
al. 2008). RORα, another member of the retinoid nuclear receptor family, is also selectively expressed 
in Th17 cells and may synergise with RORγt to promote Th17 differentiation although its deletion in 
mice has a minimal effect of IL-17 production (Yang, Pappu et al. 2008). Finally it is likely that RORγt 
must associate with other transcription factors, some still unidentified, to ensure full commitment of 
precursors to the IL-17 lineage, and both IRF4 and Runx1 have been found to play an essential role 




Figure 1.5 – Differentiation of Th17 cells in mice. TGFβ and IL-6, produced by activated innate immune cells such as DCs, 
act in concert to induce STAT3-dependent expression of RORγt in naïve T cells (blue) and activate the Th17 transcription 
program leading to secretion of IL-17 the hallmark cytokine of Th17 cells and expression of IL-23R at the cell-surface. IL-21 
amplifies Th17 differentiation in an autocrine loop. Downstream of IL-21 signalling, IL-23 is required to induce further effector 
molecules in committed Th17 cells (purple) and establish their terminally differentiated effector phenotype (orange). Adapted 
from (Korn, Bettelli et al. 2009).  
 
Although there are some discrepancies in the various cytokine combinations that drive human Th17 
cell differentiation, a common feature is the essential presence of a STAT3-dependent cytokine signal 
(IL-6, IL-21 or IL-23) to induce the expression of ROR-c, the human counterpart of murine RORγt 
(Wilson, Boniface et al. 2007; Manel, Unutmaz et al. 2008; Yang, Anderson et al. 2008). 
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1.3.3.3. Treg subset 
CD4+ Treg cells are central to the maintenance of immunological tolerance by suppressing T cell 
proliferation and function and attenuate immune responses against self- or non self-antigens 
(Sakaguchi, Sakaguchi et al. 1995; Sakaguchi, Ono et al. 2006).  
 
Natural regulatory T cells (nTreg) develop in the thymus and are exported to the periphery where 
they act as a long-lived population intended to maintain peripheral self-tolerance and prevent 
potential pathological autoimmune responses (Sakaguchi, Sakaguchi et al. 1995). nTregs express the 
transcription factor FoxP3 (Fontenot, Gavin et al. 2003; Hori, Nomura et al. 2003; Khattri, Cox et al. 
2003), which is essential for their development and function and is expressed in around 5-10% of 
peripheral CD4+ T cells (Zheng and Rudensky 2007).  
 
FoxP3 is thought to regulate Treg cell regulatory functions through interactions with AML1 (acute 
myeloid leukaemia 1), Runx1 (Runt-related transcription factor 1) and NFAT to generate a complex 
that induces either transcriptional activation or repression of a range of target genes (Ono, Yaguchi et 
al. 2007; Gorman and Cope 2008).  For example, it is required for the expression of CD25, the α-chain 
of the high-affinity IL-2 receptor which is also transiently expressed on activated effector T cells, GITR 
(glucocorticoid-induced TNF receptor) and the inhibitory molecule CTLA-4, both cell-surface markers 
that characterise nTregs (Salomon, Lenschow et al. 2000; Shimizu, Yamazaki et al. 2002); conversely, 
IL-2 gene transcription is suppressed (Zheng, Josefowicz et al. 2007). nTreg cells are anergic upon TCR 
stimulation and suppress CD4+ and CD8+ effector T cell proliferation and cytokine production through 
cell-cell contact with either responding effector T cells or APCs, thereby playing an essential role in 
maintaining peripheral self-tolerance (Shevach 2002).  
  
Following TCR stimulation in the presence of TGFβ and IL-2, peripheral naive CD4+ T cells can also be 
converted to become inducible Treg cells (iTregs), another subset of Treg cells whose expression of 
FoxP3 and CD25 is more variable, which result in up-regulation of the transcription factor FoxP3 
(Chen, Jin et al. 2003; Fantini, Becker et al. 2004; Zheng, Wang et al. 2004). iTregs are thought to 
develop in response to environmental antigens and to maintain tolerance to non-self components 
such as gut flora and ingested material and are more prominent in mucosal tissues such as the gut 
and lungs (Izcue, Coombes et al. 2006; Izcue, Coombes et al. 2009). iTregs mediate their suppressive 
functions by producing immuno-suppressive cytokines such as IL-10 and TGFβ (Nakamura, Kitani et al. 
2001; Kingsley, Karim et al. 2002), although direct cell-cell contact might still be required for effective 
suppression (Bluestone and Abbas 2003). Another means for Treg cells to control inflammation is by 
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suppressing the recruitment and function of innate immune cells, such as NK cells, DCs and 
monocytes (Misra, Bayry et al. 2004; Ghiringhelli, Menard et al. 2005; Tiemessen, Jagger et al. 2007).  
 
Cell-fate decisions between Th17 cells and iTregs are reciprocally related (Bettelli, Carrier et al. 2006). 
Although TGFβ has essentially immuno-suppressive functions (Shull, Ormsby et al. 1992; Letterio and 
Roberts 1998) and can promote Treg cell differentiation, it is also clear that this cytokine serves a pro-
inflammatory role since it is indispensable for Th17 differentiation (Veldhoen, Hocking et al. 2006; Xu, 
Kitani et al. 2007). It is thought that both FoxP3 and RORγt are co-expressed in naive CD4+ T cells 
exposed to TGFβ, where FoxP3 directly antagonises RORγt function through a physical interaction, 
preventing the binding of RORγt to the IL-17 promoter (Ichiyama, Yoshida et al. 2008; Zhou, Lopes et 
al. 2008), therefore inhibiting the production of various effector cytokines of Th17 cells. This is 
supported by the finding that FoxP3 binds both RORα and RORγt and inhibit their biological activity in 
a dose-dependent manner (Du, Huang et al. 2008; Zhou, Lopes et al. 2008). Only the addition of IL-6 
or IL-21 can relieve the inhibitory effect of FoxP3 on RORγt and promote the Th17 transcriptional 
program (Manel, Unutmaz et al. 2008; Zhou, Lopes et al. 2008). IL-6 is also a potent inhibitor of TGFβ-
induced induction of FoxP3+ Treg cells (Bettelli, Carrier et al. 2006).  
 
1.3.3.4. T cell subset plasticity 
The acquisition of heritable traits in cell differentiation is carried out through the activation of 
lineage-specific transcription factors which play essential roles in regulating gene expression through 
epigenetic modifications of genes. Thus the lineage commitment of Th cells is intricately linked to 
epigenetic changes such as chromatin remodelling, DNA methylation, histone modifications and 
incorporation of histone variants, all mechanisms that alter gene expression through facilitating or 
repressing gene locus access to the transcription machinery (Ansel, Lee et al. 2003; Merkenschlager 
and Wilson 2008; Wilson, Rowell et al. 2009). For instance tri-methylation of histone H3 lysine 4 
(H3K4me3) is a permissive mark found at the promoter and the enhancer regions of active genes to 
maintain them in an accessible transcriptional state, whereas tri-methylation of histone H3 lysine 27 
(H3K27me3) is a repressive mark found in inactive genes. Bivalent modifications, comprising both the 
permissive H3K4me3 and repressive H3K27me3 present at the same gene locus, have been suggested 
to poise genes ready for either activation or repression during differentiation (Wei, Wei et al. 2009).    
Th1 and Th2 differentiated cells are characterised by the silencing of the gene encoding the signature 
cytokine of the opposing fate. Permissive H3K4me3 are found at the IFNγ locus and repressive 
H3K27me3 at the IL-4 and IL-17 loci in Th1 cells. Conversely permissive H3K4me3 marks are present at 
the IL-4 locus in Th2 cells whilst the IFNγ and IL-17 loci show repressive H3K27me3 modification (Wei, 
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Wei et al. 2009). In this respect, Th1 and Th2 cells appear to be terminally differentiated and the 
epigenetic marks found at the IFNγ, IL-4, and IL-17 gene loci correlate with Th1 and Th2 cell lineages. 
Th1-specific epigenetic modifications are STAT4-dependent (Fields, Kim et al. 2002) whereas GATA3 
and STA6 are essential for silencing of the IFNγ locus in differentiating Th2 cells (Chang and Aune 
2007).  
 
While Th1 and Th2 differentiated cells are rendered resistant to further differentiation via epigenetic 
modifications of gene loci associated with the reciprocal lineage (Wilson, Rowell et al. 2009) both 
Th17 cells and Treg cells show a degree of plasticity and can convert to other phenotypes.  Therefore 
although lineage commitment was traditionally seen as fixed once achieved, additional complexity is 
becoming evident (figure 1.6). 
 
The conversion of nTreg cells to Th17 cells has been reported in both mouse and human T cells 
although with some differences. Murine Treg cells were converted predominantly to Th17 under the 
influence of IL-6 (Xu, Kitani et al. 2007; Beriou, Costantino et al. 2009), the cytokine which also drives 
naïve Th differentiation away from Treg and towards Th17. In contrast, human Treg cells were largely 
resistant to IL-6 yet they differentiated to the Th17 lineage in an IL-1-dependent manner (Koenen, 
Smeets et al. 2008; Osorio, LeibundGut-Landmann et al. 2008; Deknuydt, Bioley et al. 2009) and the 
observation of double-positive human cells for FoxP3 and IL 17 seem to suggest a transitional stage 
between both phenotypes (Voo, Wang et al. 2009). Although human and mouse Treg cells may 
differentiate to Th17 phenotypes under the influence of different pro inflammatory cytokines, both 
IL-6 and IL-1 activate STAT3 to promote a loss of FoxP3, the induction of RORγt expression and IL-17 
production (Yang, Nurieva et al. 2008). Consistent with the plasticity demonstrated for Treg cells, 
Tbx21, which encodes for T-bet, GATA3, and RORc, which encodes for RORγt, were all bivalently 
modified  thus enabling Treg cell reprogramming into other lineages (Wei, Wei et al. 2009).  
 
Both Th17 cells derived from naïve precursors and those derived from Treg cells share common 
phenotypic features such as the expression of CCR6 (Koenen, Smeets et al. 2008; Singh, Zhang et al. 
2008), a chemokine receptor which direct Th17 migration to sites of inflammation, although only 
naïve precursor-derived Th17 express CCL20 (chemokine CC motif ligand 20) the only known ligand 
for CCR6 (Yamazaki, Yang et al. 2008). Therefore it has been suggested that infiltrating CD4+ Treg cells 
at sites of infection (Lundgren, Stromberg et al. 2005), where IL-1 and IL-6 are highly expressed may 
subvert the suppressive function of Treg cells and lead to conversion to Th17 phenotype to amplify 
the clearance of the pathogen. Therefore the ability of Treg cells to be converted into effector cells in 
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vivo may be an additional mechanism to contribute to host protection after infection with microbial 
pathogens (Afzali, Mitchell et al. 2010).  
Equally Th17 cells have shown a degree of phenotypic flexibility. Although Th17 cells were originally 
seen as a subset of Th1 lineage (Bettelli and Kuchroo 2005; McKenzie, Kastelein et al. 2006), they are 
now considered to be a distinct Th subset from Th1 or Th2 lineages (Harrington, Hatton et al. 2005; 
Park, Li et al. 2005). Yet the detection of double-positive human and murine cells for IFNγ and IL-17 
suggests the existence of some intricate relationship between these two developmental programs 
(Acosta-Rodriguez, Rivino et al. 2007; Lexberg, Taubner et al. 2010). Indeed the plasticity of Th17 cells 
has been highlighted in recent studies (Annunziato and Romagnani 2010; Kurschus, Croxford et al. 
2010) and the conversion of Th17 cells to Th1, or intermediary Th17/Th1, phenotype has been 
observed in human disease states (Nistala, Adams et al. 2010).   
 
In particular Th17 cells generated in vitro required continuous addition of TGFβ to maintain 
expression of IL-17 and IL-17F expression, and could be converted to Th1 or Th2 cells in the presence 
of IL-12 or IL-4, respectively (Lexberg, Taubner et al. 2008; Lee, Turner et al. 2009). This suggests that 
although TGFβ and IL-6 act synergistically to promote permissive modifications on IL-17 and IL-17F 
promoters and increase chromatin accessibility of the locus to transcription factors, these epigenetic 
modifications might not be sufficient to imprint the IL-17 genes for re-expression and in vitro 
generated Th17 cells still display a degree of phenotypic instability and are not resistant to re-
programming to Th1/Th2 phenotypes. This is further supported by the finding that Th17 cells 
differentiated  in vitro displayed bivalent epigenetic status at the Tbx21, which encodes for T-bet, and 
GATA3 loci, suggesting that these cells are pre-conditioned to be re-directed toward other 
phenotypes (Wei, Wei et al. 2009). In contrast, in vivo memory Th17 cells were found to be more 
resistant to conversion (Lexberg, Taubner et al. 2008), suggesting epigenetic differences between in 
vitro- and in vivo-generated Th17 cells. 
 






Figure 1.6 – T cell plasticity. Upon contact with MHC-Ag, naïve CD4+ T cells can differentiate into Th1, Th2, Th17 or iTregs. 
These differentiation programs are controlled – at least partly – by cytokines which are produced by innate and other adaptive 
immune cell. Even after differentiation, plasticity can occur allowing for conversion to other phenotypes. Although Th1 and 
Th2 cells display stable lineage, Th17 and Treg cells can readily switch to other phenotypes under certain cytokine 
conditions. Adapted from (Weaver, Harrington et al. 2006). 
 
1.3.4. The role of IL-2 in T cell function 
IL-2, a 15,000 kDa 4-bundle α-helical protein, was first discovered in 1976 as a growth factor for bone 
marrow-derived T lymphocytes (Morgan, Ruscetti et al. 1976). IL-2 is predominantly produced upon 
stimulation of naïve CD4+ T cells and to a lesser extent by CD8+ T cells (Malek 2008). IL-2 binds to a 
high-affinity IL-2 receptor (IL-2R) made of three sub-units: IL-2Rα (CD25) (Leonard, Depper et al. 1982; 
Leonard, Depper et al. 1984; Nikaido, Shimizu et al. 1984), IL-2Rβ (CD122) (Sharon, Klausner et al. 
1986; Tsudo, Kozak et al. 1986; Hatakeyama, Tsudo et al. 1989) and the common cytokine γ receptor 
chain (γc, CD132) (Takeshita, Asao et al. 1992; Noguchi, Nakamura et al. 1993; Leonard 1996). All 
three sub-units are required for the formation of the high-affinity IL-2R (Stauber, Debler et al. 2006).  
 
IL-2 is rapidly and transiently produced upon the engagement of the TCR and co-stimulatory 
molecules such as CD28. The induction of IL-2 production depends on TCR-induced signalling events 
including phosphorylation of the CD3-ζ chain, ZAP-70 and LAT, sustained mobilisation of intra-cellular 
Ca2+, MAPK induction and transcriptional activation of NF-κB and NFAT (Jain, Loh et al. 1995; Alberola-
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Ila, Takaki et al. 1997; Leitenberg and Bottomly 1999). Co-stimulatory signals are required to stabilise 
IL-2 mRNAs (Shaw, Meerovitch et al. 1988; Lindstein, June et al. 1989; Fraser, Irving et al. 1991; Jain, 
Loh et al. 1995; Serfling, Avots et al. 1995) but also to enable TCR-induced chromatin remodelling and 
epigenetic modifications at the IL-2 promoter  (Ward, Hernandez-Hoyos et al. 1998; Bruniquel and 
Schwartz 2003; Thomas, Gao et al. 2005). Indeed TCR activation alone produces anergic T cells in 
vitro. In these cells IL-2 promoters do not undergo chromatin remodelling and remain inaccessible to 
DNA binding proteins. 
 
TCR signalling also induces the up-regulation of CD25 leading to the formation of the high-affinity 
ternary IL-2R complex at the cell surface. In a positive feedback loop, secreted IL-2 binds to the IL-2R 
in an autocrine and paracrine fashion and induces IL-2/IL-2R signalling events (figure 1.7). This triggers 
the recruitment of JAKs which phosphorylate tyrosine residues on the cytoplasmic domain of the IL-
2R complex (Lin and Leonard 1997) thereby generating docking sites for the adapter protein SHC (Src 
homologous and collagen) and the transcription factor STAT5 (Friedmann, Migone et al. 1996; 
Ravichandran, Igras et al. 1996). SHC provides a platform to activate the MAPK and PI3K 
(phosphatidylinositol 3-kinase) pathways (Gadina, Sudarshan et al. 2000; Gaffen 2001; Waldmann, 
Dubois et al. 2001). The associated STAT5 proteins are further phosphorylated, enabling them to 
dimerize and translocate into the nucleus to activate and regulate the expression of several target 
genes, including IL-2Rα. Therefore the activation of MAPK, PI3K and STAT5 pathways is important for 
the proper effector function of T cells such as cytokine production, cell-cycle entry, growth and 
survival (Lord, McIntosh et al. 2000). IL-2 also plays a role in the subsequent reduction in the number 
of specific T cells for a given antigen by mediating the process of activation-induced cell death (AICD) 
(Lenardo 1991).  
 




Figure 1.7 – IL-2/IL-2R signalling in effector and regulatory T cells. Binding of IL-2 to IL-2R results in the activation and 
binding of JAKs to the intra-cellular domains of IL-2R. JAKs phosphorylate tyrosine residues which then recruit adaptor 
proteins which activate the MAPK and PI3K pathways. PTEN inhibits the PI3K pathway in Tregs. Activated STAT5 dimers 
translocate to the nucleus and bind to GAS motifs to activate gene transcription. Diagram from (Lan, Selmi et al. 2008) 
 
Only antigen-activated conventional T cells and CD4+FoxP3+ Treg cells readily co-express the three 
sub-units required to form the high-affinity IL-2R complex, and consequently are poised to respond to 
IL-2 in vivo. In addition to regulating and influencing several critical aspects of conventional T cell 
biology, the IL-2/IL-2R signal also plays a critical role in the development and function of Treg cells 
(Fontenot, Rasmussen et al. 2005) although IL-2 signalling in Treg cells differs from effector T cells. In 
contrast to conventional T cells, STAT5 is the main pathway contributing to Treg cell generation and 
homeostasis, and the PI3K pathway is only poorly activated in Treg cells due to increased activity of 
PTEN (phosphatase and tensin homolog) (Bensinger, Walsh et al. 2004; Walsh, Buckler et al. 2006; 
Malek 2008). 
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IL-2-dependent STAT5 signalling has been shown to be important during thymic development of 
nTregs to directly regulate expression of FoxP3 and CD25 (Yao, Cui et al. 2006; Burchill, Yang et al. 
2007). IL-2, through induction of STAT5, also directly contributes to Treg homeostasis and regulatory 
activity by promoting FoxP3 expression which is essential to reinforce and maintain Treg cell 
suppressive function (Fontenot, Rasmussen et al. 2005; Bayer, Yu et al. 2007; Gavin, Rasmussen et al. 
2007). Similarly, TGF-β-induced expression of FoxP3 is strictly dependent on IL-2 in iTregs (Zheng, 
Wang et al. 2007) although distinct conserved non-coding regions of FoxP3 are remodelled in iTreg 
versus nTreg cells (Zheng, Josefowicz et al. 2010), suggesting possible distinct contribution by IL-2R 
signalling in these lineage choices.  
 
In addition to its action on Treg cells, IL-2 signalling also limits antigen and self-antigen-induced 
inflammation through two additional mechanisms, by up-regulating FasL and down-regulating anti-
apoptotic FLIP (FLICE-inhibitory protein) to induce AICD (Lenardo 1991; Refaeli, Van Parijs et al. 1998), 
and by inhibiting effector T cell differentiation to the Th17 phenotype (Laurence, Tato et al. 2007).  
 
Therefore, the balance of IL-2 pro- and anti-inflammatory signals regulates the appropriate mounting 
and resolution of immune responses and is critical for a controlled inflammatory response. 
Accordingly major IL-2 dysfunctions, resulting from defects in self-tolerance and T cell homeostasis, 
have led to the development of autoimmunity and immunodeficiencies in both humans and mice 
(Sadlack, Merz et al. 1993; Suzuki, Kundig et al. 1995; DiSanto, Guy-Grand et al. 1996; Aoki, Roifman 
et al. 2006). Thus even modest alterations of IL-2 levels may have important pathogenic or 
therapeutic consequences, as illustrated by the genetic pre-disposition of type 1-diabetes in NOD 
mice which is associated with a seemingly small two-fold reduction in IL-2 levels (Yamanouchi, 
Rainbow et al. 2007; Malek 2008). 
 
1.4. Rheumatoid arthritis  
 
RA is a chronic inflammatory, destructive disorder that can affect any diarthrodial joint, with a 
predilection for the wrist and small joints of the hands and feet. Although the major target tissue is 
the synovial membrane of joints, RA is also systemic and often affects extra-articular tissues including 
the skin, blood vessels, lungs, heart and muscles (Imboden 2008).  
 
RA prevalence, which varies depending on ethnic origin, ranges between 0.5% to 1% of the European 
and North American Caucasian populations, predominantly affecting females and is associated with 
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significant morbidity and increased mortality (Silman, MacGregor et al. 1993). The exact aetiology 
remains unknown but crucial triggers for the onset of RA are thought to arise from interactions 
between genetic factors, sex hormones and environmental factors, which might also be influenced by 
lifestyle and exposure to infectious agents.  
 
RA has long been considered a disease with features of autoimmunity though there is no consensus 
on the autoantigen(s) involved or the environmental factors that trigger the autoimmune process. 
Nonetheless, the imbalance between pro- and anti-inflammatory cytokine activities observed in 
rheumatoid joints favours the induction of several key features of RA such as autoimmunity via the 
production of autoantibodies, chronic inflammation (synovitis) and over time progressive articular 
damage, joint destruction and disability (McInnes and Schett 2007).  
 
Although RA remains a clinical diagnosis, there is increasing agreement that the disease is clinically, 
pathologically, serologically and genetically heterogeneous. For instance the presence of 
autoantibodies to cyclic citrullinated peptides (anti-CCP), seen in around 70% of RA patients 
(Nishimura, Sugiyama et al. 2007), has high specificity for RA and likely defines a clinically and 
genetically distinct form of the disease (Huizinga, Amos et al. 2005). 
 
1.4.1. Synovial pathology and join damage in RA  
RA is characterised by progressive joint damage that is mediated by several mechanisms (figure 1.8). 
Following onset of clinical disease – whose specific triggers are still ill-defined - the normally 
hypocellular synovial membrane becomes hyperplastic and highly vascularised. Resident stromal 
elements such as fibroblast-like synoviocytes (FLS) and macrophage-like synoviocytes (Smith, Barg et 
al. 2003) become activated and subsequent production of chemokines (Szekanecz, Kim et al. 2003) 
and up-regulation of adhesion molecules (Haskard 1995) promote the migration of mononuclear 
inflammatory cells – including T cells (predominantly CD4+), B cells and plasma cells, neutrophils and 
DCs. These cells further exacerbate synovitis through the production of a wide range of pro-
inflammatory cytokines. In chronic, established disease the inflamed synovium give rise to a 
proliferating pannus which promotes articular destruction by invading and degrading adjacent 
cartilage and subchondral bone via the secretion of destructive enzymes, such as matrix 
metalloproteinases (MMPs) and aggrecanases (Hembry, Bagga et al. 1995; Ahrens, Koch et al. 1996; 
Yoshihara, Nakamura et al. 2000; Cawston and Wilson 2006).  
 




Figure 1.8 - Pathogenesis of Rheumatoid Arthritis. In the normal knee joint, the synovium consists of a hypoplastic 
synovial membrane and underlying loose connective tissue. In early RA, the synovium thickens and gets highly vascularised. 
T cells (predominantly CD4+) and B cells (some of which become plasma cells) infiltrate the synovial membrane. These cells 
are also found in the synovial fluid, along with large numbers of neutrophils and other leukocytes. In established RA, the 
synovial membrane transforms into inflammatory tissue, the pannus, which invades and destroys adjacent cartilage and 
bone. From (Choy and Panayi 2001).  
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1.4.2. Genetics of RA  
The contribution of genetic factors to susceptibility to RA has been estimated to be around 60% from 
twin studies performed on a national scale in Finland and in the United Kingdom (MacGregor, Snieder 
et al. 2000). Multiple loci contribute to disease susceptibility for RA with the HLA locus being the most 
important and accounting for 30% to 50% of overall genetic risk (Seldin, Amos et al. 1999; Bowes and 
Barton 2008; Lee, Lee et al. 2008). HLA genes encode cell-surface antigen-presenting proteins that 
associate to produce MHC αβ heterodimers whose only known function is to bind to and present 
antigenic peptides to T lymphocyte. Within the HLA locus, the multiple alleles of HLA-DRB1 which 
encodes the HLA-DRβ-chain of the MHC class II, present the strongest association.  
 
HLA-DRB1 alleles associated with susceptibility to RA encode a region of sequence similarity – the 
‘shared epitope’ - in the α-helix wall of the β-chain’s peptide-binding groove which can influence 
disease severity as well as susceptibility (Gregersen, Silver et al. 1987). Recent analysis of HLA-DRB1 
alleles in French RA patients demonstrated that the disease-association is mediated by the sequence 
Arg-Ala-Ala at positions 72–74 of the shared-epitope whereas residues at positions 70 and 71 are 
associated with reduced risk of developing RA (du Montcel, Michou et al. 2005). Structural studies 
have additionally shown that residues 70 and 71 of the shared epitope contact, respectively, the TCR 
and the antigenic peptide, therefore influencing both TCR recognition and peptide binding (Dessen, 
Lawrence et al. 1997; Hennecke and Wiley 2002; Rosloniec, Ivey et al. 2006). This suggests that the 
disease-associated class II HLA-DR molecules may predispose to RA through presentation of peptides 
to pathogenic T cells although the exact mechanisms and antigen specificity remain unknown.  
 
Interestingly, the HLA-DRB1 shared-epitope appears to confer susceptibility only for development of 
the subgroup of RA that is associated with anti-CCP antibodies and no association was observed with 
anti-CCP-negative RA patients (Huizinga, Amos et al. 2005). This suggests that the shared-epitope 
alleles associate with a specific disease phenotype rather than the disease itself. The simplest model 
to explain this strong association is that shared epitope-expressing HLA-DR molecules bind certain key 
citrullinated peptide antigens with higher affinity than do shared-epitope-negative HLA-DR molecules 
and facilitate their presentation to T cells. However, it remains to be determined whether selective 
binding of citrullinated peptides by shared epitope-expressing HLA-DR molecules plays a direct role in 
the pathogenesis of RA. Nonetheless, experiments undertaken in HLA-DRB1*0401 (DR4) transgenic 
mice immunised with native or citrullinated human fibrinogen would suggest preferential binding of 
citrullinated peptides to HLA-DR4 leading to an arthritogenic T cell response (Hill, Bell et al. 2008). 
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The second strongest association identified thus far is with the PTPN22 gene (Gregersen 2005). 
PTPN22 is a lymphocyte intra-cellular tyrosine phosphatase that down-regulates the initiation of T cell 
activation (see section 1.2.3.7). Based on recent functional studies, substitution of tryptophan for 
arginine at residue 620 in the disease-associated variant results in a more potent down-regulation of 
T cell activation, leading to attenuated TCR signalling, decreased production of IL-2 and reduced 
proliferative responses (Vang, Congia et al. 2005). Two models have been proposed to explain the 
apparent association between RA and hypo-responsiveness of the TCR upon engagement. First, 
weaker TCR signalling in PTPN22R620W thymocytes may result in a failure to delete autoreactive T cells 
during thymic selection. Second, PTPN22R620W Treg cells may have a diminished ability to control 
peripheral tolerance (Gregersen 2005; Vang, Congia et al. 2005; Rieck, Arechiga et al. 2007). 
 
As is the case with HLA-DRB1 shared-epitope alleles, PTPN22R620W confers susceptibility for anti-CCP-
positive RA, and there is no significant association with anti-CCP-negative RA (Plenge, Padyukov et al. 
2005). Additionally the PTPNP22 polymorphism has been associated with rheumatoid factors, 
therefore suggesting that the gain-of-function mutant LypR620W might be involved in the initiation of 
the disease by influencing autoantibody production (Cope 2007).  
 
Recent genome-wide association studies (GWAS) have identified additional RA risk loci although they 
all have low penetrance and are associated with low to moderate risk (Bowes and Barton 2008). A 
single nucleotide polymorphism (SNP) in STAT4 was shown to be associated with RA in a North 
American population (Amos, Chen et al. 2006; Remmers, Plenge et al. 2007). Although it is not known 
whether the disease-associated SNP affects the function or expression of STAT4, direct participation 
of this molecule in RA susceptibility is biologically plausible since STAT4 is a critical regulator of 
inflammation in vivo (Kaplan 2005). The association of SNPs mapping close to both the α and β chains 
of the IL-2R is also of particular interest and biologically relevant since, as previously described, the IL-
2R mediates IL-2 stimulation of T cells (The Wellcome Trust Case Control Consortium 2007) 
 
1.4.3. Autoimmunity to citrullinated protein antigens 
Citrullination of proteins is a post-translational modification carried out by peptidylarginine deiminase 
(PAD) enzymes (Schellekens, de Jong et al. 1998). Citrullinated proteins can be found in a variety of 
physiologic and pathologic conditions (Tsuji, Akiyama et al. 2003; Cuthbert, Daujat et al. 2004; Wang, 
Wysocka et al. 2004). Therefore it is not their presence per se which is specific for RA but rather the 
development of autoimmunity to well-defined citrullinated epitopes (Cantaert, De Rycke et al. 2006). 
 
Chapter 1  Introduction 
38 
 
Clinical observations that anti-CCP antibodies can appear years before the onset of clinical symptoms 
(Rantapaa-Dahlqvist, de Jong et al. 2003; Nielen, van Schaardenburg et al. 2004), can be detected in 
up to 80% of RA patients (Vossenaar, Smeets et al. 2004) and are strong predictors of more aggressive 
disease course with more severe joint destruction (van Gaalen, Linn-Rasker et al. 2004) argue in 
favour of a pathogenic role for anti-CCP antibodies. Yet the mere presence of anti-CCP antibodies is 
not sufficient to cause arthritis and additional factors are likely to be required in order for anti-CCP 
antibodies to exert their pathogenic effect. Recently a link between smoking, the presence of shared-
epitope HLA-DRB1 alleles, and the development of anti-CCP positive RA was found in a Swedish 
cohort (Klareskog, Stolt et al. 2006) although the strength of this association was not reproduced in 
three North American RA cohorts (Lee, Irigoyen et al. 2007). 
 
1.4.4. The role of T cells in RA  
In addition to the association of RA with three genes - HLA-DRB1, PTPN22, and STAT4 - that have the 
potential to impact T cell biology through effects on T cell thymic selection, antigen-presentation, 
activation thresholds, as well as Th cell differentiation (Gregersen 2005; Vang, Congia et al. 2005; 
Rieck, Arechiga et al. 2007), there is additional evidence for the role of T cells in the pathogenesis of 
RA including the large number of T cells in the inflamed RA synovium, the role of T cells in 
experimental models of RA and the pathogenic effects of T cell-derived cytokines. 
 
1.4.4.1. Presence of T cells in synovial inflammatory infiltrate  
The inflamed RA synovium contains up to 35% of infiltrating T cells (Cope 2007). Although clinical 
trials with monoclonal antibodies to CD4, CD5, and CD52 failed to materialise as valid biologic agents 
to treat RA, despite substantial depletion of the targeted T cells in peripheral blood but maybe not in 
the synovium of affected joints (Moreland, Heck et al. 1997), the therapeutic success of abatacept, a 
CTLA-4-Ig fusion protein that blocks the CD28-mediated co-stimulation of T cells by antigen 
presenting cells (APCs), provides direct evidence for a role for T cells in ongoing RA synovial 
inflammation (Kremer, Westhovens et al. 2003; Genovese, Becker et al. 2005). 
 
1.4.4.2. Animal models 
Although most mouse models of arthritis are induced, such as collagen-induced arthritis or adjuvant-
induced arthritis, several models of spontaneous arthritis have recently been identified due to 
perturbations in the TCR and alterations of cytokine regulation (Lundy, Sarkar et al. 2007). In the SKG 
model, an intrinsic defect in TCR signalling can lead to T cell dependent arthritis in mice and adoptive 
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transfer of spleen or lymph node T cells leads to chronic arthritis in T and B cell deficient SCID mice 
(Sakaguchi, Takahashi et al. 2003).  
 
IL-1 receptor antagonist (IL-1Ra)-deficient mice spontaneously develop chronic inflammatory arthritis. 
Yet the disease fails to develop in the absence of mature T cells and transfer of IL-1Ra-deficient mice T 
cells into nude mice results in arthritis (Horai, Saijo et al. 2000; Horai, Nakajima et al. 2004). In 
another model of spontaneous arthritis, K/BxN mice expressing both the transgenic TCR KRN and the 
MHC class II molecule Ag7 develop severe inflammatory arthritis due to the recognition of the self-
antigen glucose-6-phosphate isomerase (GPI) and the consequent production of arthritogenic anti-
GPI IgGs by plasma cells (Ditzel 2004; Monach, Mathis et al. 2008). A crucial role for T cells was 
highlighted in the early development of this disease since administration of anti-CD4 antibodies 
before, but not during or after, the onset of arthritis blocks disease development (Maccioni, Zeder-
Lutz et al. 2002). Therefore these models emphasise that inflammatory arthritis can be generated by 
T cell auto-reactivity and that RA can be thought of as a T cell mediated-disease although 
participation of other arms of both the innate and adaptive immune systems are likely to be required. 
 
1.4.4.3. T cell-derived cytokines  
Synovial T cells, activated through engagement of their TCR, cytokine receptor or TLR, produce 
directly or via other cells, key cytokines that drive inflammation in RA (McInnes and Schett 2007). 
High concentrations of IL-1 and TNFα are detected in synovial fluid from RA patients (Saxne, Palladino 
et al. 1988; Chikanza, Kingsley et al. 1995). Both are potent inflammatory cytokines that can promote 
joint destruction by stimulating stromal cells, such as synovial fibroblasts, osteoclasts, and 
chondrocytes, through cell-surface signalling as well as through the release of soluble mediators such 
as IFNγ and IL-17 to secrete tissue-destroying MMPs (Shingu, Nagai et al. 1993).  
 
The success of anti-TNF therapies has highlighted the primary role of TNFα in the pathogenesis of RA 
through effects on cell activation, cellular adhesion and migration, as well as paracrine induction of 
other inflammatory cytokines (Nawroth, Bank et al. 1986; Haworth, Brennan et al. 1991; Butler, Maini 
et al. 1995).  
 
1.4.4.4. Th17 cells in RA 
Th17 cells have been found to express genes essential in the chronic inflammatory response 
(Langrish, Chen et al. 2005) and are strongly implicated in the pathogenesis of chronic inflammation. 
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As described earlier, Th17 differentiation in mice is orchestrated by RORγt and is initiated by IL-6 
acting in concert with TGFβ. This process is further enhanced by TNFα and IL-1β providing a 
mechanism whereby Th17 cells might differentiate and expand within the arthritic joint (Veldhoen, 
Hocking et al. 2006). IL-23 which as been shown to be important for Th17 survival and amplification 
(Aggarwal, Ghilardi et al. 2003) and also plays an important role in Th17-mediated tissue damage 
(Kolls and Linden 2004).  
 
IL-17, the signature inflammatory cytokine produced by Th17 cells, is capable of mediating many of 
the well-described mechanisms of synovial inflammation and joint damage in RA by acting on many 
cell types found in inflamed joints such as FLS, monocytes, macrophages, chondrocytes and 
osteoclasts (Lundy, Sarkar et al. 2007; Steinman 2007). Thus IL-17 can directly or indirectly induce a 
wide range of effector molecules including pro-inflammatory cytokines (e.g., IL-1β, IL-6, and TNFα), 
multiple chemokines, cyclooxygenase-2, prostaglandin E2, nitric oxide and MMPs known to be 
implicated in the different aspect of RA pathogenesis: inflammation, leukocyte recruitment, 
angiogenesis, osteoclastogenesis, bone resorption as well as cartilage and tissue destruction (Lundy, 
Sarkar et al. 2007; Imboden 2008).  
 
Therefore the cellular targets and effector functions of Th17 cells are consistent with the hypothesis 
that those cells have a key role in mediating synovitis and articular damage.  
 
Although it has been shown that IL-17 is both necessary and sufficient for joint inflammation in 
several murine models (Murphy, Langrish et al. 2003; Lubberts, Koenders et al. 2005; Hirota, 
Hashimoto et al. 2007), that IL-17 is over-expressed in RA synovial fluids and that IL-17 can be 
spontaneously produced from RA synovial membrane cultures (Kotake, Udagawa et al. 1999; Hwang 
and Kim 2005) further characterisation of human Th17 will be required to determine how relevant IL-
17 is to RA. Interestingly a recent two-year prospective study showed that levels of IL-17 expression in 
RA synovial membrane were predictive of future joint damage (Kirkham, Lassere et al. 2006). 
 
1.4.4.5. Regulatory T cells in RA 
CD4+CD25+ Treg cells were found to be enriched in RA patients and have increased suppressive 
activity in synovial fluid relative to peripheral blood (Cao, van Vollenhoven et al. 2004; van Amelsfort, 
Jacobs et al. 2004) raising the question as to why synovitis persists in the presence of functionally 
active regulatory T cells and suggesting that synovial effector T cells might have become resistant to 
suppression.  
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In RA, there remains some controversy regarding differences in numbers and/or functions of 
peripheral blood Treg cells (Cao, van Vollenhoven et al. 2004; van Amelsfort, Jacobs et al. 2004; 
Mottonen, Heikkinen et al. 2005). CD4+CD25hi nTreg cells isolated in the peripheral blood of patients 
with active RA appeared to be functionally abnormal since, although they were able to suppress the 
proliferation of CD4+CD25− effector T cells, they failed to inhibit production of TNFα and IFNγ by those 
same effector cells (Ehrenstein, Evans et al. 2004). In contrast, Valencia et al. (2006) observed that 
peripheral blood CD4+CD25hi Treg cells from RA patients expressed reduced levels of FoxP3 mRNA and 
protein and were not able to efficiently suppress either the proliferation of or cytokine production by 
conventional CD4+ Th cells. Importantly, they reported that TNFα, via signalling through TNF receptor 
2 which is constitutively expressed on non-stimulated Treg cells and up-regulated in the presence of 
TNF, inhibits the suppressive function of both nTreg cells and iTreg cells, and that anti-TNF therapy, 
such as infliximab, can restore their suppressive function (Valencia, Stephens et al. 2006). Thus, these 
results suggest a model in which high levels of TNFα within inflamed rheumatoid synovium limit the 
activity of Treg cells.  
 
1.5. The SKG mouse model of autoimmune inflammatory arthritis  
 
SKG mice spontaneously develop CD4+ T cell-mediated systemic inflammatory arthritis which 
resembles human RA in many respects (Sakaguchi, Takahashi et al. 2003). Clinically, the disease 
primarily affects the synovial membranes of multiple joints eventually leading to ankylosis of wrists 
and ankles, with more severe arthritis in females. Histologically, there is severe synovitis with massive 
infiltration of inflammatory cells, neovascularisation of the synovium and pannus formation 
eventually leading to the erosion of adjacent cartilage and bone. Serologically, the presence of high 
titres of rheumatoid factor (RF) and autoantibodies specific for type II collagen were reported, as well 
as high concentration of circulating immune complexes (Sakaguchi, Sakaguchi et al. 2006). 
Additionally the established phase of the disease is strongly driven by inflammatory cytokines. Thus, 
the synovial fluid of arthritic SKG contains high amounts of TNFα, IL-1 and IL-6 and disease 
progression and severity is significantly reduced or inhibited in TNFα, IL-1 or IL-6 deficient SKG mice 
(Hata, Sakaguchi et al. 2004) comparable to the effects of anti-cytokine therapy in human RA 
(Firestein 2003). Therefore the SKG mouse strain may be used as an autoimmune mouse model to 
study various aspects of the pathogenesis of human RA (Sakaguchi, Takahashi et al. 2003). 
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Homozygous SKG mice have two copies of a single base-pair substitution at nucleotide 489 in the 
gene encoding ZAP-70. Consequently codon 163, which codes for the first amino acid residue of the 
C-terminal SH2 domain of ZAP-70 (Hatada, Lu et al. 1995), is altered from tryptophan to cysteine.  
 
The ZAP-70W163C mutant is thought to bind poorly to ITAMS on CD3-ζ leading to attenuated antigen-
activated TCR signalling and subsequent impaired calcium mobilisation, reduced proliferation and IL-2 
production. SKG T cells are profoundly hyporesponsive to in vitro polyclonal TCR stimulation with 
anti-CD3 monoclonal antibodies (mAb) whereas they respond well to stimulation of TCR-distal 
pathways with phorbol ester and calcium ionophore (Sakaguchi, Takahashi et al. 2003.). 
 
Developing T cells undergo positive and negative selection in the thymus which is mediated by the 
strength of the TCR signalling to self-peptide presented by medullary APCs (Kappler, Roehm et al. 
1987). The SKG genetic anomaly is thought to alter the thymic selection of the T cell repertoire as 
reduced signalling through ZAP-70W163C may raise the threshold of TCR avidity required for each 
selection event and lead to a selection shift of the T cell repertoire towards higher self-reactivity, 
resulting in high affinity autoreactive T cells, including arthritogenic T cells, being able to escape the 
negative selection they would not normally survive in wild type ZAP-70 animals. Furthermore, the 
defective TCR signalling also attenuates positive selection leading to a reduced number of peripheral 
CD4+ and CD8+ T cells in SKG mice (Sakaguchi, Takahashi et al. 2003).  
 
Naïve autoreactive SKG CD4+ T cells spontaneously differentiate into arthritogenic IL-17-secreting 
CD4+ helper T cells, Th17, which are essential for the development of autoimmune arthritis (Hirota, 
Hashimoto et al. 2007). The pro-inflammatory cytokine IL-6 is required to drive the differentiation 
process whereby peripheral autoreactive CD4+ T cells become activated following recognition of 
MHC-self peptide complexes and stimulate APCs to secrete IL-6 which in turn, together with T cell-
derived IL-6, forms a cytokine milieu for the preferential differentiation into arthritogenic Th17 cells. 
Subsequently, Th17 cells secrete IL-17 which will recruit and activate other inflammatory cells (Kolls 
and Linden 2004). Both IL-17 and IL-6 are critical for the occurrence of SKG arthritis as neither IL-6-/- 
nor IL-17-/- mice develop the disease. 
 
The SKG genetic mutation, inherited in an autosomal recessive manner with almost 100% penetrance 
of the trait in homozygotes, is thought to be the primary cause of SKG arthritis since ZAP-70skg/- mice 
develop arthritis whereas ZAP-70skg/+ are protected (Sakaguchi, Takahashi et al. 2003). Autoimmune 
arthritis in SKG mice is mediated by CD4+ T cells since transfer of SKG spleen and lymph node T cells, 
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especially CD4+, induce severe arthritis in immunodeficient Balb/c nude mice or SCID mice whereas 
transfer of serum does not. Similar results were obtained from transfer of thymocyte suspensions. 
SKG T cell-depleted bone marrow cell suspensions produced severe arthritis in SCID recipients but not 
in thymectomised SCID mice, indicating that arthritogenic T cells are produced through the normal 
thymic environment and suggesting that the SKG arthritogenic abnormality is intrinsic to T cells 
(Sakaguchi, Takahashi et al. 2003). Finally the mutated ZAP-70 is also thought to impair the function 
of CD4+CD25+FoxP3+ nTreg cells and reduce their ability to control and inhibit autoimmune activity 
(Sakaguchi, Sakaguchi et al. 2006). 
 
It should be noted that ZAP-70W163C is not always sufficient for clinical manifestation of arthritis in SKG 
mice. When bred in a microbe-free environment, SKG mice do not develop spontaneous arthritis 
although they develop the disease with high incidence in a conventional environment, suggesting that 
certain microbes are able to activate the peripheral arthritogenic SKG T cells. Indeed stimulation of 
the innate immunity with a single injection of microbial products such as zymosan or β-glucans can 
induce arthritis in SKG mice whereas this triggers only transient synovitis in normal mice (Yoshitomi, 
Sakaguchi et al. 2005). Interestingly homeostatic proliferation following transfer of dormant 
arthritogenic SKG T cells, from non-arthritic SKG mice, into SCID mice is also enough to trigger their 
activation and expansion and produce arthritis, even in a microbe-free environment (Sakaguchi, 
Sakaguchi et al. 2006). This suggests that Th17 cells per se are not sufficient in this model for 
producing full clinical manifestation of the disease which needs to be precipitated by further 
activation of autoimmune Th17 cells via additional stimuli. 
 
Taken together, these findings illustrate that the SKG mutation is a useful model to explore how 
genetic and environmental factors contribute to the development of autoimmune inflammatory 
arthritis. More specifically, the SKG model illustrates that a genetic defect in TCR signalling can 
compromise T cell function and immunity mechanisms, and lead to chronic inflammation and joint 
destruction.  
 
1.6. Low-amplitude TCR signalling 
 
The integrity of TCR signalling, both in effector and regulatory T cells, plays a vital role in immune 
homeostasis through effects on thymic selection, T cell activation and differentiation, and recent data 
would support a model in which RA is be a disease of chronic low amplitude of TCR signalling, arising 
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through the combined effects of inherited factors such as PTPN22 polymorphism (Begovich, Carlton 
et al. 2004), the inflammatory environment and especially chronic exposure to inflammatory 
cytokines and oxidative stress, as well as accelerated immune senescence (Zhang, Gorman et al. 
2006). The majority of RA synovial T cells express phenotypic markers of antigen-experienced, 
terminally differentiated T cells with enhanced migratory capacity (Cope 2007). RA synovial T cells 
have a modest reduction in expression of CD3-ε and a more significant loss of expression of CD3-ζ 
when compared to peripheral blood T cells, and consequently are hyporesponsive to TCR ligation, 
proliferate poorly and have low levels of IL-2 in vitro (Thomas, McIlraith et al. 1992). In contrast, they 
retain the ability to mediate chronic inflammation through stimulation of B cell production of 
antibodies, secretion of IFNγ and IL-17 and activation of other inflammatory cells (Thomas, Turner et 
al. 2008).  
 
Therefore the SKG mouse model - whose TCR signalling is dramatically attenuated and peripheral 
CD4+ T cells exhibit a phenotype of antigen-experienced, post-activated cells with reduced 
proliferative ability - provides a unique opportunity to study in vivo the effects of TCR signalling 
thresholds on disease progression and more specifically to determine whether manipulating TCR 
signals offers a realistic therapeutic approach to restoring immune homeostasis in an arthritis prone 
individual.  
 
The relationship between TCR signalling defects and autoimmunity is complex and multi-factorial as 
illustrated by recent studies carried out in the Goodnow laboratory which revealed how ZAP-70-
mediated quantitative differences in T cell signalling may influence T cell development and function 
and ultimately the outcome of immune responses (Siggs, Miosge et al. 2007). Using an N-ethyl-N-
nitrosourea (ENU) mutagenesis approach, they compared the immune perturbations caused in mice 
by an allelic series derived from two distinct ZAP-70 mutations (mrd and mrt) which impose step-wise 
decreases in TCR signalling.  These mutant mouse models revealed that distinct immunological 
phenotypes arise as a consequence of subtle changes in thresholds of TCR signalling. For instance 
different quantitative changes in TCR signals compromised thymic deletion, regulatory and effector T 
cell formation and function, and induced lymphopenia to variable degrees resulting in pathologies 
differing in severity from mild immunodeficiency, to autoimmunity, to profound immune deficiency. 
The impact of the defective signal, and how compromised it is, is therefore context dependent as it 
will affect T cell subsets and processes differently, and consequently create a cellular imbalance 
between the opposing functions of immunity and tolerance (figure 1.9).  
 





Figure 1.9 – Graded TCR signalling defects in ZAP70 mutant mice. A hypomorphic ZAP-70 allelic series, which confers 
quantitative changes in TCR signal strength, differentially influenced regulatory and effector T cell development and functions, 
and eventually outcomes of immune responses. Therefore, mutations compromising ZAP-70 function, and by extension the 
entire TCR pathway, can lead to paradoxical outcomes such as immunodeficiency or autoimmunity, and sometimes both. 
 
In this context, the SKG model and the proposed reconstitution of TCR signalling in defective T cells, 
enables us to further explore how genetic variations in TCR function affect the susceptibility to 
autoimmunity by breaking down how intrinsic T cell functions are affected by such mutations, and 
thus better clarifying the paradoxical fact that T cells with low TCR signalling capacity can 
nevertheless initiate and maintain autoimmune inflammation in arthritis. 
 
1.7. Aims of the study 
 
RA is a chronic inflammatory disorder with features of autoimmunity whose exact aetiology remains 
unknown although interactions between genetic factors, sex hormones and environmental factors 
are thought to play a role. Recent data support the view that RA is a disease characterised by 
aberrant adaptive immune responses, imposed in part via defective signalling through antigen TCRs 
(Mirza, Relias et al. 1993; Fulop, Larbi et al. 2003; Vang, Congia et al. 2005; Thomas, Turner et al. 
2008).   
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As discussed above, SKG mice carry a mutation in the protein tyrosine kinase ZAP-70, leading to 
attenuated TCR signalling and activation, and develop an autoimmune inflammatory arthritis 
resembling human RA, mediated by T cells. 
 
Hypothesis and aims 
The main hypothesis to be addressed is that sub-optimal TCR signalling results in loss of immune 
homeostasis and the development of arthritis, possibly through effects on cell survival, 
differentiation, migration and/or immune regulation, and that reconstitution of TCR signalling in 
arthritogenic SKG T cells will restore immune homeostasis which in turn will suppress the disease 
process.  
 
More specifically, the aims are to: 
 Explore how defective TCR signals contribute to autoimmune arthritis in the SKG mouse model. 
 Specifically test the hypothesis that the integrity of TCR signalling in CD4+ T cells plays a vital role 
in immune homeostasis through effects on T cell activation and differentiation, and immune 
regulation in peripheral T cells.  
 Determine whether manipulating TCR signals in vivo is a valid therapeutic approach. 
 
Experimental approach 
The mechanism through which defective TCR signalling in SKG T cells favours the generation of 
arthritogenic T cells and contributes to disease was investigated using two complimentary 
approaches.  
The first approach was to establish a system, using virus-mediated gene transfer protocols, for the 
stable integration of the murine wild-type ZAP-70 into SKG mutant T cells thereby restoring the 
integrity of TCR signalling within these cells. Then, investigate the contribution of defective TCR 
signals on the development of autoimmune arthritis in vivo, via transfer of reconstituted SKG T cells 
into SCID recipient mice to assess whether inflammatory arthritis develops in vivo and whether the 
disease is clinically, histologically and serologically different from the disease observed when 
transferring un-manipulated arthritogenic SKG T cells.  
 
The second approach was to compare the pathways of Th differentiation between BALB/c and SKG 
naïve CD4+ T cells. More specifically, I set out to highlight any differences in patterns of cytokines 
produced by wild-type BALB/c and SKG T cells when stimulated with antigenic peptide in a cytokine-
neutral milieu which might directly or indirectly be due to the ZAP-70 variant and explain the skewing 
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towards Th17 cells in SKG animals. I then tested the effects of reconstituting in vitro the defects in 
cytokine expression observed during differentiation of SKG T cells, in an attempt to restore the wild-
type phenotype.  
 
  






















All viral and cloning work was carried out at the Bone and Joint Research Unit (Queen Mary, London, 
UK). All in vitro cell-based and in vivo animal-based work was carried out at the Kennedy Institute of 
Rheumatology (Imperial College, London, UK). 
 
2.1.1. Antibodies 
2.1.1.1. Antibodies for Western blotting 
Antigen specificity Clone Concentration Source 
Primary    
ZAP-70 1E7.2 1:1000 eBioscience 
eGFP 7.1 and 13.2 1:1000 Roche 
V5-tag - 1:5000 Invitrogen 
STAT5 - 1:1000 Cell signalling 
Phospho-STAT5 C11C5 1:1000 Cell signalling 
Secondary (HRP-conjugated)    
Goat anti-mouse IgG  1:5000 Santa-Cruz 
Donkey anti-rabbit IgG  1:5000 GE healthcare 
 
2.1.1.2. Antibodies for Flow Cytometry 
Antigen specificity 
(mouse) 
Conjugates Clone Isotype Dilution Source 
Cell-surface      
CD62L PE Mel-14 IgG2a 1:100 BD Biosciences 
CD3e FITC 145-2C11 IgG 1:100 eBioscience 
CD4 
PE, FITC GK 1.5 IgG2b 1:100 eBioscience 
PeCy7, APC RM 4.5 IgG2a 1:100 eBioscience 
Intra-cellular      
FoxP3 PE FJK-16s IgG2a 1:100 eBioscience 
TNF 
PE TN3-19 IgG1 1:100 BD Biosciences 
APC MP6-XT22 IgG1 1:100 eBioscience 
IL-4 APC 11B11 IgG1 1:100 eBioscience 
IL-10 APC, FITC JESS-16E3 IgG2b 1:100 eBioscience 
IL-17 
PE TC11-18H10 IgG1 1:100 BD Biosciences 
FITC eBio17B7 IgG2a 1:100 eBioscience 
IFN-γ PE, APC XMG1.2 IgG1 1:100 eBioscience 
Chapter 2  Material and methods 
50 
 
V5-tag AF647 - IgG2a 1:100 AbD Serotec 
Isotype controls      
IgG1 PE, APC -  1:100 eBioscience 
IgG2a 
AF647 -  1:100 AbD Serotec 
FITC, PE, 
PeCy7, APC 
-  1:100 eBioscience 
IgG2b PE, FITC, APC -  1:100 eBioscience 
FcR block      
CD16/CD32  2.4G2  0.5 µg BD Biosciences 
Mouse serum    1 μl/10
6
 cells Abcam 
 
2.1.1.3. Antibodies for cell culture 
Antigen specificity Clone Concentration Source 
Mouse CD3e 145-2C11 0.5 – 10 µg/ml eBioscience 
Mouse CD28 37.51 0.5 – 10 µg/ml eBioscience 
Mouse IL-4 (neutralising) 11B11 10 µg/ml BD Biosciences 
 
2.1.2. Recombinant proteins 
Cytokine Use Concentration Source 
Murine IL-2  Cell culture 1 – 100 U/ml Peprotech 
Murine IFNγ  Cell culture 1 – 50 ng/ml Peprotech 
Murine IL-4  Cell culture 1 – 50 ng/ml Peprotech 
Murine IL-7  Cell culture 10 ng/ml Peprotech 
Human IL-2 (Proleukin) i.p. injections 25,000 U Prometheus 
 
2.1.3. Peptides 
Peptide Source Use Concentration 
Hemagglutinin peptide (HA 126-138) Imperial College Cell culture 0.1-50 µg/ml 
Ovalbumin peptide (OVA 323-339) Imperial College Cell culture 50 µg/ml 
 
2.1.4. PCR primers 
Primer Sequence (5’  3’) Comments 
ΔNGFR   




NGFR truncated at aa 248, with 
3’-NotI 
ZAP70   
5mZAP70_BamHI CATGAGGATCCATGCCCGATCCCGCGGCGCACCTGC ZAP7-0 with 5’-BamHI 
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3mZAP70_BstBI CATGATTCGAAGCCACATGCAGCCTCGGCCAC PCR of ZAP-70 with 3’-BstBI 
3mZAP70_SpeI CATGAACTAGTCAGCCACATGCAGCCTCGGCCAC PCR of ZAP-70 with 3’-SpeI 
 
2.1.5. RT-PCR primers 
Gene Primer ABI code  
Tbx21 Mm01299453_m1 Murine gene for transcription factor T-bet 
GATA3 Mm01337569_m1 Murine gene for transcription factor GATA3 
RORc Mm01261022_m1 Murine gene for transcription factor RORγt 
FoxP3 Mm00475165_m1 Murine gene for transcription factor FoxP3 
Hprt1 Mm00446968_m1 Murine housekeeping gene 
 
2.1.6. Cell lines  
Cell line Progenitor cell line 
HEK 293T cells Human embryonic kidney 
NIH 3T3 Murine fibroblast 
Phoenix-Eco cells Virus packaging cell line (transformed HEK 293T cells) 
PT67  Virus packaging cell line (transformed NIH 3T3 cells) 
 
2.1.7. Tissue culture medium and reagents 
Roswell Park Memorial Institute (RPMI) containing 25 mM L-glutamine, Dulbecco’s Modified Eagle’s 
Media (DMEM) with glucose and L-glutamine, Penicillin-Streptomycin mixture containing 10,000 units 
(U)/ml penicillin and 10,000 mg/ml of streptomycin (Pen-strep), 2-mercaptoethanol (2-ME), sodium 
pyruvate, trypsin-EDTA were purchased from Biowhittaker, Belgium.  Heat inactivated foetal calf 
serum (FCS) was purchased from PAA, UK and BioWest/ Labtech, UK.  
 
Primary T cell  
culture medium 
RPMI 1640 containing: 
1 % (v/v) heat inactivated FCS 
100 U/ml penicillin 
100 µg/ml streptomycin 
1 mM sodium pyruvate  
50 µM 2-ME 
Cell line  
culture medium 
DMEM containing: 
10% (v/v) FCS 
100 U/ml penicillin 
100 µg/ml streptomycin 
 





300 µg/ml Hygromycin B (Sigma-Aldrich, UK) 
1 µg/ml Diptheria toxin (Sigma-Aldrich, UK) 
PT67 cells 
re-selection reagents 
100 nM Amethopterin (Sigma-Aldrich, UK) 
30 mM Hypoxanthine (Sigma-Aldrich, UK) 
20 mM Thymidine (Sigma-Aldrich, UK) 
 
2.1.8. Molecular biology reagents 
Reagent  Source 
Electrophoresis grade agarose 1% w/v Invitrogen, UK 
Ethidium Bromide 0.5 µg/ml Sigma-Aldrich, UK 
All restriction enzymes 
Except: AarI 
 
New England Biolabs, USA 
Fermentas, Germany 
DNA T4 ligase  New England Biolabs, USA 
Platinum Pfx DNA polymerase  Invitrogen. UK 
LB Agar 15 g/L Invitrogen, UK 
LB Broth 25 g/L Invitrogen, UK 




2.1.9.1. General buffers 
 Phosphate-buffered saline (PBS) 
4.3 mM Na2HPO4 
1.4 mM KH2CO3 
1.4 mM KCl 
137 mM NaCl 
pH 7.0 
Tris-buffered saline (TBS) 
20 mM Tris-HCL 
137 mM NaCl 
pH 7.6 
0.5x Tris-acetate-EDTA (TAE) buffer 
0.02 M Tris-acetate 
0.5 mM EDTA 
pH 8.0 
Coating buffer 
0.2 M Na2CO3 
0.2 M NaHCO3 
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2.1.9.2. Flow cytometry buffers 
FACS wash buffer 
PBS containing: 
2% (w/v) bovine serum albumin (BSA) 
0.02% (v/v) sodium azide 
FACS fixing buffer 
PBS containing: 
2% (v/v) formaldehyde 
0.02% (v/v) sodium azide 




2.1.9.3. SDS-PAGE and immunoblotting buffers 
Running buffer 
25 mM Tris 
200 mM glycine 
0.1% (w/v) SDS 
4x Reducing sample buffer  
(Laemmli buffer) 
250 mM Tris-Cl, pH 6.8 
40% (v/v) glycerol 
0.05% (w/v) bromophenol blue 
50 mM  DTT 
8% (w/v) SDS 
Transfer buffer 
25 mM Tris 
150 mM glycine 








5% Marvel dried skimmed milk 
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2.1.9.4. Protein lysis buffer 
Whole cell lysis buffer 
50 mM Tris-HCl, ph 7.5 
150 mM NaCl 
0.10% (v/v) NP-40 
1 µl/10
6
 cells protease inhibitor cocktail (Sigma-Aldrich, UK) 
If required, add phosphatase inhibitors: 
1 mM Na3VO4 
50 mM NaF 
1 µl microcystine 
10 mM β-glycerophosphate 
 
2.1.9.5. Cell sorting buffers 






0.1% (w/v) BSA 
2 mM (v/v) EDTA 






0.5% (w/v) BSA 
2 mM (v/v) EDTA 
 
2.1.9.6. Calcium-phosphate transfection buffer 
2x HEPES-buffered saline (HBS) 
280 mM NaCl 
10 mM KCl 
1.5 mM Na2HPO4 
12 mM Dextrose 
50 mM HEPES 
pH 7.05 
 
2.2. Cell culture 
 
Unless otherwise indicated, cell culture plates and components were purchased from BD Biosciences 
Discovery Labware, UK. 
 
2.2.1. Cell line culture 
Cell lines, described in section 2.1.4, and murine primary cells were cultured in the appropriate 
medium (section 2.1.5) at 37°C in a humidified incubator with 5% CO2.  
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Adherent cells were split when >60-70% confluent by briefly washing the cells with sterile PBS, 
followed by brief incubation with trypsin-EDTA mixture. Cells were then re-suspended in DMEM 
complete culture media and sub-cultured into new tissue culture plates or flasks.  
Cells for cryopreservation were re-suspended in 10% dimethylsulfoxide (DMSO) at a cell density of 1-5 
x 106/ml in cryovials. Aliquots were frozen slowly to -70°C then transferred to liquid nitrogen for long-
term storage. Cells were thawed quickly and the DMSO removed by washing the cells in DMEM 
complete culture medium. 
 
2.2.2. Primary murine cells 
2.2.2.1. Isolation of cells from lymphoid organs 
Excised spleens or lymph nodes (mandibular, axilliary, brachial, inguinal, popliteal and mesenteric 
were routinely collected) were kept in serum-free RPMI media on ice until processed.  Cells were 
passed through a 70 μm nylon cell strainer using a sterile 2 ml syringe plunger. The strained cells were 
transferred into a 50 ml Falcon with serum-free media, before centrifugation (1,500 rpm, 5 min, 4°C).  
For splenocytes only, re-suspended cells were incubated in 1 ml/spleen of Red Cell Lysis Buffer 
(Sigma-Aldrich, UK) and left at room temperature (RT) for 5 min, before being passed through a 
strainer into a 50 ml Falcon with serum-free medium and pelleted by centrifugation. Cells, both from 
spleens and lymph nodes, were washed in serum-free medium and re-suspended in a small amount 
of complete medium and counted for future steps.  
 
2.2.2.2. Negative selection of CD4+ T cells  
Negative selection was performed using Dynal mouse CD4 negative isolation kit according to 
manufacturer’s instructions (Invitrogen, UK). Briefly, cells harvested from lymphoid organs were re-
suspended at 107 cells/100 µl in Dynabeads separation buffer. A mixture of monoclonal antibodies 
against the non-CD4+ T cells was added to the cells and left to incubate for 20 min at 4°C. Cells were 
washed with separation buffer, centrifuged (300 g, 8 min, 4°C) and re-suspended in separation buffer. 
Mouse depletion dynabeads were added to the cells and incubated for 15 min at RT with gentle tilting 
and rotation. Bead-bound cells were re-suspended and placed in a magnet for 2 min. The 
supernatant, which contained the negatively-isolated mouse CD4+ T cells, was transferred to a new 
tube.  
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2.2.2.3. Selection of naïve CD4+CD62L+ T cells 
Naïve CD4+ T cells were selected using the MACS CD4+CD62L+ T cell isolation kit II according to 
manufacturer’s instructions (Miltenyi Biotec, Germany). For isolation of CD4+CD62L+ Th cells, the non-
Th cells as well as Treg cells were depleted by indirect magnetic labelling using a cocktail of lineage-
specific biotin-conjugated antibodies, as well as antibodies against CD25 and TCRγδ in combination 
with anti-biotin microbeads. Subsequently, CD4+CD62L+ T cells were positively selected from the 
enriched CD4+ Th cells fraction with CD62L (L-selectin) microbeads.  
 
Briefly, cells harvested from lymphoid organs were re-suspended at 108 cells/400 µl in MACS 
separation buffer. CD4+ T cell biotin-antibody cocktail was added to the cells and left to incubate for 
10 min at 4°C. Anti-biotin microbeads were added and left to incubate for 15 min at 4°C. Cells were 
washed with separation buffer and centrifuged (300 g, 10 min, 4°C) before being transferred to a LS 
column placed in a magnetic field. Unlabelled C4+ T cells were washed through the column three 
times and collected in a falcon tube. Those cells were then labelled with anti-CD62L-coated 
microbeads, incubated for 15 min at 4°C, washed and positively selected though a MS column placed 
in a magnetic field. The labelled cell fraction was flushed with separation buffer from the MS column 
into a new falcon tube. The cell population purity was validated by flow cytometry (figure 2.1).  
 
 
Figure 2.1 – Flow cytometry assessment of naïve CD4+CD62L+ T cell purity. Cells harvested from lymph nodes were 
assessed for the expression of CD4 and CD62L pre-selection and post-selection. The target population of naïve 
CD4+CD62L+ T cells was enriched from 44% in the starting population to 97.8% in the final selected population, with only 
minimal loss in the intermediate step.  
  
2.2.2.4. Mitomycin C treatment of APCs 
Mitomycin C inhibits DNA synthesis by forming covalent cross-links between the complementary 
strands of DNA. For the differentiation and cytokine production assays, APCs were treated with 
Mitomycin C (Sigma-Aldrich, USA). 107 APCs were treated with 500 µl Mitomycin C at 25 µg/ml for 30 
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min at 37°C. Cells were then washed four times with complete culture medium. The inhibition of 
cytokine production by APCs was controlled with CBA assay (figure 2.2) 
 
       
Figure 2.2 – Cytokine production by Mitomycin C-treated APCs. APCs treated with mitomycin C only produced minimal 
amounts of IL-17 and IL-4 when compared to BALB/c and SKG T cells post-TCR stimulation. Cytokine production is assessed 
by CBA assay (section 2.6.3)  
 
2.3. Immunoblotting  
 
2.3.1. Preparation of whole cell lysates 
Cells (1-5 x 106) were gently washed in ice-cold PBS (or TBS when working with phospho-proteins), 
centrifuged, re-suspended in whole cell lysis buffer and kept on ice for at least 30 minutes. Protease 
and phosphatase inhibitors, when required, were added to the buffer just prior to the lysis. Lysed 
cells were then centrifuged (13,000 rpm, 15 min, 4°C) to clear the lysate of any cell debris. 
 
2.3.2. Protein concentration estimation  
Cell lysates were assessed for protein content with a BCA protein assay kit (Thermo scientific, USA). 
Briefly, 25 µl of samples were transferred to a p96 microtitre plate in duplicate, along with 25 µl of a 
serial dilution of BSA concentration ranging from 2 mg/ml to 25 µg/ml and dH2O blanks. The BCA 
solutions were mixed in a 50:1 ratio of reagents A:B and 200 µl added to each well. The samples were 
then incubated for 1h at 37°C and the absorbance measured at 620 nM on a Multiskan Biochromatic 
plate reader using Ascent software (Thermo scientific, USA).  
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2.3.3. SDS-PAGE and protein transfer 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) allows the separation of 
proteins by their individual molecular weights. SDS is a molecule that coats the denatured protein in a 
uniform charge, thus negating the individual charges that would alter the electrophoretic mobility of 
the protein.  
 
Lysate samples, containing 10-20 μg protein, were combined with 4x reducing Laemmli buffer and 
boiled for 5 min to denature proteins. Proteins were resolved on 10% (or other appropriate gradient) 
polyacrylamide gels at 200 V for 1h in running buffer. A sample (10 µl) of a 10-250 kDa Precision Plus 
protein ladder was run alongside the samples.  
 
Gels of SDS-PAGE separated proteins were transferred onto polyvinylidene fluoride (PVDF) 
membranes cut to size and hydrated in methanol before being equilibrated in transfer buffer. The 
transfer was carried out by electro-blotting at 30 V for at least 1h in transfer buffer.  
 
2.3.4. Western blotting 
Western blotting allows the identification and semi-quantification of specific proteins by labelling 
with primary antibodies and enzyme-linked secondary antibodies.  
 
After 1h incubation in blocking buffer at RT, the membranes were incubated overnight at 4°C with 
specific primary antibodies (section 2.1.1.1) diluted in blocking solution. Membranes were washed 4 
times for 20 min in washing buffer before incubation for 60 min with peroxidase-conjugated 
secondary antibodies diluted in blocking solution. Membranes were washed as before and the 
protein of interest was detected with the enhanced chemiluminescence (ECL) technique (GE 
Healthcare, UK). Membranes were exposed to autoradiography films for different periods of time, 
depending on signal intensity, and films were developed using an Agfa Curix 60 processor (Agfa-
Gevaert, Belgium).  
 
2.3.5. Re-probing of membranes 
In cases when membranes were required for multiple protein detections, the membrane was stripped 
of antibodies with Re-Blot Plus (Millipore, USA) for a minimum of 15 min and re-blocked as described 
in 2.3.4. 
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2.4. Molecular biology techniques 
 
2.4.1. RNA isolation 
Total RNA was isolated from cells using the QIAamp RNA isolation kit following the manufacturer’s 
protocol (Qiagen, UK). Briefly, cells were lysed in the provided buffer and further homogenised by use 
of shredder columns provided. Homogenised cell lysates were then applied to a second column to 
which the total RNA was bound and impurities washed away. Total RNA was then eluted and re-
suspended in RNase-free water. 
2.4.2. Reverse transcription of total RNA to cDNA 
Reverse transcription of total single-stranded RNA into complementary DNA (cDNA) was performed 
using an ABI High Capacity Kit according to the manufacturer’s instructions (Applied Biosystems, UK). 
The 2x master mix for each reaction contained: 
 
Reagent Volume (µl) 
10x RT buffer 4.0 
25x dNTP mix (100 mM) 1.6 
10x RT random primers 4 
MultiScribe Reverse transcriptase 2 
RNase inhibitor 2 
Nuclease-free water 6.4 
 
The total reaction volume was 20 μl of 2x master mix with an equal volume of RNA template. The 
reaction was then reverse transcribed using a thermal cycler with the following programme: 
 
Step Temp (°C)  Time (min) 
1 25 10 
2 37 120 
3 85 5 
4 4 ∞ 
 
The cDNA was diluted to 100 μl with nuclease-free H2O prior to real-time PCR. 
 
2.4.3. Polymerase chain reaction (PCR) 
The genes of interest, necessary for cloning into viral vectors, were amplified by PCR. For ZAP-70, the 
RNA was extracted from BALB/c and SKG splenocytes. The modified ΔNGFR coding sequenced was 
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amplified from murine brain DNA kindly provided by Dr Alexander Annenkov (Bone and Joint 
Research Unit, Queen Mary, London, UK). PCR primers (described in section 2.1.3) were designed for 
ZAP-70 to create a 5’_BamHI site and either a BstBI or SpeI restriction site at the 3’ end. NGFR primers 
were designed to add a 5’_BspHI restriction site and to truncate the intra-cytoplasmic tail from 
residue 248 and add a NotI site. PCR reactions were carried out with the following PCR mix: 
 
Reagent PCR mix 
Template DNA 200 ng 
Forward/reverse primer 0.3 µM each 
Platinum Pfx DNA polymerase 2 units 
10x Pfx amplification buffer 1x 
dNTPs 0.3 mM each 
MgSO4 
1.5 mM (NGFR) 
1 mM (ZAP-70) 
dH2O Complete to 100 µl  
 
Samples (25 µl) were subjected to an initial denaturation step followed by 40 amplification cycles 
using a Peltier Technology Thermal Cycler (PTC-200, MJ Research Inc.):  
 
Step  Temp (°C)  Time 
1 Denature template 94 2 min 
2 Denature 94 15 sec 
3 Anneal 
63 (NGFR) 
68 (ZAP-70)  
30 sec 
4 Extend 68 1 min 
5 Go to step 2  x39 
6 Fill gaps 68 10 min 
7 Store 10 ∞ 
 
2.4.4. Assessment of DNA on agarose gels and DNA purification 
Amplification of the correct size fragment was assessed by agarose gel electrophoresis. Thus, PCR 
products, as well as plasmid DNA, were mixed with appropriate volume of 6x bromophenol blue 
loading dye (0.25% bromophenol blue, 0.25% xylene cyanol, 30% v/v glycerol in TAE buffer). DNA was 
separated on a 1% agarose gel with 0.5x TAE buffer  at 100 V. Ethidium bromide (0.5 μg/ml) was 
incorporated in the agarose gel to visualise DNA under ultraviolet light. The DNA products were then 
excised from the gel by cutting the agarose matrix, and further purified using the Qiaquick Gel 
Extraction Kit following manufacturer’s instructions (Quiagen, UK). Briefly, the gel fragment was 
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dissolved in high salt buffer, which allows DNA binding to the silica membrane of the Qiaquick 
column. DNA was then eluted with low-salt buffer, or with water. Purified DNA products were verified 
by DNA sequencing analysis (Genome Center, Queen Mary, London, UK). 
 
2.4.5. Quantitative PCR 
Quantitative PCR (qPCR), also called real-time PCR, enables to monitor the progress of the PCR as it 
occurs since data is therefore collected throughout the PCR process, rather than at the end of the 
PCR. In qPCR, the reactions are characterised by the point in time during cycling when amplification of 
a target gene is first detected rather than the amount of target accumulated after a fixed number of 
cycles. The higher the starting copy number of the nucleic acid target, the sooner a significant 
increase in fluorescence is observed. qPCR reactions were carried out using ABI Taqman fluorogenic 





cDNA template 2.4 
FAST qPCR Mastermix 3 
Taqman probe 0.3 
dH20 0.3 
 
PCR was performed using a two-step amplification method as detailed here, and performed on a 
Corbett Lifesciences Rotorgene 6000 thermocycler (Corbett Lifesciences, Sydney) or ABI AB7900HT 
384 platform system (Applied Biosystems):  
 
Step Temp (°C)  Time 
1 95 10 min 
2 95 2 sec 
3 60 20 sec 
4 Go to step 1 x44 
 
The concentration of each target gene was calculated using the comparative Ct method and 
expressed as relative units using a naïve/non-treated sample as a calibrator (arbitrary unit 1). To 
control for variations in the absolute quantity of cDNA input, the Ct values of both the calibrator and 
the samples of interest were normalised to the level of an endogenous housekeeping gene, in this 
case Hprt1, which is assumed to remain at constant levels between samples.  
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2.4.6. Cloning of bi-cistronic constructs 
All DNA restriction enzymes were purchased from New England Biolabs Inc. (Hitchin, UK) unless 
otherwise stated. All DNA constructs were sequenced at the Genome Centre, Queen Mary (London, 
UK). 
 
The self-inactivating lentiviral vector pHR’SIN.cPPT-SEW was kindly provided by Dr Y. Ikeda (Mayo 
Clinic, Rochester, MN, USA). I first cloned bi-cistronic constructs - containing a primary gene (wild-
type or SKG ZAP-70) and a secondary gene (eGFP or ΔNGFR) downstream of an IRES sequence, and 
sub-cloned those constructs into the pHR’SIN.cPPT-SEW lentiviral vector.  
 
In the second phase of the project, the bi-cistronic constructs were sub-cloned in murine Moloney 
leukaemia virus vector MFG, kindly provided by Dr Alexander Annenkov (Bone and Joint research 
Unit, Queen Mary, London, UK). 
 
2.4.6.1. Digestion and Ligation of DNA 
Following amplification of the genes of interest by PCR (section 2.5.3.), DNA products and plasmid 
vectors were digested with the appropriate restriction enzymes, and separated on 1% agarose gels 
and purified (section 2.4.4). The DNA fragment to be inserted was added in molar excess (5 to 10 
folds) to vector DNA and ligated at 16°C overnight with T4 DNA ligase (200 units per reaction) in a 
final volume of 10 μl. 
 
2.4.6.2. Preparation of competent DH5α E.coli cells 
Fresh DH5α E.coli cells were made competent for uptake of plasmid DNA by a calcium chloride 
protocol. DH5α E.coli cells were grown overnight in 5 ml Luria Bertani medium (1% bactotryptone, 
0.5% bactoyeast extract, 0.17 M NaCl, pH 7.4) at 37°C with shaking. This starter culture was 
transferred to 500 ml of pre-warmed lysogeny broth (LB) medium and grown at 37°C with shaking 
until the optical density (OD) read at 600 nm reached values between 0.4 and 0.6. The bacteria 
culture was pelleted by centrifugation (4,000 g, 10 min, 4°C) and re-suspended in 50 ml of freshly 
made ice-cold 0.1 M MgCl2. Cells were sedimented again by centrifugation (1,500 g, 10 min, 4°C), and 
re-suspended in 50 ml of ice-cold 0.1 M CaCl2 and incubated on ice for 20 min. A final centrifugation 
step (15,000 g, 10 min, 4°C) was performed. Cells were re-suspended in 12.5 ml of ice-cold 0.1 M 
CaCl2 with 14% glycerol. Competent cells were aliquoted into Eppendorf tubes and snap-frozen in 
liquid nitrogen before storing at -70°C until future use. 
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2.4.6.3. Transformation of E.coli 
50 μl of competent DH5α E.coli cells and 3 μl of ligation reaction were incubated on ice for 30 min, 
heat-shocked for 2 min at 42°C, then grown in 5 ml LB medium at 37°C  for 60 min with shaking, to 
allow recovery and plasmid gene expression. 200 µl of these cultures were plated onto LB Agar plates 
(1.5% w/v bactoagar) with ampicillin (100 µg/ml) and grown overnight at 37°C. Individual clones were 
picked and grown in 5 ml LB with ampicillin (100 μg/ml) at 37°C overnight with vigorous shaking.  
 
2.4.6.4. Purification of Plasmid DNA 
Bacterial cells were sedimented by centrifugation (11,000 g, 1 min, RT) and DNA was purified using 
the PureLink HiPure Plasmid Miniprep Kit following manufacturer’s instructions (Invitrogen, UK). The 
protocol is based on anion-exchange chromatography. Briefly, bacterial cells were re-suspended in 
the presence of RNase and lysed under high alkaline conditions to solubilise the cell membrane. Cells 
lysate was passed through a pre-packed anion exchange column and the negatively charged 
phosphates on the DNA backbone interacted with the positive charges on the surface of the resin. 
RNA, proteins, carbohydrates and other impurities were washed away under moderate salt 
conditions, before elution of the plasmid DNA under high salt conditions.  
 
A restriction analysis digest was carried out on each clone to verify the presence of the correct insert. 
Appropriate clones were picked (1 ml of the 5 ml culture) for large-scale culture grown in 500 ml LB 
with ampicillin (100 µg/ml). DNA was purified using the PureLinK HiPure Plasmid Maxiprep Kit 
following manufacturer’s instructions (Invitrogen, UK). Plasmid DNA concentration was determined 
with Pharmacia GeneQuant spectrophotometer (Cambridge, UK) at 260nm. Correct cloning was 
confirmed by sequencing analysis. 
 
2.4.6.5. Transient expression of protein 
To verify that the bi-cistronic constructs cloned in viral vectors were functional, HEK 293T cells were 
transfected by calcium phosphate DNA co-precipitation (Chen and Okayama 1988) to transiently 
express the primary and secondary genes contained in the viral vector. Cells were seeded (2.5 x 106 / 
10 cm plate) the day before to achieve 60-80% confluence on the day of transfection. One hour 
before transfection, 25 µg/ml chloroquine (Sigma-Aldrich, UK) was added to each plate. The 
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Per 10 cm plate Volume / concentration 
2x HBS 500 µl 
DNA plasmid 20 µg DNA 
2.5 M CaCl2 50 µl 
dH2O Complete to 1 ml 
 
The CaCl2 was added last to the transfection mix and very gradually with constant gentle shaking. The 
precipitation mix was left at RT for 20 min. The transfection mix was then added gradually to the cells 
and incubated at 37°C for 6h before replacing the chloroquine-containing medium with fresh DMEM 
complete medium. Cells were collected 2-4 days post-transfection for assessment of protein 
expression, either via flow cytometry (section 2.6.) or Western blotting (section 2.3.) 
2.5. In vitro assays 
2.5.1. Proliferation assay 
For analysis of T cell proliferative response, cells were harvested from BALB/c and SKG spleen and 
lymph nodes and cultured (105 cells/well) in triplicate and stimulated for 72h with 50 μg/ml OVA, 100 
ng/ml anti-CD3, 1 μg/ml Con A or 5-fold serial dilutions of HA from 50 μg/ml. On day 2, all cultures 
were pulsed with 0.5 μCi/well of *3H]thymidine for the last 16h, and the cells were then harvested 
and counted by standard liquid scintillation (count per minute, CPM) in a MicroBeta Jet plate reader 
(PerkinElmer, UK). 
 
2.5.2. CFSE assay 
Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a cell-tracing fluorescent dye used to 
examine the proliferative capacity of cells by the labelling of a parent generation and the inheritance 
of the label by daughter generations. CFSE, which passively diffuses into cells, is colourless and non-
fluorescent until its acetate groups are cleaved by intra-cellular esterases to yield a highly fluorescent 
derivative that is retained in the cell and can be detected by flow cytometry. Cell division results in 
sequential halving of fluorescence and up to eight divisions can be monitored before the fluorescence 
is decreased to the background fluorescence of unstained cells.  
T cell division was analysed using a Cell Trace CFSE cell proliferation kit (Molecular Probes, USA). 
Briefly, cells were harvested from BALB/c and SKG lymph nodes and CD4+ T cells were negatively 
selected from the whole population (section 2.2.2.2.). CD4+ T cells (107/ml) were stained with 5 µM 
CFSE for 10 min at RT in the dark. Excess dye was quenched with ice-cold complete culture medium 
and left to rest for 1.5h at 37°C. Cells were then re-suspended in RPMI complete medium at 2-4 x 106 
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/ml and seeded on plate-bound anti-CD3 (2 µg/ml) and in the presence of soluble anti-CD28 (1 
µg/ml). Cells were left in culture for 3 days before flow cytometry analysis (section 2.6).  
 
2.5.3. Differentiation of primary naive CD4+ T cells 
Naïve CD4+CD62L+ T cells were purified from BALB/c and SKG mice (section 2.2.2.1), primed with HA 
peptide (2 µg/ml) and cultured for six days in the presence of mitomycin C-treated APCs (section 
2.2.2.4).  Culture supernatants were collected at different time-points during early differentiation for 
assessment of cytokine production using the CBA system (section 2.5.5). On day 7, cells were 
assumed to have acquired a specific Th phenotype and were then re-stimulated with the same dose 
of HA antigen. Following antigen recall, supernatants were harvested on day 9 and 11. Cells were also 
harvested at the same time-points and analysed for inducible mRNA levels of lineage-specific 
transcription factors using qPCR (section 2.4.5).  
 
Supplementation with exogenous cytokine was carried as follows (with Day 0 (D0) being the day 
when cells are harvested and first activated with HA peptide): 
 























For long-term differentiation: 
 







2.5.4. Cytometric Bead Array (CBA) 
Assessment of cytokine concentration in cell culture supernatants was done using CBA according to 
manufacturer’s instructions (BD Biosciences, USA). CBA is a flow cytometry application that enables to 
quantify multiple proteins simultaneously. Each cytokine-specific bead in the array has a unique 
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fluorescence intensity so that beads can be mixed and run simultaneously in a single tube. The assay 
includes a recombinant protein standard that provides an internal control as well as a means to 
generate a standard curve and subsequent quantitative analysis.  
 
Cell culture supernatant (50 μl) was incubated with cytokine-specific antibody-coated beads for 1h at 
RT, then incubated for an extra hour in the presence of PE-conjugated detection antibodies. Cells 
were then centrifuged (1,800 rpm, 2 min, RT) before being re-suspended in wash buffer and 
subjected to flow cytometry analysis (section 2.6). Data were analysed with FCAP Array (Soft Flow, 
USA).   
 
2.6. Flow cytometry 
Fluorochrome-labelled antibodies are used to stain cell-surface or intra-cellular antigens in a single 
cell suspension. Each stained cell is then passed over a panel of lasers which excite the fluorochromes 
and measure the light emitted by the labelled cells, thus providing detection and quantification of an 
antigen of choice. Flow cytometry can also be used to directly measure fluorescent proteins (e.g. 
eGFP) or fluorescent compounds (e.g. CFSE).   
 
2.6.1. Cell-surface antigen staining 
Cells were collected and washed with FACS wash buffer. Cells were incubated for 20 min at 4°C with 
either mouse serum (1 μl/106 cells) or anti-CD16/CD32 (0.5 µg) to block Fc receptors (FcR) and 
prevent non-specific staining. Cells were then stained with fluorochrome-conjugated antibodies 
(section 2.1.1.2) and kept in the dark for 30 min at 4°C. Control cell aliquots were stained with isotype 
controls conjugated to the same fluorochrome. Samples were washed twice with FACS buffer before 
being re-suspended for flow cytometry acquisition and analysis. Antigen or eGFP expression was 
acquired on either a FACSCalibur or FACSCanto or FACS LSR II flow cytometer, and data analysed 
using either CellQuest (v3.3) or BD FACSDiva (v6.1.2) software (BD Biosciences, USA). 
 
2.6.2. Intra-cellular staining 
Following cell-surface antigen staining, cells were washed once with FACS buffer and once with PBS 
before being fixed with 2% paraformaldehyde for 20 min at 4°C in the dark. Following fixation, cells 
were washed once with PBS and once with FACS buffer before incubation in permeabilisation buffer 
for 10 min at 4°C. Without washing, cells were incubated for a further 15 min with FcR block. 
Fluorochrome-conjugated antibodies or isotypes were then added to the cells and left to stain for 30 
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min at 4°C in the dark. This was followed by one wash with permeabilisation buffer, one wash with 
FACS buffer, then cell were re-suspended in FACS buffer for acquisition and analysis.  
 
Alternatively, a FoxP3 intra-cellular staining kit was used and fixation and permeabilisation were 
carried out with the buffers provided and according to manufacturer’s instructions (eBioscience, UK).  
 
2.7. Lentiviral-based gene transfer 
 
2.7.1. Production of lentiviral stock 
Lentiviruses were produced by triple calcium phosphate-mediated transfection of HEK 293T cells. 
Cells (5-6 x 106) were seeded in 15 cm plates the day before to achieve 60-70% confluence on the day 
of transfection. One hour before transfection, 25 µg/ml chloroquine (Sigma-Aldrich, UK) was added to 
each plate. The transfection mix was prepared as shown below and contained the pHR’SIN.cPPT-SEW 
transfer plasmid, the pCMVR8.2 packaging plasmid and the pMD.G plasmid, encoding the VSV-G 
envelope:  
Per 15 cm plate Volume / concentration 
2x HBS 1 ml 
pHR’SIN.cPPT-SEW 18 µg DNA 
pCMVR8.2 18 µg DNA 
pMD.G 4 µg DNA 
2.5 M CaCl2 100 µl 
dH2O Complete to 2 ml 
 
The CaCl2 was added last to the transfection mix and very gradually with constant gentle shaking. The 
precipitation mix was left at RT for 20 min. The transfection mix was then added gradually to the cells 
and incubated at 37°C for 6h before replacing the chloroquine-containing medium with fresh DMEM 
complete medium and left to recover overnight. Medium was replaced the next day with 15 ml of 
fresh medium. Viral supernatant was collected every 24h for the next 2 days, filtered to remove cells 
and debris (0.45 μm) and concentrated by ultracentrifugation in a Beckman XL90 (rotor 70 Ti) at 
23,000 rpm for 2h at 4°C. Lentiviral sediments were re-suspended in a total of 10-50 µl PBS, 
depending on pellet size, and aliquoted for storage at -70 °C until required. 
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2.7.2. Lentivirus titration in HEK 293T cells 
HEK 293T cells were plated in p48 microtitre plates (10,000 cells/0.5 ml/well) and left to incubate 
overnight. The following day, the cells were infected with serial dilutions of viral sup in DMEM (0.5 
ml) containing 6 µg/ml polybrene (Sigma-Aldrich, UK).  Medium was replaced the next day and cells 
were left to grow for 4 days. Cells were then harvested and analysed by flow cytometry for eGFP 
expression.   
 
2.7.3. Pre-activation protocol for primary murine T cells  
Murine primary cells harvested from lymphoid organs were seeded in p24 microtitre plates (1-5 x 
106/ml) and activated for a pre-determined duration. The following activation conditions were tested 
during protocol optimisation: 
 
Activation Concentration Duration 
Monoclonal antibodies   
Immobilised/soluble anti-CD3 1 – 10 µg/ml 
24h – 48h 
± immobilised/soluble anti-CD28 1 – 10 µg/ml 
Mitogen   
Concanavalin A (Con A) 1 - 5 µg/ml 24h 
Cytokines   
IL-2   100 U/ml 24h – 96h 
IL-7  10 ng/ml  96h 
 
2.7.4. Lentiviral-mediated transduction in murine splenocytes  
Activated cells (0.5-5 x 106/ml) were incubated with various concentrations of lentivirus in the 
presence of either polybrene (4-8 μg/ml) or DEAE-dextran (70 μg/ml). When using spinoculation, p24 
microtitre plates were centrifuged (2,000 g, 1h, 24°C). Cells were left to incubate overnight and 
medium was replaced on the next day. Cells were then left to grow for 5 days at 37°C in 5% CO2 
before flow cytometry analysis for eGFP expression (section 2.6). During that time, cells were 
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2.7.5. Optimisation of protocol 
RetroNectin™ 
For transduction on recombinant fibronectin (RetroNectin), activated murine splenocytes were 
seeded on wells coated with RetroNectin (Takara Bio Inc., Otsu, Japan). Wells from p24 microtitre 
plates were coated for 2h at RT with Retronectin at 35 µg/ml in order to obtain a final amount of 10 
µg of coated protein per cm2. After coating, wells were blocked with PBS and 2% BSA for 30 min at RT, 
before being washed with PBS and stored at 4°C until required.  
 
Co-culture 
On day 1, HEK 293T cells (0.5 x 106) were seeded in p6 microtitre plates and left overnight to adhere 
to the wells. On day 2, the HEK 293T cells were transfected with the three lentiviral plasmids (section 
2.7.1) and left to incubate overnight. On day 3, splenocytes - pre-activated with either monoclonal 
TCR antibodies or Con A -  were seeded on top of the transfected 293T cells at a concentration of 5 x 
106 cells/ml, in the presence of polybrene (6 µg/ml). On day 4, splenocytes and the conditioned 
medium were transferred to a new plate and left in culture until flow cytometry analysis of eGFP 
expression (section 2.6). 
 
2.8. Retroviral-based gene transfer 
 
2.8.1. Transduction of T cells with mono-cistronic retroviral vector 
On day 1, wells from p24 microtitre plates were coated with anti-CD3 (2 µg/ml) and anti-CD28 (10 
µg/ml) in coating buffer (500 µl) and left overnight at 4°C. On day 2, the plates were washed with PBS 
and freshly harvested primary cells from lymphoid organs (section 2.2.2.1) were seeded into the wells 
(1-5 x 106/ml). On day 3, retroviral supernatant (section 2.8.2.3) was added to the cells in the 
presence of polybrene (6 µg/ml) and murine recombinant IL-2 (10 U/ml) and centrifuged (2,000 g, 1h, 
24°C) before incubation overnight. On day 4, medium was carefully replaced with fresh RMPI 
complete medium. Cells and conditioned medium were split into new non-coated wells on day 5, and 
fresh medium with IL-2 was added (10 U/ml). On day 7, cells were harvested for flow cytometry 
analysis for eGFP expression (section 2.6)  
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2.8.2. Generating packaging cell lines for retrovirus production 
2.8.2.1. Ping-Pong approach  
The ping-pong approach is a method used to deliver the viral construct to the packaging cell line, 
which eliminates the need for selecting individual clones when making stable packaging cell line 
(Parente and Wolfe 1996). This is achieved by infecting the packaging cell line (PT67) with the virus 
obtained from another packaging cell line (Phoenix-Eco).  
 
On day 1, Phoenix-Eco cells were plated (2.5 x 106/10 cm plate) to reach 60-80% confluence the 
following day. On day 1, cells were transfected (as described in section 2.4.6.5) with the following 
transfection mix: 
Per 10 cm plate Volume / concentration 
2x HBS 500 µl 
DNA plasmid 20 µg DNA 
2.5 M CaCl2 50 µl 
dH2O Complete to 1 ml 
 
The phoenix cells should be 95-100% confluent 24h post-transfection (day 2). Under these 
circumstances the viral supernatant can be collected on day 3. If cells were not confluent, the viral 
supernatant collection had to wait until day 4. Concurrently on day 2, PT67 were plated at a density 
of 1-2 x 106/6 cm plate in complete medium.  
 
On day 3, Phoenix-Eco supernatants was collected, centrifuged (500 g, 5 min, 4°C), filtered (0.45 µm) 
and used fresh or frozen at -70°C for future use. If used fresh, the Phoenix-Eco virus-containing 
medium (3 ml) was added to plated PT67 cells whose medium had been changed two hours prior (3 
ml). Polybrene was added at a final concentration of 6 µg/ml. PT67 cells were incubated overnight 
and medium was replaced on day 4. PT67 were then left to grow. 
 
2.8.2.2. Producing virus from stable packaging cell line 
Transduced PT67 cells were cultured to establish the cell line. The reverse transcription and 
integration takes place within 24-36h, depending on cell growth kinetics. Expression can start to be 
observed at 24h, usually maxing out at 48h. From there on, continued retroviral expression might 
drop over a period of weeks to months depending on cell line, site of integration, relative toxicity of 
insert and other factors. Virus are produced at the highest titer when cells are 90-95% confluent and 
form a monolayer. When cells reach this confluence, medium should be changed and left for 24h 
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before collecting viral supernatants (Pear, Nolan et al. 1993). Retroviral supernatant was harvested 
and filtered (0.45 µm) to remove cells and debris. Retroviral supernatant was kept on ice until used or 
frozen and stored at -70°C for future use.  
Stocks of virus-producing cells for cryopreservation were made when cells confluence was around 70-
80% (section 2.2.1).  
 
2.8.2.3. Virus titration in NIH 3T3 cells 
Retroviral supernatants titer was assessed in NIH 3T3 cells following the protocol described in section 
2.7.2. 
 
2.8.3. Selection of cell lines 
Re-selection of virus-producing packaging cell lines enables to discard cells that have lost the ability to 
package virus and select cells that produce high-titre virus. Phoenix-Eco and PT67 packaging cell lines 
were re-selected as follows: 
 
Phoenix-Eco Grow cells with: Duration 
Step 1 
Hygromycin (300 µg/ml) 
Diphteria toxin (1 µg/ml) 
1 week 
Step 2 Normal medium 1 week 
 
PT67  Grow cells with: Duration 
Step 1 Amethopterin (100 nM) 5 days 
Step 2 
Hypoxanthine (30 µM) 
Amethopterin (1 µM)  
Thymidine (20 µM) 
5 days 
Step 3 
Hypoxanthine (30 µM) 
Thymidine (20 µM) 
5 days 
Step 4 Normal medium 5 days 
 
2.8.4. Optimisation of retroviral gene transfer with bi-cistronic vectors 
2.8.4.1. Multiple rounds of infections 
Multiple rounds of infection of PT67 cells with virus-containing Phoenix-Eco medium were carried out 
to increase the number of infected cells as well as increasing the copy number per cell (as described 
in section 2.8.2.1).  
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2.8.4.2. Concentration of viral supernatant 
The viral supernatant was concentrated ten times by centrifugation in a Vivaspin column with a 
MWCO of 300 kDa (Sartorius Stedim Biotech, Germany) at 4°C.  
2.8.4.3. Double-transduction of target cells 
Primary murine T cells were transduced with PT67-generated viral supernatant (section 2.8.1), with 
the following amendment: 
On day 4, cells were subjected to another round of transduction with viral supernatant as per day 3. 
Cells were then cultured as described previously.  
 
2.9. In vivo studies 
2.9.1. Mice 
Mice strain  
BALB/c  Bred in house. 
SKG  
Bred in-house. Originally donated by Prof. S. Sakaguchi (Osaka university, 
Japan). Mutation in ZAP-70 leading to CD4
+
 T cell-mediated autoimmune 
arthritis.  
HNT-TCR BALB/c  Express an α and β TCR complex recognising an influenza HA peptide.  




(Harlan, UK). SCID mice the recessive mutation 
‘severe combined immunodeficiency’. Homozygotes are deficient in both 
B and T cell function and consequently in both humoral and cell-
mediated immune function and lack detecting levels of circulating Igs.  
 
2.9.2. Adoptive transfer into SCID mice 
Single-cell suspensions were prepared with cells harvested from female BALB/c or non-arthritic 
female SKG lymphoid organs (8-10 week-old). Cells were un-manipulated, pre-activated in vitro 
(section 2.7.3) or differentiated in vitro (section 2.5.4). Cells (100 µl) were intravenously transferred 
to SCID mice.  
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2.9.3. Clinical scoring 
The incidence and severity of arthritis developing in SCID mouse recipients was assessed on a weekly 
basis. Swelling of the wrist and ankle joints was measured with callipers and each joint was 
individually scored for clinical severity of disease according to the following scale:  
 
Clinical arthritic score / joint Description 
0 No joint swelling 
0.5 Erythema 
1 Mild swelling 
2 Severe swelling 
3 Ankylosis 
 
Scores were totalled for each mouse with a maximum of 12 points per animal.  
 
2.9.4. Tissue collection and histological analysis 
Blood was collected by cardiac puncture and centrifuged (13,000 rpm, 10 min, RT) for serum 
separation. Serum was stored at -70°C and analysed using the CBA system (section 2.5.4). 
 
Wrist and ankle tissues were collected and fixed in 10% neutral formalin, decalcified in EDTA, paraffin 
embedded, sectioned and stained with Haematoxylin & Eosin (H&E) by the Histology Department 
(Charing Cross Hospital, Imperial College London, UK).  
 
Stained joint tissues were assessed for signs of tissue inflammation and joint destruction. Histological 
assessment was performed microscopically and each animal joint was scored as follows:  
 
Histology score / joint Description 
0 No inflammation 
1 
Mild inflammation with preservation of the joint 
architecture 
2 
Additional synovium hyperplasia, oedema and partial loss 
of cartilage and bone structure 
3 
Very severe inflammation accompanied by pannus 
formation and complete joint destruction 
 
Scores were totalled for each mouse with a maximum of 12 points per animal.  




2.10. Statistical analysis 
 
Data are expressed as means ± SEM and were analysed using two-tailed unpaired t-tests or one-way 
ANOVA and Dunnet or Tukey post-test when appropriate. All tests were undertaken using GraphPad 
Prism 5. The levels of statistical significance were defined as follows:  
 
P value Symbol 
< 0.001 *** 
0.001 to 0.01 ** 
0.01 to 0.05 * 
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Since SKG mice develop a spontaneous CD4+ T cell-mediated chronic autoimmune arthritis, I initially 
compared the phenotype and function of CD4+ T cells from SKG and wild type BALB/c.  
 
Cytokines have been shown to play key and distinct roles in the development and maintenance of 
auto-immune arthritis in SKG mice. For instance the disease is crucially dependent on Th17 cells and 
deficiency of either IL-17 or IL-6 completely inhibits arthritis in SKG mice whereas deficiency in IL-1 or 
TNFα only retards the onset of arthritis and reduces its severity and incidence. IL-10 deficiency on the 
other hand exacerbates the disease (Hata, Sakaguchi et al. 2004; Hirota, Hashimoto et al. 2007).  
 
Following stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin - two compounds 
that by-pass the upstream kinase activity of ZAP-70 to equally stimulate wild-type and SKG cells - SKG 
T cells were shown to be competent at secreting various cytokines, including IL-2, IL-4, IL-10, TNFα 
and IFNγ, in a pattern of cytokine production and kinetics similar to that of BALB/c T cells (Hata, 
Sakaguchi et al. 2004). Additionally, a significant fraction of SKG CD4+ T cells from non-arthritic SKG 
mice, following ex vivo PMA/ionomycin treatment, produced IL-17 whereas BALB/c CD4+ T cells did 
not (Hirota, Hashimoto et al. 2007) and injection of zymosan – a crude fungal β-glucan known to 
induce severe arthritis in SKG mice - increased three- to four-fold the number of IL-17+ cells in SKG, 
but not in BALB/c mice (Hirota, Hashimoto et al. 2007). Therefore it seems that the molecular 
machinery to express cytokines in SKG animals is not intrinsically defective, but that the ZAP-70 
mutation modulates the TCR signalling pathways in such ways that SKG T cells have a propensity to 
produce higher levels of IL-17, and that this population of cells expand widely during the 
development of arthritis in SKG mice.  
 
Consequently, I aimed to further study the pathways of Th differentiation in SKG mice. First, I was 
interested in looking into the cytokines that were preferentially produced by SKG T cells stimulated 
with antigenic peptide to determine whether specific patterns could be identified and whether those 
might give us insight into the mechanisms that link the ZAP-70 mutation to the development of a pro-
inflammatory autoimmune disease in SKG mice. This first phase was carried out using un-manipulated 
bulk cultures from BALB/c and SKG lymphoid organs so as to best mimic the in vivo cellular 
composition and environment.  
Second, I set out to establish whether highly purified naïve CD4+ SKG cells, when taken in isolation 
from SKG accessory cells, were still differentiating differently from naïve BALB/c CD4+ T cells when 
Chapter 3  Results 
77 
 
subjected to identical priming conditions and in a cytokine-neutral milieu; and if so, highlight any 
differences in the T cell differentiation process which might directly or indirectly be due to the ZAP-70 
variant and explain the skew towards Th17 cells in SKG animals.  
To carry out those experiments, I used BALB/c and SKG mice which were crossed to HNT-TCR 
transgenic mice to generate wild-type and ZAP-70 mutant T cells expressing an α and β TCR chain 
complex recognising an influenza hemagglutinin peptide (HA126-138) in the context of I-Ad (Scott, 
Liblau et al. 1994; Cope, Liblau et al. 1997). The protocol of cell activation and differentiation used in 
this chapter is briefly described below (figure 3.1) and will be further described in the text when 




Figure 3.1 – Studying pathways of Th differentiation in HNT-TCR x SKG+/+ mice. Bulk cells or naïve CD4+ T cells were 
harvested/purified from HNT-TCR BALB/c and SKG mice. T cells were activated with HA peptide and left in culture without 
addition of polarising cytokines. Antigen recalls were carried out on a weekly basis. At various time-points supernatants were 
collected and analysed for the presence of secreted cytokines. Cell aliquots were harvested and either analysed for the intra-
cellular production of cytokines following PMA/ionomycin stimulation, or lysed for qPCR analysis of lineage-specific 
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3.2. CD4+ T cells numbers are reduced in the spleen of SKG mice 
 
Splenocytes from 10-week old BALB/c or SKG mice were stained for CD4 expression and analysed by 
flow cytometry. Although overall the number of total cells was not significantly different between 
wild-type and SKG spleens, the mean number of CD4+ splenocytes was reduced by a third in SKG 
compared to their wild-type counterparts (figure 3.2). This result was consistent with previously 







Figure 3.2 – Reduced number of CD4+ T cells in SKG mice. Splenocytes from 10-week old BALB/c and SKG mice 
were harvested and stained with anti-CD4 monoclonal antibodies. A – On average there were 1.5 times more CD4+ 
splenocytes in wild type animals than in SKG mice (n = 4). B – Flow-cytometry figure representative of four 
independent experiments.  
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3.3. FoxP3+ T cells are increased in the spleen of SKG mice 
 
Regulatory T cells (Tregs) are a specialised subpopulation of CD4+ T cells that acts to suppress T-cell 
proliferation and function and consequently attenuate immune responses against self- or non self-
antigens. Treg cells constitutively express the transcription factor forkhead box P3 (FoxP3) and high 
levels of the low-affinity IL-2 receptor (IL-2R) α chain (CD25) and represent about 5-10% of both 
mouse and human peripheral CD4+ T cells (Sakaguchi, Sakaguchi et al. 1995; Sakaguchi, Ono et al. 
2006; Yi, Zhen et al. 2006).  
 
FoxP3 has been shown to be an essential transcriptional regulator of Treg cell differentiation 
(Fontenot, Gavin et al. 2003; Hori, Nomura et al. 2003) and is currently the best molecular marker for 
Treg cells. 
 
Splenocytes from 10-week old BALB/c or SKG mice were stained for cell-surface expression of CD4 
and intra-cellular expression of FoxP3 and subsequently analysed by flow cytometry. On average 13% 
of BALB/c CD4+ T cells were FoxP3+ and therefore could be classified as Treg cells whereas the 
percentage of SKG CD4+ cells that expressed FoxP3 was 34% (figure 3.3, panel A). Given that the total 
of CD4+ splenocytes is reduced in SKG mice, this difference in the numbers of CD4+FoxP3+ splenocytes 
is actually less pronounced, with on average 2.2% of BALB/c splenocytes being CD4+FoxP3+ compared 
to 3.9% for SKG splenocytes  (figure 3.3, panel B). Equivalent results were found when staining for 
CD4+CD25+FoxP3+ T cells (data not shown).  
 
  








Figure 3.3 – Increased number of CD4+FoxP3+ T cells in SKG mice. Splenocytes harvested from 10-week old BALB/c and 
SKG mice were stained with anti-CD4 and anti-FoxP3 monoclonal antibodies. A – Shows the proportion of FoxP3+ population 
in the CD4+-gated population. On average there were 2.5 times less FoxP3+ cells in the wild-type CD4+ population when 
compared to SKG mice (n = 3). B – This figure shows the proportion of CD4+FoxP3+ cells in the total splenocytes population 
to account for the reduced number of CD4+ T cells in SKG mice.  
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3.4. The proliferative response of SKG T cells to antigen is profoundly 
attenuated 
 
Recent studies have reported that the proliferation of CD4+ T cells, induced by anti-CD3 or antigenic 
peptide, requires the catalytic kinase activity of ZAP-70 (Au-Yeung, Levin et al. 2010).   
 
Since the SKG mutation inhibits binding of the ZAP-70 variant to phosphorylated TCRζ ITAM residues, 
thereby uncoupling membrane proximal TCR signalling events, I compared the proliferative capacity 
of BALB/c and SKG T cells using HNT-TCR transgenic mice.  
 
I harvested lymph nodes cells from HNT-TCR BALB/c and HNT-TCR SKG mice and cells were cultured 
for three days following stimulation with soluble anti-CD3 and anti-CD28 antibodies (100 ng/ml and 5 
μg/ml respectively), Concanavalin A (1 μg/ml) or increasing concentrations of HA peptides (up-to 50 
μg/ml). The ovalbumin peptide OVA322-336 (50 μg/ml), which binds to I-Ad as efficiently as the HA 
peptide but is not recognised by the transgenic HNT-TCR, was used as a negative control.  
 
Cell proliferation was assessed by measuring 3[H] thymidine incorporation at the end of a 72h period 
of stimulation.  
 
HNT-TCR BALB/c T cells responded robustly to HA peptide in a dose-dependent fashion. Consistent 
with the attenuated signal transduction associated with mutant ZAP-70, SKG T cells were significantly 
hypo-responsive to TCR stimulation with antigen in vitro. A 2.5 to 8-fold decrease in the proliferation 
of T cells from SKG mice was documented when compared to BALB/c T cells. The increased 
proliferation observed in wild-type T cells compared to SKG T cells when stimulated with anti-
CD3/anti-CD28 was not as pronounced but was still significant (figure 3.4) probably due to strong 
agonistic co-stimulation from anti-CD28. 
 
Concanavalin A (Con A) is a lectin that acts as a lymphocyte mitogen by-passing the TCR and therefore 
the ZAP-70 mutation. Although the proliferation of SKG cells following Con A stimulation was not 
quite as effective as in BALB/c cells, the difference was not significant, highlighting a causal 
relationship between proximal TCR signalling events and the deficient proliferative response of SKG T 
cells. The strong proliferation of SKG cells following Con A treatment also shows that the variation in 
HA-driven proliferation is not due to increased cell death in the SKG population.  
 





Figure 3.4 – Proliferative response of SKG T cells to various in vitro stimuli. T cells from transgenic HNT-
TCR BALB/c and SKG mice were seeded and stimulated for three days with monoclonal antibodies, Con A or an 
increasing dose of HA peptide, which is specific for the transgenic HNT-TCR. OVA, which is not recognised by the 
transgenic TCR, was used as a negative control. Results presented as mean ± SD of triplicate cultures.  
 
To confirm these results the proliferative capacity of wild-type and SKG T cells was also compared 
using the carboxyfluorescein succinimidyl ester (CFSE) dye dilution assay. CFSE is a fluorescent dye 
which can be used to stain lymphocytes and monitor their proliferation due to the progressive halving 
of CFSE fluorescence within daughter cells following each round of cell division (Lyons and Parish 
1994). 
 
CD4+ cells were purified from lymph nodes by negative selection using magnetic beads and cultured 
for 3 days in the presence or absence of plate-bound anti-CD3 (2 µg/ml) and soluble anti-CD28 (1 
µg/ml). 
 
At 72h post-activation, BALB/c cells showed a clear loss of CFSE dye with successive rounds of cell 
division. In contrast, SKG cells did not undergo cell division following stimulation with antibodies at 
those concentrations (figure 3.5).  
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Although this result, if seen in isolation, may suggest that SKG cells are completely anergic to TCR 
stimulation, we know from the previous tritiated thymidine incorporation assay that SKG cells can 
proliferate and undergo cell division (figure 3.4) but that they are hypo-responsive in comparison to 
BALB/c cells. In fact recent reports showed that when higher concentrations of antibodies were used 
(10 µg/ml anti-CD3 and 1 µg/ml anti-CD28), SKG cells divided and showed CFSE dye dilution although 
to a much lesser extent than wild-type cells (Hsu, Tan et al. 2009). So it is not that SKG cannot 
respond to TCR stimulation and undergo cell proliferation but they need a stronger signal than their 
wild-type counterparts to do so.  Therefore both assays show conclusively that SKG cell proliferation 
and cell division is not equal to that observed in wild-type cells although some of the differences 
observed between the methods are likely to be due to different conditions of stimulations such as 





Figure 3.5 – Proliferative response by SKG CD4+ T cells to in vitro TCR stimulation. CD4+ T cells purified from 
wild-type and SKG mice were stimulated with plate-bound anti-CD3 (2 µg/ml) and soluble anti-CD28 (1 µg/ml) for 
72h.  The top row shows the CFSE fluorescence from cells stimulated with medium only.  
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3.5. Cytokine expression profiles of wild-type and SKG derived CD4+ T cells  
 
Effector T helper (Th) cells derive from naïve CD4+ T cells precursors following a differentiation 
process induced by antigenic stimulation and influenced by the cytokine environment. Committed 
CD4+ T cells may differentiate into Th1, Th2 or Th17 subsets, each with distinct cytokine products and 
biological functions, or differentiate into the inducible Treg lineage (iTregs), with immuno-regulatory 
properties.  
 
 In the following experiments, , using the assay described in figure 3.6, I aimed to determine which 
cytokines were produced by SKG cells following antigen stimulation and how this differed from the 




Figure 3.6 – Assay of cytokine production using bulk cells from lymphoid organs. Cells were harvested from 
HNT-TCR BALB/c and SKG and cultured in bulk for two weeks following antigenic peptide stimulation (2 µg/ml) on 
day 0. Cells were re-stimulated every 7 days with the same concentration of peptide and in the presence of non-
transgenic APCs. Supernatants were collected on day 2 and day 7 for flow analysis of secreted cytokines using the 
CBA system. Cell aliquots were collected on day 7 and day 14 for intra-cellular staining of various cytokines following 
PMA/ionomycin stimulation for 6 hours.  
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3.5.1. SKG T cells secrete low amounts of IL-2 following TCR activation  
Upon TCR engagement, several signalling pathways are triggered within naïve T cells eventually 
leading to rapid and transient production of IL-2. During an immune response IL-2 is consumed in an 
autocrine or paracrine manner by cells in close proximity bearing the high-affinity IL-2R. The capacity 
to secrete IL-2 by effector T-cells represents a hallmark which distinguishes them from Treg cells that 
do not produce IL-2 (Su, Creusot et al. 2004; Ono, Yaguchi et al. 2007). Accordingly, IL-2 production in 
cultures of differentiating T cells was examined using a cytometric bead array (CBA) system, 
comparing expression in wild-type BALB/c and SKG cells. 
 
Total cells were harvested from peripheral lymphoid organs of HNT-TCR BALB/c and SKG mice and 
stimulated with HA peptide (2 μg/ml). Supernatants were collected 48 hours later and assayed for the 
presence of IL-2. The ZAP-70 mutation found in SKG mice led to profoundly impaired IL-2 production, 
symptomatic of deficient T cell activation. On average SKG cells only produced 18% of the IL-2 levels 

























A – Bulk cell cultures from spleens 
 
B – Bulk cell cultures from lymph nodes 
 
Figure 3.7 – Production of IL-2 by BALB/c and SKG CD4+ T cells following TCR stimulation. CD4+ T cells 
from HNT-TCR wild-type and SKG mice were stimulated with HA peptide (2 µg/ml) and supernatants were 
harvested and assayed for IL-2 production after 48h. The impaired TCR signalling in SKG mice led to a significant 
decrease in IL-2 production in both (A) spleens (n = 5) and (B) lymph nodes (n = 4).  
 
3.5.2. SKG T cells are high producers of IL-17   
In this thesis we assayed the presence of IL-17A which will be referred to as IL-17 throughout.  
 
Previous reports have shown that autoimmune arthritis in SKG mice is highly dependent on the 
development of CD4+ T cells secreting IL-17, a pro-inflammatory cytokine capable of recruiting and 
activating neutrophils and other inflammatory cells (Kolls and Linden 2004; Hirota, Hashimoto et al. 
2007).  
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We activated splenocytes from BALB/c and SKG mice with HA peptide (2 µg/ml) and cultured them 
for six days in the presence of low levels of IL-2 (5 U/ml) to maintain cell survival. On day 7, the cells 
were harvested, washed and re-stimulated with a similar dose of antigen in the presence of mitogen-
C treated non-transgenic wild-type APCs. Culture supernatants were collected on day 2 (48h after the 
first exposure to HA antigen) and on day 9 (48h after the peptide re-stimulation) and analysed for 
cytokine production using the CBA system.  
 
Significantly higher levels of IL-17 were found in the SKG supernatants compared to BALB/c 
supernatants at both time-points (figure 3.8).  
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A – Bulk cell cultures from spleens 
 
 
B – Bulk cell cultures from lymph nodes 
 
Figure 3.8 – Production of IL-17 by BALB/c and SKG CD4+ T cells following TCR stimulation. CD4+ T cells from 
HNT-TCR wild-type and SKG mice were stimulated with HA peptide (2 µg/ml) and cultured for six days before being 
re-stimulated with an identical concentration of HA peptide on day 7. The presence of IL-17 was assayed 48h after 
either the initial activation (D2) or after re-stimulation (D9). At both time-points SKG T cells produced a significantly 
increased amount of IL-17 compared to wild-type counterparts (n = 4).  
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Although the production of IL-17 slightly decreased in both cultures following the re-stimulation on 
day 7, the fold-difference in IL-17 production between BALB/c and SKG T cells actually increased from 
3.5 on day 2 to 5.5 on day 9. 
 
The increased production of IL-17 by SKG cells was confirmed by intra-cellular staining following in 
vitro PMA/ionomycin. The use of this method specifically allowed me to observe which cytokine gene 
loci were in the open/closed conformation following chromatin modifications which were imposed by 
the TCR/cytokine signals. Such an assay was also a good complement to the CBA assay as it helped 
clarify whether the observed increased secretion of IL-17 in SKG cell culture supernatants was due to 
an increased number of IL-17-expressing SKG cells or whether it was the result of an increased 
production from an overall number of IL-17+ SKG T cells which did not differ from the number of wild-
type IL-17+ cells. 
 
When cells were maintained in culture and re-stimulated weekly over a two-week period, according 
to the protocol previously described (figure 3.6), the proportion of CD4+ cells producing IL-17 was 
significantly higher in SKG bulk cells sourced from either spleens or lymph nodes (figure 3.9). The data 
suggest that the increased levels of IL-17 present in the supernatants of SKG cell cultures is indeed 
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A – Bulk cell cultures from spleens 
 
B – Bulk cell cultures from lymph nodes 
 
Figure 3.9 – Intra-cellular staining of IL-17 in BALB/c and SKG CD4+ T cells following TCR stimulation. CD4+ T cells 
from HNT-TCR wild-type and SKG mice were stimulated with HA peptide (2 µg/ml) and cultured for either one or two weeks. 
Cells that were cultured for two weeks were re-stimulated with an identical concentration of HA peptide on day 7. On either 
day 7 or day 14, aliquots of cells were treated with PMA/ionomycin for 6 hours before being assayed for IL-17 production. At 
both time-points SKG T cells from either spleens or lymph nodes produced increased amount of IL-17 compared to wild-type 
counterparts (n = 2 on D7, n=1 on D14). 
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Since the differentiation of naïve T cells is strongly influenced by their cytokine milieu, we felt that in 
addition to IL-17 it was important to consider the production of other cytokines which are either the 
hallmarks of specific Th phenotypes or can be reasonably assumed to play a role in the SKG 
pathology; IL-6 and TNFα being good examples of such pro-inflammatory mediators implicated in the 
disease. Consequently, the production of IFN-γ, IL-4, IL-6, IL-10 and TNF-α by bulk splenocyte cultures 
on day 2 and day 9 was also examined.  
 
On day 2, IFN-γ and IL-10 levels were significantly reduced in SKG cultures whilst, as previously 
documented, IL-17 was significantly increased. Levels of other cytokines were not significantly 
different between the two strains (figure 3.10), suggesting that there may be some selectivity in 
terms of the impact of the ZAP-70 mutation on pathways of T cell activation.  
 
 
Figure 3.10 – Cytokine profile of BALB/c and SKG CD4+ T in bulk cultures, 48h after initial TCR activation (day 2). 
CD4+ T cells from HNT-TCR wild-type and SKG mice were stimulated in bulk cultures with HA peptide (2 µg/ml). 48h later, 
supernatants were collected and assessed for cytokine production. On day 2, BALB/c cells were producing amounts of IFN-γ 
and IL-10 which were significantly greater than SKG, whilst SKG produced significantly higher amounts of IL-17 (n = 4).  
 
On day 9 i.e. 48h following re-stimulation with peptide, both BALB/c and SKG splenocytes produced 
similar amounts of IL-10 which were considerably higher than those produced on day 2 (figure 3.11). 
Levels of IL-6 and TNF-α also increased in both cultures compared to day 2 but the difference 
between BALB/c and SKG was not significant. Although the level of IFN-γ produced by SKG cells was 
Chapter 3  Results 
92 
 
significantly reduced at day 2, the production of IFN-γ by SKG T cells recovered by day 9 to reach 
levels produced by T cells from wild-type mice (figure 3.11). By day 9, IL-17 was the only cytokine 
whose levels remained significantly different between BALB/c and SKG, providing evidence that 
increased IL-17 production is a stable characteristic of SKG cells (figure 3.11).  
 
 
Figure 3.11 – Cytokine profile of BALB/c and SKG CD4+ T cells in bulk cultures following TCR re-stimulation (day 9). 
CD4+ T cells from HNT-TCR wild-type and SKG mice were stimulated with HA peptide (2 µg/ml) and cultured for six days 
before being re-stimulated with a similar concentration of HA peptide on day 7. By day 9, only IL-17 production was 
significantly different between BALB/c and SKG T cells (n = 4).  
 
3.6. Th differentiation of highly purified naïve SKG precursors   
 
In section 3.5, we assayed cytokine production after stimulation of 8 x 106 cells from wild-type and 
SKG lymphoid organs which would have contained heterogeneous populations of naïve cells, memory 
effector cells and other various accessory cells. Since SKG mice have a repertoire of auto-reactive 
CD4+ T cells in the periphery (Sakaguchi, Takahashi et al. 2003), it can be reasonably assumed that the 
SKG lymphoid organs, when compared to their wild-type counterparts, would contain a higher 
proportion of cells that have been previously activated in vivo and present a memory phenotype and 
this may account for the differences in cytokine production observed between T cells from SKG and 
wild-type mice. Indeed it was demonstrated that SKG CD4+ T cells express more cell-surface markers 
of activation than wild-type cells (figure 3.12) and therefore the observed increase in IL-17 production 
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from bulk SKG cell cultures may be the result of expansion of fully differentiated effector Th17 cells 
rather than de novo lineage differentiation of naïve T cells (figure 3.13).  
 
 
Figure 3.12 – SKG T cells express cell-surface markers of activation. A larger proportion of CD4+ cells from SKG mice 
express cell-surface markers of activation than in wild-type mice. Work carried out in collaboration with Tharsana 
Tharmalingam in Prof Cope’s lab (KCL). 
 
 




Figure 3.13 – Differentiation of naïve T cells versus expansion of effector T cell clones. If, when compared to BALB/c 
cells, the starting SKG population contains more fully differentiated Th17 cells, then the increased production of IL-17, 
observed following antigenic peptide stimulation, might the result of expanded effector Th17 cells rather than de novo 
differentiation of Th precursors into Th17 cells. 
 
In the following experiments I sought to address this by purifying naïve T cells from wild-type and SKG 
mice and studying patterns of Th differentiation in vitro in the absence of a dominant pre-existing 
cytokine environment. 
 
In these experiments, and in order to homogenise the starting populations, HNT-TCR transgenic T 
cells from BALB/c and SKG mice were both stimulated with  peptide in the presence of non-transgenic 
APCs derived from wild-type mice and treated with mitomycin-C. This allowed us to exclude the 
possibility that any differences observed during differentiation of SKG T cells were due to subtle 
differences in APCs function, as opposed to the T cells.   
 
Consequently this in vitro model of T cell differentiation allowed the comparison of the early 
biochemical signalling events which occur following peptide presentation to naïve T cells under 
identical priming conditions, and enabled the correlation of these events with the generation of 
distinct effector cell populations (figure 3.14).  
 





Figure 3.14 – In vitro model of naïve T cell differentiation – By subjecting selected BALB/c and SKG naïve CD4+ T cells 
to strictly identical priming conditions, we will be able to observe how differential TCR signalling thresholds might affect the 
generation of distinct effector T cell subsets.  
 
For the following assays, naïve CD4+ cells were purified from peripheral lymphoid organs of HNT-TCR 
BALB/c and SKG mice. Naïve T cells which have not yet encountered their specific antigen express 
CD62L, also known as L-selectin, an adhesion molecule which acts as a homing receptor for 
lymphocytes to enter secondary lymphoid organs. Upon activation and differentiation, effector and 
memory T cells down-regulate expression of CD62L prior to re-encountering antigens in the periphery 
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3.6.1. Basal levels of lineage-specific transcription factors differ in naïve SKG 
T cells  
 
RNA from naïve CD4+CD62L+ T cells was reversed transcribed to cDNA and analysed by real-time PCR 
for basal expression of lineage-specific transcription factors. The gene Tbx21 codes for the 
transcription factor T-bet which activates transcription of IFNγ and is considered the master-regulator 
of Th1 differentiation (Szabo, Kim et al. 2000). The transcription factor GATA3, along with the proto-
oncogene c-MAF, is essential for Th2 differentiation (Ho, Hodge et al. 1996; Zhou and Ouyang 2003), 
while RORc encodes for the orphan nuclear receptor RORγt, whose up-regulation is required for both 
in vitro and in vivo differentiation of the Th17 cell lineage (Ivanov, McKenzie et al. 2006). Finally, the 
transcription factor FoxP3 is expressed by Treg cells and is an important regulator for their 
development and function (Fontenot, Gavin et al. 2003).  
 
Naïve BALB/c and SKG T cells contained similar levels of mRNA for Tbx21 and for GATA3. Interestingly, 
basal levels of mRNAs for RORc and FoxP3 were around three times higher in naïve SKG than in naïve 
BALB/c (figure 3.15). That is not to say that mRNA levels of RORc and FoxP3 in SKG were equivalent to 
each other, as each was expressed relative to its BALB/c equivalent baseline.  
 
 
Figure 3.15 – Basal expression of lineage-specific transcription factors in naïve CD4+ T cells. Levels of Tbx21 and 
GATA3 mRNAs were similar in BALB/c and SKG naïve T cells, whereas levels of RORc and FoxP3 were roughly three times 
higher in SKG naïve T cells. Data shown were derived from two independent experiments and normalised with expression 
amounts of the house-keeping gene hprt. Expression in SKG is relative to the expression in BALB/c for each individual gene.  
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3.6.2. Naïve SKG CD4+ T cells show profound deficiency in IL-2 production 
Purified naïve CD4+CD62L+ T cells from BALB/c and SKG mice were primed with HA peptide (2 µg/ml) 
and cultured for six days.  Culture supernatants were collected during the early differentiation period 
on day 2, 4 and 6. On day 7, cells were assumed to have acquired a specific Th phenotype and were 
then re-stimulated with the same dose of antigen. Following antigen recall, supernatants were 
harvested on day 9 and 11. All supernatants were assayed for IL-2, IL-4, IL-6, IL-10, IL-17, IFNγ and 
TNFα using the CBA system. Cells were also harvested at the same time-points and analysed for 
inducible mRNA levels of lineage-specific transcription factors (figure 3.16).  
 
 
Figure 3.16 – Assay of cytokine production using naïve CD4+ T cells from lymphoid organs. Naïve CD4+ T 
cells were purified from HNT-TCR BALB/c and SKG and activated with HA peptide (2 µg/ml) on day 0. Cells were re-
stimulated on day 7 with the same concentration of peptide and in the presence of non-transgenic APCs. 
Supernatants were collected on day 2, 4, 6, 9 and 11 for flow analysis of secreted cytokines using the CBA system. 
Cells were collected at the same time-points and lysed for qPCR analysis of lineage-specific transcription factors.  
 
As previously seen with total splenocytes, this assay confirmed that the production of IL-2 in SKG 
naïve cell cultures was drastically decreased when compared to BALB/c cells, confirming impaired cell 
activation following TCR stimulation with peptide (figure 3.17). IL-2 levels were undetectable upon 
antigen recall, as would be expected for fully differentiated Th cells.  
 




Figure 3.17 – Production of IL-2 by BALB/c and SKG naïve CD4+ T cells. CD4+CD62L+  T cells from HNT-TCR wild-type 
and SKG mice were stimulated with HA peptide (2 µg/ml) and cultured for six days before being re-stimulated with an 
identical concentration of HA peptide on day 7. The presence of IL-2 was assayed during early differentiation of the naïve 
cells (day 2, 4 and 6) and upon antigen re-stimulation of differentiated effector T cells (day 9 and 11). The production of IL-2 
by SKG cells upon first antigen encounter was substantially reduced compared to BALB/c (n = 2).  
 
3.6.3. Naïve SKG CD4+ T cells spontaneously differentiate to Th17 phenotype 
Since upon recognition of antigen, naïve CD4+ T cells can differentiate into distinct effector subsets 
characterised by the production of specific cytokines, we looked systematically for those lineage-
specific cytokines and associated transcription factors in order to attempt to characterise the 
differentiation of the naïve BALB/c and SKG cells. 
 
Both BALB/c and SKG produced IL-17 during the early differentiation period with levels slightly more 
elevated in SKG cultures. Upon antigen recall on day 7, levels of IL-17 by SKG effector Th cells was 
markedly higher than those of wild-type mice (figure 3.18). This might suggest that when exposed to 
identical priming conditions, naïve BALB/c and naïve SKG CD4+ T cells spontaneously differentiate 
towards different effector phenotypes, with SKG cells being high producers of the IL-17 cytokine, the 
hallmark of Th17 cells.  




Figure 3.18 – Production of IL-17 by BALB/c and SKG differentiating CD4+ T cells. CD4+CD62L+  T cells from HNT-TCR 
wild-type and SKG mice were stimulated with HA peptide (2 µg/ml) and cultured for six days before being re-stimulated with 
an identical concentration of HA peptide on day 7. The presence of IL-17 was assayed during early differentiation of the naïve 
cells (day 2, 4 and 6) and upon antigen re-stimulation of the differentiated effector T cells (day 9 and 11). Following antigen 
re-stimulation, differentiated SKG T cells produced on average almost 4 times as much IL-17 as BALB/c differentiate T cells  
(n = 2).  
 
In agreement with these data, real-time PCR analysis showed that antigen stimulation induced 
consistently higher levels of RORc mRNAs in SKG T cells than in BALB/c (figure 3.19). The increased 
levels in SKG cells were especially manifest in the later stages of differentiation (6-fold increase by day 
6), but also upon antigen recall (2.5 fold-increase on day 9 and 8-fold increase on day 11) remaining 
low in BALB/c T cells.  
   




Figure 3.19 – Differentiating SKG CD4+ T cells express high levels of RORc mRNA. By the end of the differentiating 
period on day 6, activated SKG CD4+ T cells express 6 times more RORc mRNA levels than BALB/c T cells. Following 
antigen recall, SKG T cells maintain higher expression of RORc (n = 1).  
 
Using the same assay, we also looked at the production of secreted IL-4 and the levels of GATA3 
mRNAs. Th2 cells, which are associated with the elimination of helminths and other extracellular 
pathogens, mainly express IL-4 which amplifies their differentiation in an autocrine loop. At the 
molecular level, the expression of IL-4 and other Th2 cytokines is controlled by the zinc finger protein 
GATA3. GATA3 is preferentially expressed in Th2 and lost in developing Th1 cells (Zheng and Flavell 
1997; Zhang, Yang et al. 1998; Ferber, Lee et al. 1999).  
 
IL-4 production was detected in BALB/c cultures from day 4, and remained at levels varying between 
1,000 and 2,000 pg/ml subsequently. SKG T cells did not produce significant amounts of IL-4 except 
24h after the antigen recall when SKG levels reached a transient peak at 1,140 pg/ml. During the early 
differentiation phase, levels of GATA3 mRNA were similar between both type of cells, but although 
the levels remained low in SKG throughout, they subtantially increased in BALB/c cells upon antigen 
recall. Taken together these data suggest that BALB/c effector T cells produce more IL-4 than their 
SKG counterparts and skew towards a Th2 phenotype in the context of this transgene (figure 3.20), as 
described previously (Scott, Liblau et al. 1994).  




Figure 3.20 – Production of IL-4 and expression of GATA3 in differentiating BALB/c and SKG T cells. Naïve CD4+ T 
cells were primed with HA peptide (2 µg/ml) and cultured for 6 days. Cells were re-stimulated with peptide on day 7. The 
presence of IL-4 was assayed during the early differentiation phase (day 2, 4 and 6) and upon antigen re-stimulation of the 
differentiated effector T cells (day 9 and 11). A: SKG cells produced only very low levels of IL-4 except for a transient peak 
shortly after antigen recall. At all time points, IL-4 production by wild-type cells was markedly higher (n=2). B: GATA3 mRNA 
levels were higher in BALB/c cells from the end of the differentiation period (n=1). 
 
Between 2,500 and 3,500 pg/ml of IFNγ were produced by BALB/c naïve cells upon the first encounter 
with antigen. Comparatively, SKG T cells produced on average between 500 and 1,500 pg/ml.  During 
that same early phase of the assay, Tbx21 mRNA levels steadily increased in SKG cells to reach, by day 
6, the same levels as wild-type cells and this level of expression was maintained up to day 11. This 
was reflected in the secretion of IFNγ which was similar in both cultures following antigen re-
stimulation (figure 3.21). 
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The presence of both IFNγ and IL-4 concurrently is at first surprising since the expression of IFNγ and 
IL-4 is thought to be mutually antagonistic (Maggi, Parronchi et al. 1992; Parronchi, De Carli et al. 
1992), yet previous reports have suggested that both cytokines can be up-regulated in short-term 
cultures of CD4+ cells (Kelso and Gough 1988; Swain, McKenzie et al. 1988; Street, Schumacher et al. 
1990). Moreover although T cells from BALB/c mice differentiate towards Th2 responses after 
infection or immunization (Chatelain, Varkila et al. 1992; Scott and Scharton 1994), it has also been 
shown that, following immunisation with an antigen such as hemocyanin, they may retain the ability 
to produce IFNγ, a key Th1 cytokine, along with Th2 cytokines such as IL-4 and IL-5 (Sedlik, Deriaud et 
al. 1997).  
 
In summary, data presented in this section show that naïve CD4+ T cells from both BALB/c mice and 
SKG mice - on a BALB/c background - produce relatively high and comparable amounts of IFNγ and 
Tbx21 mRNA by the time they are differentiated, and irrespective of the differentiation subset they 
seem to belong to.  
 




Figure 3.21 – Production of IFNγ and expression of Tbx21 in differentiating BALB/c and SKG T cells. Naïve 
CD4+ T cells were primed with HA peptide (2 µg/ml) and cultured for 6 days. Cells were re-stimulated with peptide on 
day 7. The presence of IFNγ was assayed during the early differentiation phase (day 2, 4 and 6) and upon antigen 
re-stimulation of the differentiated effector T cells (day 9 and 11). A: SKG cells produced lower levels of IFNγ during 
cell priming, but similar levels after antigen recall (n=2). B: Tbx21 mRNA levels increased in SKG cells during cell 
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The production of IL-10 from both strains was detectable from day 4 and increased rapidly to 
extremely high levels, especially in BALB/c cell cultures (figure 3.22). Post-antigen re-stimulation, the 
secretion of IL-10 from the effectors T cells remained high for both type of cells, although the levels 
were higher in BALB/c than in SKG supernatants. Although IL-10 can be secreted by Th1 cells, 
especially in humans, Th2 cells are known to express high levels of IL-10 (Fiorentino, Bond et al. 1989; 
Moore, de Waal Malefyt et al. 2001). Moreover GATA3, which was found to be up-regulated in 
differentiating BALB/c cells, is thought to have a direct role in remodelling the IL-10 locus in CD4+ T 
cells and regulate its production (Shoemaker, Saraiva et al. 2006). This lends further support to the 





Figure 3.22 – Production of IL-6, IL-10 and TNFα by BALB/c and SKG differentiating CD4+ T cells. Naïve BALB/c and 
SKG CD4+ T cells were primed with HA peptide (2 µg/ml) and cultured for 6 days. Upon antigen recall on day 7, BALB/c cells 
showed preferential expression of IL-10, a Th2 cytokine, whereas SKG cells expressed higher amounts of IL-6, a Th17 
cytokine. Surprisingly, BALB/c cells showed consistent higher secretion of TNFα throughout the observed period (n = 2).  
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Although TNFα is a pro-inflammatory cytokine often linked with chronic inflammatory conditions such 
as arthritis, the production of TNFα in our assay was higher, though not significantly, in wild-type cell 
cultures compared to cultures from SKG mice (figure 3.22).  
 
IL-6 shows a production pattern which is similar to IFNγ in the sense that the cytokine level was 
initially reduced in cultures of naïve SKG cells which were not yet differentiated (D0 to D6), but 
eventually reached similar levels on day 9 and day 11 once the differentiated Th cells were re-
stimulated with antigenic peptide. This suggests that the mutant ZAP-70 does not influence the 
downstream expression of such cytokines by effector SKG T cells. This is in contrast to cytokines such 
as IL-17 or IL-4 for which the mutant ZAP-70-mediated signalling cascade seems to differentially 
influence intra-cellular events (for instances up/down-regulation of transcription factors or chromatin 
remodelling and epigenetic modifications in specific gene loci), resulting in pronounced differences in 
cytokine production levels once the cells are differentiated.  
 
Finally we looked at the production of mRNA levels for FoxP3 as a marker for the Treg subset. As 
previously discussed, there was initially higher levels of FoxP3 mRNA expression in naïve SKG T cells. 
However FoxP3 was rapidly down-regulated in both strains following peptide priming. The levels of 
FoxP3 remained relatively low in BALB/c cells throughout the assay, whereas SKG cells showed slightly 









Figure 3.23 – Production of FoxP3 mRNA in differentiating BALB/c and SKG CD4+ T cells. Transcription of 
FoxP3 is down-regulated upon initial priming and remains relatively low through the differentiation period, even 
following re-stimulation (n = 1).  
 
The difference of FoxP3 mRNA expression between naïve BALB/c and SKG T cells correlated well with 
the difference which was observed at the protein levels (figure 3.24) whereby three times more SKG 
CD4+ T cells expressed FoxP3+ that wild-type CD4+ T cells. It should be pointed out that since CD25+ 




Figure 3.24 – Intra-cellular expression of FoxP3 in purified naïve BALB/c and SKG T cells. Naïve CD4+ T cells, purified 
from HNT-TCR BALB/c and SKG lymphoid organs, were stained with anti-CD4 and anti-FoxP3 monoclonal antibodies. On 
average there were 3 times less FoxP3+ cells in the wild-type naïve CD4+ population when compared to SKG mice. Flow-
cytometry figures representative of two independent experiments. 
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Although it is unclear whether the CD4+CD25-FoxP3+ T cell subset is functionality relevant, the 
difference in BALB/c and SKG naïve populations is likely to stem from the observation that both 
BALB/c and SKG total splenocytes contained a subset of CD4+ T cells which was CD25-FoxP3+ (figure 
3.25), with a 2-fold difference between BALB/c  and SKG CD4+ T cells (respectively 4.5% and 9% were 
CD25-). Presumably these cells expressed CD62L as they were selected on this basis, with a higher 




Figure 3.25 – CD25+FoxP3+ and FoxP3+ BALB/c and SKG splenocytes. Both BALB/c and SKG splenocytes contain a 
subset of CD4+ T cells which is CD25-FoxP3+, as shown by the difference between columns on the left and their counterpart 











A point-mutation in ZAP-70 results in an alteration in T cell signal transduction in SKG T cells, leading 
to abnormal thymic selection and the survival of auto-reactive cells that should normally have been 
deleted (Sakaguchi, Takahashi et al. 2003). Consequently SKG mice develop T cell-mediated 
autoimmune arthritis with features of human RA. 
 
Although CD4+ T cells play a pivotal role in SKG arthritis (Sakaguchi, Takahashi et al. 2003), I observed 
that SKG lymphoid organs have reduced numbers of CD4+ T cells, and that those cells did not 
proliferate as well as BALB/c T cells in vitro when stimulated with equivalent concentrations of 
peptide or anti-TCR monoclonal antibodies. They also produced significantly lower amounts of IL-2 
upon activation, indicative of their impaired TCR signalling pathways. 
Despite the ZAP-70 defect, SKG T cells, when stimulated in bulk cultures via their TCR with antigenic 
peptide, were able to secrete a variety of cytokines - including IL-4, IL-6, IL-10, IL-17, TNF-α and IFN-γ - 
although at levels and in patterns that differed from wild-type BALB/c T cells. 
 
Upon antigen re-stimulation, differentiated effector Th cells, derived from highly purified SKG naïve 
CD4+ precursors, showed significant differences in the production of two cytokines in particular: IL-4, 
the signature-cytokine of Th2 cells and IL-17, the signature-cytokine of Th17 cells (summarised in 
figure 3.26). Although the assessment of additional cytokines or markers (for instance IL-5 and IL-13 
for Th2; IL-17F, IL-22 and IL-23R for Th17) would be required to confirm more precisely which Th 
subsets BALB/c and SKG naïve T cells differentiate into, the data demonstrate that when stimulated 
under identical priming conditions and without the need for polarising cytokines and anti-cytokine 
neutralising antibodies, BALB/c and SKG naïve T cells differentiate into Th cell subsets whose 
expression profiles are distinct. Furthermore, the differences in expression of IL-4 and IL-17 observed 
were also reflected at the mRNA level since BALB/c Th cells expressed higher amounts of mRNA for 
GATA3 whereas SKG Th cells contained increased levels of RORc mRNAs. These data indicate that the 
ZAP-70 mutation in SKG naïve T cells differentially influenced the differentiation process and led to 
the re-organisation and modifications of chromatin at the gene loci of selected cytokines. 
 




Figure 3.26 – Cytokine production by effector CD4+ Th cells – derived from naïve CD4+ T cells - 4 days after 
re-stimulation with peptide (day 11). Highly purified naïve CD4+ T cells were stimulated with HA peptide in the 
absence of polarising cytokines, and left in cultures for 6 days. On day 7, they were re-stimulated with antigenic 
peptide. On day 11, differentiated BALB/c and SKG T cells secreted different amounts of cytokines, showing that 
naïve BALB/c and SKG T cells, although primed in exactly identical conditions, differentiated into distinct Th subsets 
(n = 2). 
 
In this experimental setting both wild-type and SKG Th cells produced relatively high amounts of IFNγ 
and IL-10, irrespective of any constraints on Th differentiation imposed by the ZAP-70 mutation. 
Although TNFα plays a role in modulating the severity and incidence of SKG arthritis, and high levels 
of TNFα are found in the ankle-joint fluid from arthritic SKG mice (Hata, Sakaguchi et al. 2004), 
differentiated SKG T cells produced lower amounts of TNFα than control BALB/c. Since this assay only 
reflected the cytokine production from T cells, it is possible that in vivo TNFα is expressed by other 
immune cells, such as macrophages, and so any increased production of TNFα in SKG mice might be 
the result of the pro-inflammatory cytokine environment sustained through cell-to-cell interactions 
within the inflamed synovium (Vey, Burger et al. 1996; McInnes, Leung et al. 1997; Parry, Sebbag et 
al. 1997; Sebbag, Parry et al. 1997).  
 
IL-6 has been shown to be important for Th17 differentiation (Bettelli, Carrier et al. 2006; Veldhoen, 
Hocking et al. 2006; Nurieva, Yang et al. 2007; Korn, Mitsdoerffer et al. 2008) and is strictly required 
for the development of SKG arthritis (Hata, Sakaguchi et al. 2004). Therefore the production of IL-6 by 
SKG T cells, although not significantly increased when compared to wild-type T cells, is likely to 
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contribute and support Th17 lineage commitment, or at least the generation of IL-17 high-producer 
cells.  
 
Although the TCR is a single transmembrane receptor it can induce a variety of cellular responses 
such as thymic selection, proliferation, elaboration of effector responses, anergy or cell death (Rocha 
and von Boehmer 1991; Celis and Saibara 1992). Fluctuations in the TCR signal strength influences 
effector functions and the use of altered peptide ligands (APLs) has provided clear evidence of the 
heterogeneity of TCR responses (Sloan-Lancaster and Allen 1996). Differential signalling through the 
TCR is achieved through qualitative differences in the effector pathways recruited by the TCR 
(Alberola-Ila, Takaki et al. 1997). When it comes to T cell development, the Th differentiation pathway 
is influenced by a complex interplay between the cytokine micro-environment, receptor ligand 
interactions on the T cell and the APCs, and the potency of the TCR signalling (Leitenberg and 
Bottomly 1999; O'Garra and Arai 2000). Such factors will impact multiple cellular mechanisms which 
form the molecular basis for commitment to a Th phenotype, including differential cytokine receptor 
expression, expression of transcription factors and/or chromatin remodelling of Th-specific gene loci 
resulting in the expression of distinct cytokine genes (Szabo, Glimcher et al. 1997; Agarwal and Rao 
1998; Agarwal and Rao 1998; O'Garra 1998; Takemoto, Koyano-Nakagawa et al. 1998; Murphy, 
Ouyang et al. 1999). 
 
T cell differentiation is a complex process which involves several coordinated steps regulated at the 
transcriptional levels. Proper T cell activation is the initial step and will trigger several signalling 
events such as the phosphorylation of the TCR ζ chain and downstream effectors (e.g. ZAP-70, LAT 
and PLC-γ), intra-cellular calcium mobilisation as well as ERK, JNK and p38 MAP kinase activation. The 
strength and duration of these signalling cascades culminate in the translocation and nuclear 
accumulation of NFAT, NF-κB and AP-1 molecules (Sundrud and Nolan 2010). Those transcription 
factors then synergise to directly control the gene transcription of many genes including IL-2, IL-2R, 
early activation markers and many other cell cycle regulators required for cell division (Alberola-Ila, 
Takaki et al. 1997). Such signalling cascades can be differentially activated depending on the potency 
of the TCR signal (Boutin, Leitenberg et al. 1997; Leitenberg and Bottomly 1999) and such variations 
will lead to distinct intra-cellular signalling events and outcomes. For instance most of the above-
mentioned pathways need to be fully activated for IL-2 gene transcription. More specifically the 
activation and physical interaction of both NFAT and AP-1 is essential for robust up-regulation of IL-2 
and activation of either one on its own will only induce weak expression of IL-2 (Chen, Glover et al. 
1998).  
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Following NFAT:AP-1-dependent T cell activation, productive T cell clones become responsive to their 
cytokine micro-environment and lineage-commitment is initiated by antigen- and cytokine-induced 
signalling and results in chromatin remodelling of genes that confer the differentiated effector 
phenotype. Consolidation of lineage-committed T cells occurs as general and lineage-specific 
transcription factors induce a first wave of gene expression strengthening  the differentiation of one 
effector subset and inhibiting shift to a different lineage (Miller and Weinmann 2009; Sundrud and 
Nolan 2010). For instance Th2 differentiation sees demethylation and chromatin remodelling of the 
IL-4 locus which, in naïve T cells, resides in a poorly accessible chromatin structure. These 
modifications are enforced by the induction of lineage-specific master transcriptional regulators, e.g. 
GATA3 and c-MAF, which bind to dispersed regulatory elements to create and maintain an accessible 
IL-4 locus structure in the absence of active transcription (Agarwal and Rao 1998). The transcription 
levels of GATA3 are themselves controlled by TCR-induced ERK (Yamashita, Shinnakasu et al. 2005) 
thereby providing a causal link to the initial TCR stimulation. Subsequent acute antigen stimulation 
results in the synthesis and activation of inducible transcription factors, including non-lineage specific 
factors such as NFAT and AP-1 (Rooney, Hodge et al. 1994), which can then easily gain access to open 
loci and stimulate rapid, high-level production of IL-4 (Szabo, Gold et al. 1993; Rooney, Sun et al. 
1995). Finally terminal differentiation largely occurs through active remodelling of chromatin that 
stabilises lineage-specific effector function (Wilson, Rowell et al. 2009) and differentiation to Th2 is 
associated with changes in chromatin structure on the IL-4 gene locus but not in the IFNγ locus 
(Agarwal and Rao 1998; Agarwal and Rao 1998; Takemoto, Koyano-Nakagawa et al. 1998). 
 
T cell differentiation results from the cumulative outcomes of a network of concurrent and interacting 
pathways in which the TCR plays a central and critical role. Therefore it is likely that the 
differentiation process can be influenced by the potency of the initial TCR stimulatory signal and the 
resulting differential activation of its various downstream pathways. The strength of the TCR 
signalling has been shown to be influenced by a number of factors including the dose and form of an 
antigen and its affinity for the TCR (Constant and Bottomly 1997). For instance, within a specific 
experimental setting, stimulation of naïve peripheral CD4+ T cells with a strong agonist peptide 
activated a full pattern of biochemical events sufficient to induce Th1 differentiation, whereas the use 
of a partial agonist on naïve CD4+ T cells, triggered a restricted and more transient pattern of 
signalling events leading to preferential Th2 generation with a variable amount of Th1 generation, as 
described in table 3.1 (Boutin, Leitenberg et al. 1997; Tao, Grant et al. 1997).  
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 Strong agonist Partial agonist 






ZAP-70 ++ - 
PLCγ ++ +/- 






Kinase activity   
JNK1 ++ + 
MAPK +++ + 
NFAT translocation + + 
 ↓ ↓ 
T cell differentiation: Th1 Th2 (± Th1) 
      Table 3.1 – Strong versus partial agonist signalling in naïve CD4+ T cells  
      (adapted from (Boutin, Leitenberg et al. 1997; Leitenberg and Bottomly 1999)). 
 
Taken together, these reports support the view that the distinct cytokine production profiles 
observed during differentiation of BALB/c and SKG Th cells are likely to reflect how, from the outset, 
downstream TCR signalling pathways in naïve SKG T cells are modulated by the defective function of 
the ZAP-70 variant, leading to differential tuning of the molecular transcription machinery by intra-
cellular events.  This is best illustrated by the cytokine profiles expressed during the differentiation 
phase and whose production was directly impacted by the TCR signal strength. Four days after the 
initial antigenic peptide activation of highly purified naïve CD4+ T cells, there were notable reductions 
in IL-2, IFNγ and IL-4 production in SKG cell cultures when compared to wild-type (figure 3.27). These 
differences at the protein level were confirmed at the transcriptional level since Tbx21 (which 
encodes for T-bet) and GATA3, which control the expression of IFNγ and IL-4 respectively, were also 
down-regulated in SKG cells.  Although the production of IL-17 during the early phase of 
differentiation was not significantly different between wild-type and SKG cells, mRNA for RORc was 
up-regulated in SKG T cells throughout the period of differentiation, leading to higher levels of IL-17 
upon antigen recall. Those data indicate that the ZAP-70 mutation in SKG naïve T cells differentially 
influences, during early differentiation, the expression of distinct lineage-specific transcription factors 
and other intra-cellular events, resulting in the impaired expression of selected cytokines. 
 
These modifications result in the production and secretion of distinct profiles of cytokines from 
BALB/c and SKG T cells as they differentiate, creating a distinct cytokine milieu which further amplifies 
Chapter 3  Results 
113 
 
the differentiation process (e.g. through expression of IL-6, and/or reduced levels of IL-4), leading to 
the generation of terminally differentiated Th effector cell subsets.  
 
 
Figure 3.27 – Cytokine production by naïve CD4+ T cells 4 days after first encounter with antigen. On D4, 
BALB/c and SKG naïve cells showed distinct cytokine profiles following antigen stimulation in comparable priming 
conditions. Of note, differentiating SKG cells showed significant deficiency in production of IL-2, IFNγ and IL-4 (n = 2).  
 
Interestingly the ZAP-70 mutation seems less permissive for the early production of cytokines which 
are known to be influential in guiding the differentiation towards distinct Th subsets, namely IFNγ for 
Th1 cells and IL-4 for Th2 cells. IL-2, although not lineage-specific to the same extent, is known to play 
an important role in the generation of iTregs (Sakaguchi, Sakaguchi et al. 1995).  Another noteworthy 
observation is that IFNγ, IL-4 and IL-2 - whose production is diminished in early activation of naïve 
SKG T cells - all share the ability to antagonize the development of Th17 cells (Harrington, Hatton et 
al. 2005; Park, Li et al. 2005; Laurence, Tato et al. 2007). So could the deficiency of one or both or all 
of them be directly responsible for the incremental production of IL-17+ SKG cells? 
 
Although IFNγ was initially reduced in SKG T cells, it was eventually produced at similar levels once 
the T cells were fully differentiated. This initial discrepancy suggests that some cytokines may require 
a stronger TCR signal to be fully expressed at the outset. In other words they may require the 
induction of transcription factors at levels which can only be reached following strong activation of 
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TCR by antigen. Still during the differentiation process, the SKG cells expressed increasing amounts of 
mRNA for Tbx21 – maybe because SKG T cells still secrete enough IFNγ to activate autocrine cytokine 
signalling – eventually levelling with BALB/c and producing similar amounts of IFNγ upon antigen 
recall. This illustrates that the ZAP-70 mutation may modulate the production of some cytokines 
during the initial TCR simulation without having a long-lasting repressive effect on their production 
once the differentiation pattern is established.  
 
In terms of phenotype, I also looked at the expression of the intra-cellular transcription factor FoxP3  
and showed that a greater proportion of CD4+ cells express FoxP3 in SKG lymphoid organs, although 
the difference is less pronounced in absolute number of cells, because of T lymphopenia in SKG mice. 
The number of FoxP3+ Treg cells in the immune system is normally kept constant at around 10% of all 
CD4+ T cells, with a general increase only occurring at sites of inflammation (Sakaguchi 2010). 
Therefore the increased number of FoxP3+ cells might be attributed, even in the absence of clinical 
manifestations of arthritis, to systemic inflammation in SKG mice due to the presence of highly 
reactive peripheral T cells.  
 
Naïve CD4+ T cells from SKG mice were also shown to contain three times as much mRNA for FoxP3 as 
BALB/c naïve T cells. Moreover, following purification of naïve T cells and removal of CD62L- T cells, 
the resulting SKG population showed a 3-fold increase of CD4+CD25-FoxP3+ T cells  compared to naïve 
BALB/c T cells. The production and/or increase in the number of CD4+CD25-FoxP3+ T cells has been 
shown to be exacerbated in ageing mice (Nishioka, Shimizu et al. 2006), which may suggest that the 
immune system in SKG mice shows early signs of ageing.  
 
Taken together these data demonstrate that naïve BALB/c and ZAP-70 mutant SKG CD4+ T cells 
expressing an identical TCR transgene differentiate de novo into distinct subsets of effector Th cells 
following stimulation with specific antigen in the absence of a polarising cytokine environment.  
Although the ZAP-70 mutation has a detrimental effect on the ability of SKG T cells to become fully 
activated and proliferate fully, it does not lead to an overall down-regulation of all cytokines but to 
selective modulation of early cytokine production which have a long-term effect on cell 
differentiation. The data suggest that the genetic attenuation of TCR signalling at a TCR-proximal step 
might be sufficient to induce differential intra-cellular events and lead to selective cytokine 
deficiencies during the initial differentiation process, resulting in specific modifications of the cellular 
transcription machinery which in turn translate into distinct effector Th subtypes. Significantly, SKG 
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effector T cells are deficient in IL-2, IL-4 and IFN-γ production during differentiation and become IL-17 
high-producers when compared to wild type BALB/c T cells.  
 
Though their main function seems to be the clearance of extra-cellular infectious pathogens, Th17 
cells also contribute to inflammation and there is ample evidence that IL-17–secreting CD4+ T cells are 
pathogenic in several murine models of autoimmune disease (Oukka 2008; Korn, Bettelli et al. 2009). 
The role of Th17 cells in human diseases is not as well established but there is mounting 
circumstantial evidence that Th17 and Th17-associated cytokines are important in human rheumatoid 
arthritis (Kirkham, Lassere et al. 2006), psoriasis (Krueger, Langley et al. 2007), multiple sclerosis 
(Matusevicius, Kivisakk et al. 1999), asthma (Molet, Hamid et al. 2001; Barczyk, Pierzchala et al. 2003) 
and inflammatory bowel disease (Duerr, Taylor et al. 2006).  Since SKG arthritis is critically dependent 
on Th17 cells and a deficiency of IL-17 totally suppresses the disease (Hirota, Hashimoto et al. 2007), 
it is crucial to understand how the ZAP-70 mutation induces naïve T cells to become pathogenic Th17 
cells and whether this process can be manipulated in order to suppress or limit the generation of IL-
17 producing cells and subsequently inhibit in vivo the development of SKG T cell-mediated 
autoimmune arthritis.  
 
In the light of these findings it would now be important to investigate further the mechanism through 
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4.1. Experimental approach 
 
One approach used to confirm that defective TCR signalling in SKG T cells favours the generation of 
arthritogenic IL-17 high-producers was to restore normal TCR function by gene therapy. I therefore 
set about establishing virus-mediated gene transfer protocols to compare the effects of reconstituting 
SKG T cells with wild type or mutant ZAP-70 on the development of inflammatory arthritis in a T cell-
mediated adoptive transfer model.  
 
Before I could carry out adoptive transfer experiments using reconstituted SKG T cells, it was 
important to optimise the experimental conditions for the adoptive transfer model that would give 
the most consistent arthritis in SCID recipients when using unmanipulated SKG T cells. This way, 
experiments could be carefully controlled and it would be possible to document any changes in 
arthritis development following reconstitution of arthritogenic T cells with wild-type ZAP-70.  
 
The adoptive transfer model involves harvesting T cells from lymphoid organs of non-arthritic SKG 
mice (T cells donors) and injecting them intra-veinously into SCID mice (T cells recipients), which are 
profoundly deficient in B and T cells. Over a period of time, the SCID recipients developed arthritis 
mediated by the injected SKG CD4+ T cells (figure 4.1). Control SCID mice received equal amounts of T 
cells from lymphoid organs of wild-type BALB/c mice. 
 
 
Figure 4.1 – Adoptive transfer model of SKG arthritis in SCID mice. SCID mice are injected in i.v. with defined quantities 
of cells harvested from lymph nodes and/or spleen of non-arthritic SKG mice. Over a period of time, SCID recipients develop 
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4.2. Determining the minimum number of SKG cells required to transfer 
arthritis  
 
The first step was to carry out a pilot study to determine the minimum amount of arthritogenic SKG 
CD4+ T cells required to induce arthritis in SCID recipients. 
 
Four groups of SCID mice received increasing doses (0.5, 2, 5 or 10 x 106) of total cells prepared from 
spleen/lymph nodes cell suspensions, derived from 10-week old non-arthritic SKG mice. As a control, 











1 6 BALB/c 10 
2 6 SKG 0.5 
3 6 SKG 2 
4 6 SKG 5 
5 5 SKG 10 
                               Table 4.1 - Protocol for first adoptive transfer. 
 
The incidence and severity of arthritis developing in SCID mouse recipients was assessed on a weekly 
basis. Swelling of the wrist and ankle joints was measured with callipers and each joint was 
individually scored for clinical severity of disease according to the following scale: 0.5. Erythema; 1. 
Slight swelling; 2. Severe swelling; 3. Ankylosis, with a maximum of 12 points per animal (figure 4.2).  
 




Figure 4.2 – Example of clinical 
presentation of arthritis in SCID 
mice. Following adoptive transfer of 
arthritogenic SKG cells, SCID mice 
developed arthritis in the ankle (right) as 
well as wrists, whereas SCID mice 
which received BALB/c cells showed no 
clinical evidence of arthritis (left).   
 
The first clinical manifestations of disease were noted by week 7 in five recipients SCID mice, mainly 
in group 3 (2 x 106 total cells) where four of six mice showed signs of inflammation in the ankles 
(figure 4.3).  By week 9, arthritis was seen in all four groups recipient of SKG T cells but not in the 
control group which received BALB/c T cells. Over the 13-week experiment, disease progression was 
earlier and steeper in the two groups that received the lower dose of SKG total cells.  
 





Figure 4.3 – Onset and progression of SKG cell-mediated arthritic disease in SCID mice recipients. SCID mice 
received either BALB/c or increasing doses of SKG total cells from lymphoid organs. Weekly scores for clinical presentation 
of arthritis in wrists and ankles were recorded over thirteen weeks. In this experiment, the severity and incidence of arthritis 
was predominant in the two groups which had received the lower doses of SKG cells (0.5 and 2 x106 total cells). N = 6 for 
each treatment group (*** = p < 0.001; ** = p < 0.01; * = p < 0.05). 
 
At week 13, the end-point of the experiment, all mice injected with SKG arthritogenic cells in groups 2 
(0.5 x 106 total cells), 3 (2 x 106 total cells) and 4 (5 x 106 total cells) presented with at least one 
affected joint (wrist or ankle), with total arthritic scores ranging from 1 to 10. Two out of six mice 
showed signs of articular inflammation in group 5 (10 x 106 total cells). No signs of disease were 
observed in the control SCID mice recipients of BALB/c total cells (figure 4.4).  
 
The severity of the disease was very significantly higher in the two groups that received the lower 
doses of total cells (0.5 and 2 x 106 cells) with mean clinical scores of 4.83 and 6.33m (p < 0.0001 for 
both), respectively. Weight was also measured on a weekly basis, but weight loss was not found to be 
predictive of disease development (data not shown).  






Figure 4.4 – Incidence and severity of SKG cell-mediated arthritic disease in SCID mice recipients by the 
experimental end-point (13 weeks post transfer). In terms of incidence, all SCID mice which received 0.5, 2 or 5 x 106 
SKG total cells showed articular swelling and signs of inflammation in at least one joint. Unexpectedly, the severity of disease 
was significantly higher in the two groups that received the lower doses of SKG cells (*** = p < 0.001; ** = p < 0.01; * = p < 
0.05).  
 
Upon completion of the experiment, mice were sacrificed and joints were harvested for histological 
analysis. Joint tissues were stained with haematoxylin and eosin and assessed for signs of tissue 
inflammation and joint destruction. Each animal joint was scored as follows: 1. Mild inflammation 
with preservation of the joint architecture; 2. Additional synovium hyperplasia, oedema and partial 
loss of cartilage and bone structure; 3. Very severe inflammation accompanied by pannus formation 
and complete joint destruction; with a maximum of 12 points per mouse.  
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Joints from SCID mice that received cells harvested from wild-type lymphoid organs did not show any 
signs of inflammation or articular damage. In contrast joints from SCID recipients of SKG T cells which 
developed severe arthritis, showed clear histological signs of disease such as swelling of the soft 
tissues, cell infiltrations, severe loss of joint structure, destruction of bones and pannus formation 
(figure 4.5).  
 
 
Figure 4.5 - Histology of arthritis in wrist of SCID mouse, recipient of SKG cells. Inflammation, synovial hyperplasia, and 
joint destruction can be seen in the wrist joints of SCID recipient animals, following adoptive transfer of SKG cells (right), 
whereas the joint remains intact following adoptive transfer of BALB/c cells (left). Tissues stained with haematoxylin/eosin 
(HE). Original magnification x10 (top panel) and x40 (bottom panel). 
 
Histological scores and clinical scores determined at week 13 were compared and were shown to be 
closely correlated with each other ion with an R2 value of 0.87 (figure 4.6) 
 




Figure 4.6 – Comparison of histological and clinical scores. Upon completion of the adoptive 
transfer experiment (week 13), joint tissues were harvested for histological analysis and scored for 
cellular signs of tissue inflammation. Histology scores correlated well with clinical scores. 
 
4.3. Comparing the arthritogenicity of total and CD4+-enriched cell 
populations 
 
The first adoptive transfer experiment proved that SKG T cell-mediated arthritic disease could be 
transferred to immunocompromised SCID recipients and that 0.5 x 106 total cells were sufficient to 
induce disease. Since SKG arthritis is mediated by CD4+ T cells (Sakaguchi, Takahashi et al. 2003), the 
next step was to compare the arthritogenicity of SKG total spleen/lymph nodes cells versus SKG 
purified spleen/lymph nodes CD4+ T cells so as to better understand the role, if any, of accessory cells 
other than CD4+ cells, in adoptive transfer of arthritis.  
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Since I had previously observed a higher incidence and severity of disease in mice receiving the lowest 
number of arthritogenic cells, a second objective was to establish whether a dose of CD4+ T cells as 
low as 50,000 would be enough to trigger arthritis in recipients. 
SCID mice received spleen/lymph nodes cell suspensions containing 5, 15 or 45 x 104 CD4+ T cells in 
the presence or absence of non-CD4+ accessory cells. Cell samples were analysed by flow cytometry 


















1 4 BALB/c 2.25 x 10
6
  0.45 x 10
6
 20 
2 4 SKG 0.25 x 10
6
  0.05 x 10
6
 20 
3 4 SKG 0.75 x 10
6
  0.15 x 10
6
 20 
4 4 SKG 2.25 x 10
6
  0.45 x 10
6
 20 
5 4 BALB/c  0.63 x 10
6
 0.45 x 10
6
 72 
6 4 SKG  0.08 x 10
6
 0.05 x 10
6
 63 
7 4 SKG  0.24 x 10
6
 0.15 x 10
6
 63 
8 4 SKG  0.72 x 10
6
 0.45 x 10
6
 63 
               Table 4.2 – Protocol for second adoptive transfer.  
 
Groups 1 to 4 received CD4+ T cells as part of unselected total spleen/lymph nodes cells. Groups 5 to 8 
received CD4+ T cells that had been negatively selected using a magnetic bead-based protocol. Flow 
cytometric analysis showed that the proportion of CD4+ T cells, in both wild-type and SKG selected T 
cell suspensions increased, after negative selection, to 72% and 63% respectively. Therefore the 
population of donor cells should be described as enriched in CD4+ T cells rather than as purified CD4+ 
T cells. 
 
As carried out previously, clinical presentation of the disease was monitored and scored on a weekly 
basis.  
 
Considering the groups that had been injected with CD4+-enriched cells from SKG lymphoid organs, 
the first signs of disease appeared noticeably from week 6 in the SCID animals which had received 
50,000 CD4+ T cells (figure 4.7). Consistent with previous findings, lower doses of CD4+ T cells induced 
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earlier and stronger inflammatory arthritis since by the end of the experiment, out of 8 mice that 
showed articular swelling symptomatic of arthritis, 4 had received 50,000 CD4+ T cells, 3 had received 
150,000 CD4+ T cells and only one had received the maximal dose of 450,000 CD4+ T cells (figure 4.7). 
None of the SCID mice that had received CD4+-enriched cell suspension from BALB/c mice developed 
arthritis.  
 
In contrast with the previous experiments, the adoptive transfer was not successful in the groups that 
received unselected total cell suspensions from SKG mice, and only 1 of 12 mice across the three 
recipients groups developed arthritis. Of interest, this mouse had also received the lowest dose of 
50,000 CD4+ T cells (data not shown).   
 
 
Figure 4.7 – Clinical scores for SCID recipients of CD4+-enriched SKG cell suspensions. SCID mice received either 
BALB/c or increasing doses of SKG CD4+ T cells. Clinical severity of arthritis was recorded over 16 weeks. In this experiment, 
arthritis was primarily seen in groups that received lower doses of CD4+-enriched SKG cells. N = 4 for each treatment group. 
 
To summarise, the experiment demonstrated that transfer of 50,000 SKG CD4+ T cells was sufficient 
to induce arthritis in SCID recipients. Again arthritis was observed earlier and at higher frequency in 
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groups receiving the lowest number of cells. Finally, I noted that clinical and histological severity of 
arthritis were concordant.  
 
4.4. Comparing arthritogenicity of SKG CD4+ T cells from different tissue 
sources 
 
Prior experiments, carried out in the Cope laboratory, highlighted variations in arthritis incidence and 
severity depending on whether the transferred SKG cells had been sourced from spleen, lymph nodes 
or thymus (data not shown). This raised the question of whether distinct SKG T cells populations have 
different effector functions and therefore different arthritogenic potential. Preliminary data from our 
lab, suggesting that SKG CD4+ T cells have different cytokine profiles depending on their tissue of 
origin, seemed to support this hypothesis. For example, SKG mesenteric lymph node T cells appeared 
to produce the most IL-10 as compared to SKG popliteal lymph node T cells which produced more IL-
17 than CD4+ T cells from any other lymph nodes (figure 4.8). Therefore based on this analysis I 
hypothesised that the ratio of IL-17-producing CD4+ T cells versus IL-10-producing CD4+ T cells would 
serve as an indicator of inflammatory potential, and that cells from mesenteric lymph nodes might 
have more of an anti-inflammatory effect whereas popliteal lymph node cells might be more 
arthritogenic.   
 
 




Figure 4.8 – Cytokine profile of SKG CD4+ T cells vary depending on their tissue of origin. Cells were harvested from 
SKG lymph nodes and stained for CD4 and various cytokines following PMA/ionomycin stimulation. SKG mesenteric lymph 
node T cells produced the most IL-10 and the least IL-17 when compared to SKG popliteal lymph node T cells which 
produced more IL-17 and less IL-10 than CD4+ T cells from any other lymph nodes or spleen (n = 14). These experiments 
were carried out by Tharsana Tharmalingam (Cope lab at KCL). 
 
In conjunction with this observation, I also saw in both previous adoptive transfer experiments more 
and earlier disease in groups receiving the lowest number of SKG T cells. This might suggest that there 
exists a critical threshold, in terms of number of transferred CD4+ T cells expressing anti-inflammatory 
cytokines such as IL-10, above which they are able to protect against disease. 
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To test this hypothesis, I compared, in an adoptive transfer experiment, the arthritogenicity of cells 
from two distinct lymph node sets (mesenteric and popliteal) in the context of low and high number 
of injected cells to ascertain whether the difference in cytokine profiles may influence the ability of 
the cells to induce disease (table 4.3). The CD4+ T cells were non-sorted and injected as part of a 




Low number of SKG CD4
+
 T cells 
(50,000) 
High number of SKG CD4
+
 T cells 
(450,000) 















                 Table 4.3 – Third adoptive transfer protocol to compare the arthritogenic potential of CD4
+
 cells from 
                 different lymph nodes. 
 
On the day of adoptive transfer, cells were harvested from either mesenteric or popliteal lymph 
nodes derived from 10 week-old non-arthritic female SKG mice. In contrast to previous findings, the 
mean ratio of IL-17/IL-10-producing CD4+ T cells in SKG popliteal lymph nodes was lower than in SKG 
mesenteric lymph nodes (figure 4.9). This meant that T cells sourced on the day had a cytokine profile 
that differed from earlier observations and that CD4+ T cells from SKG mesenteric lymph nodes might 
be more pro-inflammatory. 
 
 




Figure 4.9 – Comparison of IL-17- vs. IL-10 producing CD4+ T cells. Previous data (left-hand columns) 
suggested that CD4+ T cells sourced from SKG popliteal lymph nodes had more of a pro-inflammatory profile 
(measured by the ratio of IL-17-producing CD4+ T cells versus IL-10-producing CD4+ T cells) than T cells 
harvested from SKG mesenteric lymph nodes. Cells harvested from SKG mice for adoptive transfer showed 
that for this specific experiment the popliteal CD4+ T cells had the lowest IL-17/IL-10 ratio and therefore the 
more protective profile. Work carried out in collaboration with Tharsana Tharmalingam in Prof Cope’s lab 
(KCL). 
 
The first signs of joint swelling appeared six weeks post-injection in group 2, which had received 
50,000 mesenteric CD4+ T cells and in group 3, which had received 50,000 CD4+ T cells from the 50%-
50% combination (figure 4.10). The disease progression was most pronounced in group 2 (mes-50K), 
followed by group 3 (mix-50K) then group 1 (pop-50K), again emphasising that groups receiving the 
lowest number of SKG T cells develop earlier and stronger disease. In contrast, the onset of arthritis 
was delayed for the three groups having received the higher doses of CD4+ T cells and arthritis was 
not seen before week 8 for group 5 (mes-450K), week 10 for group 6 (mix-450K) and week 15 for 
group 4 (pop-450K). These data suggest that although both variations in the number of cells injected 
and variations in the tissue source of those cells contribute differently to the disease onset and 
development, the cell-number effect is dominant over the tissue source effect.  
 
 




Figure 4.10 – Influence of tissue source in adoptive transfer model. In order to compare the arthritogenicity of SKG T 
cells from two distinct lymph node sets in the context of low and high numbers of injected cells, SCID mice received either 
50,000 or 450,000 SKG CD4+ T cells derived from mesenteric lymph nodes, popliteal lymph nodes or a mixture of both. Prior 
to injection, mesenteric T cells showed the most pro-inflammatory profile as measured by the ratio of IL-17- over IL-10-
producing CD4+ T cells. Disease onset was earlier and the severity and incidence of arthritis was greater in the three groups 
that received the low number of CD4+ T cells. As for the cytokine profile, CD4+ T cells sourced from SKG mesenteric lymph 
nodes produced a more severe form of disease when compared to those from popliteal lymph nodes, irrespective of the dose 
of transferred cells. N = 5 for each treatment group. 
 
By week 11, all mice from group 2 (mes-50K) showed evidence of severe swelling or ankylosis in all 
four joints monitored (figure 4.11) and some mice also suffered from diarrhoea and alopecia around 
the snout. Because of the severity of disease in this group all mice were culled at this time-point. In 
contrast, only two mice showed signs of arthritis such as slight or severe swelling in group 1 (pop-
50K). The mean arthritic score of group 2 (mes-50K) was significantly different from that of group 1 
(pop-50K) and group 3 (mix-50K), demonstrating that T cells from distinct tissues can have different 
arthritogenic potential; the mean arthritic score from group 2 (mes-50K) was also significantly 
different from that of group 4 (mes-450K), consistent with previous findings that the number of 
injected T cells play a critical role in disease development in recipient SCID mice. As previously stated, 
the disease onset in groups 4, 5 and 6 – which received 450,000 CD4+ T cells - was delayed by several 
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weeks, but when the experiment was stopped at week 16, the disease was still progressing in those 
three groups. Therefore it is possible that more severe forms of disease would have eventually arisen 
in those groups, although the slope in early disease progression suggested that it was unlikely to 
match that of groups 1, 2 and 3.  
 
 
Figure 4.11 – Clinical scores at week 11. By week 11, two different effects could be seen. The ‘tissue source effect’, 
whereby at equal doses of 50,000 CD4+ T cells, SCID mice having received T cells sources from mesenteric lymph nodes 
developed a significantly more severe form of arthritis than those recipients of T cells from popliteal lymph nodes. The ‘cell 
number effect’, consistent with previous findings, SCID mice who received 50,000 mesenteric lymph nodes T cells developed 
a significantly more severe form of arthritis than those who had received 450,000 T cell from the same lymphoid organs. N = 
5 for each treatment group (*** = p < 0.001; ** = p < 0.01; * = p < 0.05).  
 
In summary, this experiment showed that SKG mesenteric lymph node cells are more arthritogenic 
than SKG popliteal lymph node cells and that more arthritis developed in the groups injected with the 
low number of SKG CD4+ T cells.  
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4.5. Assessing the arthritogenicity of activated SKG CD4+ T cells  
 
In order to reconstitute SKG T cells with wild type ZAP-70, both lentivirus and retrovirus-mediated 
gene transfer protocols were used. Since retroviruses are only able to integrate in cycling cells due to 
their inability to translocate the viral genome across the nuclear envelope (Miller, Adam et al. 1990; 
Roe, Reynolds et al. 1993), and since ex vivo activation of cells for an extended period of time has 
been shown to potentially change the functional capacity of T cells (Sauce, Tonnelier et al. 2002), I 
needed to confirm that adoptive transfer of arthritis could still be successfully achieved using SKG 
CD4+ T cells whose TCR had been stimulated in vitro with the activation protocol required for 
retrovirus-based transduction. 
 
T cells were harvested from SKG lymph nodes and activated in vitro with anti-CD3 and anti-CD28 and 
left to expand for seven days, before being washed and injected into SCID recipients. All SCID groups 
received 50,000 CD4+ T cells. Group 1, the negative control, received activated T cells from BALB/c 
lymph nodes. Group 2, the positive control, received arthritogenic T cells freshly harvested from SKG 




T cell  
source 
In vitro activation Dose  
Group 1 BALB/c LNs Yes 50,000 CD4
+
 T cells  
Group 2 SKG LNs No 50,000 CD4
+
 T cells  
Group 3 SKG LNs Yes 50,000 CD4
+
 T cells  
                          Table 4.4 – Fourth Adoptive transfer protocol to ascertain the arthritogenicity of SKG CD4
+
 T cells 
                          activated in vitro. 
 
Following adoptive transfer of activated SKG T cells, SCID recipients showed the first signs of 
inflammation from week 4 (figure 4.12), two weeks earlier than previously observed. Onset of disease 
in the group which received non-activated SKG T cells was noted by week 7, consistent with previous 
experiments. The arthritis progression and severity in those two groups was similar and by week 10 
the mean clinical arthritic scores had equalised in both groups. Clinical symptoms of arthritis 
transferred by activated SKG T cells did not differ from that of non-activated SKG T cells. No 
differences were detected at the histological level either.    
 




Figure 4.12 – SKG CD4+ T cells activated and expanded in vitro can transfer arthritis to SCID recipients. SCID mice 
were injected with either BALB/c or SKG T cells activated and expanded in vitro for seven days, or with non-activated SKG T 
cells. SKG T cell-mediated arthritis developed in SCID recipients irrespective of whether the T cells had been previously 
activated in vitro. Although disease onset was three-week early for activated SKG T cells, disease progression, incidence, 
severity, clinical symptoms and histological scores were similar in both activated and non-activated SKG T cells groups. N = 4 




Adoptive transfer experiments that were carried out showed that transfer of un-manipulated CD4+ T 
cells derived from the spleen and lymph nodes of female, non-arthritic SKG mice, was sufficient to 
induce inflammatory arthritis in SCID recipients. Arthritis in recipient animals was detected 6-to-7 
weeks after the adoptive transfer took place, and the disease was always noticed first in the ankles. 
There was a strong correlation between histological severity of the inflammatory process (synovial 
hyperplasia, cell infiltration, pannus formation, cartilage and bone damage and subsequent loss of 
joint structure) observed in the histological tissues and clinical signs (erythema, swelling of joints, 
ankylosis and articular stiffness) in recipient mice. 
 
In the first experiment, 86% of mice that had received arthritogenic SKG cell suspensions developed 
arthritis. The average score, reflective of the severity of the disease, varied depending on the amount 
of cells transferred. Interestingly, the groups that received the lowest amounts of total cells (0.5 and 2 
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x 106) were the groups with the highest average arthritic score, 4.83 and 6.33 respectively. Additional 
signs of disease such as diarrhoea and loss of weight were also observed in some animals, although 
the loss of weight seemed to arise after clinical onset of the arthritis and therefore is unlikely to be 
useful as a predictor of disease.  
 
The incidence of disease was lower in the second adoptive transfer experiment: 8.3% of animals that 
received total cells and 58.3% of animals that received CD4+-enriched cells developed disease. 
Although some minor technical parameters were modified between the first and second experiments 
(such as the gauge of the needles used for injection, from 29G to 30G, or the donor mice being older 
by 2-3 weeks) there was no obvious factor to explain the differences observed in the incidence of 
arthritis between the two experiments. One potential cause could be the extra manipulation of 
selecting CD4+ T cells which extended by several hours the time that all cells remained ex vivo in the 
second experiment compared to the first one. It is possible that cellular damage occurring during that 
time led to impaired effector function (e.g. ability to survive, activate or migrate) or reduced viability 
post-transfer. This, in turn, might have hindered the development of the disease.  
 
Overall, two main issues arose from the first two adoptive transfer experiments. First, variations in 
arthritis incidence and severity were noted depending on cell source (spleen, lymph nodes, thymus) 
and CD4+ T cells harvested from distinct lymph nodes showed differential production of cytokines 
such as IL-17 and IL-10. This observation was also consistent with additional prior experiments carried 
out in the Cope laboratory. These findings suggest that T cells from specific lymph nodes might have 
more of an anti-inflammatory or pro-inflammatory profile and, more generally, that distinct SKG T cell 
populations might have different effector functions leading to different arthritogenic potential. 
 
The second finding was two-fold. First, I demonstrated that as few as 50,000 CD4+ cells were sufficient 
to trigger arthritis whether they were injected as part of a total cell suspension or in an enriched 
suspension. This was an important observation, for practical reasons, since the low number of cells 
required to transfer arthritis should greatly facilitate future reconstitution experiments. Second, in 
both experiments I saw more and earlier disease in groups receiving the lowest number of cells. 
 
Taken together, these findings suggest that there exists a critical threshold, in terms of number of 
transferred CD4+ T cells expressing anti-inflammatory cytokines, above which they are able to protect 
against disease. For instance if, based on the cytokine profile defined in the Cope lab, the hypothesis 
that SKG mesenteric lymph node cells are more protective is correct, then it is clear that although the 
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ratio of mesenteric cells to total cells would be the same irrespective of whether the total number of 
cells was low or high, the actual number of effector T cells in mesenteric lymph nodes in the injected 
cell suspension would increase as the total number of cells increases, and might then reach that 
critical threshold which is sufficient to exert a protective effect. In fact, this could also help to explain 
some of the differences observed between the two initial adoptive transfer experiments. Although I 
used, in both experiments, pooled T cells derived from spleen and lymph nodes, the specific 
anatomical location of the lymph nodes was not documented. Therefore a different mix of lymph 
nodes with different properties and arthritogenicity might have been used in these experiments. One 
can speculate that a similar phenomenon might arise with cells other than effector CD4+ T cells. For 
instance, although SKG regulatory FoxP3+CD25+CD4+ T cells, when co-transferred with SKG CD25-CD4+ 
T cells, are much less effective in inhibiting the development of arthritis than wild-type regulatory 
cells (Sakaguchi, Sakaguchi et al. 2006), they may be in sufficient number in cell suspensions with 
large numbers of total cells to inhibit some of the autoimmune processes triggered by the adoptive 
transfer and delay the onset of disease.  
 
To test the hypothesis of differential arthritogenic potential depending on tissue source, I compared 
the arthritogenicity of either low or high number of injected mesenteric CD4+ T cells and popliteal 
CD4+ T cells. Flow cytometry analysis of intracellular cytokine showed that, in contrast to previous 
findings from the Cope lab, SKG mesenteric CD4+ T cells produced more IL-17 and less IL-10 than cells 
from SKG popliteal lymph nodes suggesting that mesenteric T cells might be more aggressive in their 
arthritogenicity.  
 
Indeed, SCID mice injected with a low number of mesenteric T cells developed arthritis with greater 
incidence and severity than the group injected with a low number of popliteal T cells as well as the 
group injected with a high number of mesenteric T cells.  
 
This experiment confirmed the two previously raised points. First, arthritogenicity of SKG CD4+ T cells 
varies depending on their lymph node origin and more specifically my results proved that mesenteric 
lymph node cells were more arthritogenic than popliteal lymph node cells.  This raises interesting 
questions. Is the protective effect of the popliteal population protective really driven by the cytokine 
profile? Is the composition of mesenteric and popliteal lymph nodes fundamentally different and is 
there a role for accessory cells other than CD4+ T cells? Do the homing receptors on mesenteric Th17 
cells somehow favour migration to the joints? Although it was not possible to investigate these 
questions because of time constraints, such questions would be worth exploring in future studies.  




In the context of my thesis the fact that particular cell populations, in isolation, can induce disease 
with very different rates of incidence and severity might prove useful in the planning of future 
experiments. For instance if the consequence of TCR signalling reconstitution in SKG T cells is to 
protect against disease, it would be useful to control the experiment using unmanipulated cells from 
the lymph nodes that proved to be the most arthritogenic, so as to amplify the differences in clinical 
presentation of the disease between both groups and make scoring easier and more robust. If on the 
other hand the reconstituted TCR signal leads to increased disease, then using lymph node cells that 
induce the least severe disease might be more informative.  
 
Second, consistent with earlier adoptive transfer experiments, more arthritis was seen in the 
recipients of low numbers of SKG T cells, even when the population of injected cells was sourced from 
the same lymph nodes. 
 
When put together these two findings seem to confirm the existence of a protective effect above a 
critical threshold in terms of number of transferred CD4+ T cells expressing anti-inflammatory 
cytokines. Although probably not significant because of the low power of the experiment, a 
noteworthy finding was the negative correlation between the mean arthritic score and the absolute 
number of IL-10 producing CD4+ T cells injected in each group (table 4.5). As the number of IL-10 
producing T cells injected per animal increases, the arthritic score diminishes suggesting that when 
present in sufficient number, IL-10 producing CD4+ T cells may be able to protect against disease. 
Such correlation was not found between the number of IL-17-producing CD4+ T cells and the mean 
arthritic score.  
 
If time and resources permitted, the relationship between the number of IL-10 producing cells and 
arthritogenicity could be further investigated. This could be done for instance by comparing the 
arthritic clinical scores obtained from adoptive transfer of different doses of cells from SKG donor 












 injected 450,000 CD4
+
 injected 
Mesent. 50/50 Popliteal Mesent. 50/50 Popliteal 
Number of IL-10 producing cells 250 425 600 2,250 3,825 5,400 
Mean arthritic score (week 11) 9.2 3 1.75 0.4 0.25 0 
Mean arthritic score (week 15) - - - 2.4 0.50 0.40 
           Table 4.5 – The arthritic clinical score increases with decreasing number of injected il-10 producing CD4
+
 T cells. 
 
Another possible explanation for the cell-number effect is that the expansion and proliferation of the 
transferred T cells may be different in the context of low and high number of cells. It is known that 
mature T cells spontaneously proliferate in response to severe depletion of T cells (Surh and Sprent 
2008) and lymphopenia-induce proliferation (LIP) is a phenomenon whereby naïve T cells begin to 
proliferate, at a slow rate, when adoptively transferred in lymphopenic hosts (Min, McHugh et al. 
2003). This phenomenon has been previously explained by the increased availability of specific self-
pMHC ligands and/or IL-7 (Ernst, Lee et al. 1999; Goldrath and Bevan 1999; Surh and Sprent 2005), i.e. 
the same factors required for survival of naïve T cells in interphase under normal non-lymphopenic 
conditions (see section 1.3.2). Since polyclonal naïve T cells are known to compete with each other for 
survival and homeostatic proliferation (Kieper, Tan et al. 2002; Moses, Thorstenson et al. 2003), and 
since it has been shown that naïve transgenic TCR CD4+ T cells display a short lifespan when 
adoptively transferred in large numbers into normal hosts, but a prolonged lifespan when transferred 
in very low numbers (Hataye, Moon et al. 2006), it is possible that the LIP of low numbers of 
adoptively transferred SKG cells was increased because of reduced competition for IL-7 which can 
then amplify the weak TCR signalling resulting from contact with limited self-pMHC (Surh and Sprent 
2005). Moreover, in the context of SKG cells versus wild-type cells, T cells with high-affinity TCR for 
self-pMHC ligands undergo faster rates of LIP than do low-affinity T cells (Kassiotis, Garcia et al. 2002; 
Kieper, Burghardt et al. 2004). Therefore SKG cells, especially in low numbers, might undergo 
increased homeostatic proliferation, which, when combined with their auto-reactivity and pro-
inflammatory profile, lead to auto-immunity in the lymphopenic hosts.  
 
Finally, I confirmed that SKG T cells activated in vitro retained arthritogenicity and could transfer 
disease to SCID recipients, and that the clinical and histological appearance of disease was similar to 
that observed in SCID mice injected with SKG T cells freshly harvested from tissues and not subjected 
to in vitro activation.  
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The main hypothesis of the project is that sub-optimal TCR signalling results in loss of immune 
homeostasis and the development of arthritis, possibly through effects on cell survival, 
differentiation, migration and/or immune regulation, and that reconstitution of TCR signalling in 
arthritogenic SKG T cells will restore immune homeostasis. One approach to test this hypothesis was 
to establish a system for the stable integration of the murine wild-type ZAP-70 into SKG mutant T 
cells, thereby restoring the integrity of TCR signalling within these cells.  
 
To investigate the contribution of defective TCR signals on the development of autoimmune arthritis 
in vivo, it was proposed to transfer reconstituted SKG T cells into SCID recipient mice to assess 
whether inflammatory arthritis develops in vivo and whether the disease is clinically, histologically 
and serologically different from the disease observed when transferring unmanipulated arthritogenic 
SKG T cells. To this end, I needed to achieve three goals. First, using unmanipulated SKG cells, 
establish an adoptive transfer model to induce, in recipient animals, disease which is consistent in 
severity and incidence. These experiments are described in Chapter 4. Second, optimise a virus-
mediated gene transfer protocol to achieve transduction rates, into the target murine primary T cells, 
which are elevated enough to enable manipulation and characterisation of reconstituted cells. Third, 
generate a panel of ZAP-70 constructs required for gene-transfer and identification of transduced 
cells, and clone those into the appropriate virus-vector backbone.  
 
Additionally, T cells from HNT-TCR SKG mutant mice could be used to evaluate the impact of gene 
transfer on antigen-specific T cell responses in vitro in order to verify that TCR signalling is restored in 
reconstituted SKG T cells (e.g. by proliferation and IL-2 production), comparing these responses with 
those of both wild-type BALB/c and unmanipulated SKG T cells (figure 5.1).  
 
 






Figure 5.1 – Reconstituting SKG TCR with virus-based transfer of wild-type ZAP-70. Wild-type ZAP-70 will be 
transduced, via a viral vector, into SKG CD4+ T cells to override the endogenous mutant ZAP-70 and restore TCR signalling. 
Such transduced cells will be used for in vivo transfer into SCID recipients and development of autoimmune arthritis will be 
compared with adoptive transfer using unmanipulated SKG T cells.  Reconstituted transgenic HNT-TCR SKG T cells will also 
be used to study antigen-specific T cell responses in vitro. Adapted from GenomeMaps.pdf at www.hiv.lanl.gov. 
 
Retroviruses are membrane enveloped viruses whose genetic material consists of two identical single 
stranded RNA molecules composed of three main structural genes. The gag gene codes for core 
proteins while pol induces expression of reverse transcriptase and integrase, and env is essential for 
the production of the viral envelope glycoprotein. Upon infection or virus cell entry, viral RNA is 
reverse transcribed into double stranded DNA and the 5’ and 3’ regions get duplicated, forming two 
identical long terminal repeats (LTRs) on either side of the viral genes. This double stranded DNA 
provirus enters the nucleus where it integrates into the host cell chromatin. Transcription is initiated 
from the 5’ LTR promoter/enhancer U3 region and terminates at the 3’ LTR transcription termination 
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and polyA tail region. Packaging of transcribed un-spliced mRNA is enabled by the cis-acting psi () 
sequence element in the 5’ terminal mRNA region. Viral proteins are translated from spliced versions 
of the viral RNA. Once transcription and packaging is completed, the virus propagates by budding 
from the cell membrane. 
 
Lentiviruses, of which the human immunodeficiency virus (HIV) is by far the most studied, are a 
complex subclass of retroviruses, which can transduce both dividing and non-dividing cells. The 
lentivirus genome comprises the same basic elements of retroviruses, including gag, pol and env 
genes, with additional mRNA spliced variant genes (figure 5.2). The tat gene activates the promoter in 
HIV LTR to efficiently produce viral RNA (Sodroski, Rosen et al. 1985) while the rev gene interacts with 
a region in the viral RNA called the rev-responsive element (RRE) to induce RNA nuclear export 
(Emerman, Vazeux et al. 1989; Cochrane, Chen et al. 1990). Although the mechanism by which viral 
RNA enters the nucleus of non-dividing cells is not fully understood, it appears that the integrase 
protein (Gallay, Swingler et al. 1995), as well as the matrix protein from the gag locus (Bukrinsky, 
Haggerty et al. 1993) and the accessory protein Vpr (Heinzinger, Bukinsky et al. 1994) facilitate 
nuclear entry in the absence of cellular division. The capacity of retroviruses to integrate with their 
host genome, and of lentiviruses to infect non-dividing cells, have widely been exploited to promote 




Figure 5.2 – HIV lentiviral DNA genome. The gag gene codes for core viral proteins, the pol locus induces expression of 
reverse transcriptase and integrase. The env locus is essential for the production of the viral envelope glycoprotein. 
Transcription is initiated from the 5’ LTR promoter region and terminated at the 3’ LTR transcription termination. The tat gene 
product activates the promoter in HIV LTR to efficiently produce viral RNA. The rev gene product interacts with the RRE 
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5.2. Cloning of wild-type and SKG ZAP-70 into lentiviral bi-cistronic vectors 
 
Viral vectors are useful vehicles for the delivery of foreign genes into target cells. Recombinant 
lentiviral vectors can be engineered by inserting the gene of interest in the viral vector backbone 
which contains only the cis-acting sequences essential for recognition by viral proteins for packaging 
and integration. The structural and enzymatic genes are typically provided in trans, by co-transfection 
with the vector transgene into packaging cell lines which work as factories for virus production. The 
recombinant virus particles are secreted in the supernatant which can be concentrated by 
ultracentrifugation and used to infect the host cell of interest. 
 
For the purpose of my experiments, I used pHR’SIN.cPPT-SEW, a lentiviral transducing vector 
originally described by Demaison et al. (2002) and schematically represented in figure 5.3. This 
lentiviral vector is derived from the HIV-1 lentivirus and has been rendered self-inactivating by 
removal of the TATA box and enhancers in the 3’ LTR U3 region (Yu, von Ruden et al. 1986; Miyoshi, 
Blomer et al. 1998; Demaison, Parsley et al. 2002). The structural proteins for packaging and 
integration are provided on a different plasmid co-transfected with the vector. The lentiviral vector is 
also pseudo-typed with a vesicular stomatitis virus envelope glycoprotein (VSV-G) which is able to 
interact with the membrane lipid bilayer of most cell types and therefore enhances and broadens the 
transduction and expression efficiency. Co-transfection of these 3 plasmids enables packaging and 
secretion of the vector. Such a recombinant virus contains all the proteins required to replicate and 
integrate once but cannot propagate further as it lacks the genes necessary for assembly and 
replication.  
 
This vector also encodes the enhanced Green Fluorescence Protein (eGFP) transgene, which is flanked 
by unique BamHI and NotI restriction sites for cloning. eGFP, whose expression has been placed 
under the control of a strong heterologous promoter: the spleen focus forming virus (SFFV) promoter 
sequence, can be used as a cellular marker of gene transfer efficiency. In addition, the vector also 
includes a Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) and a central 
polypurine tract (cPPT) cis-acting sequence which have been shown to improve transduction 
efficiency by, respectively, stabilising the mRNA and facilitating nuclear entry of the pre-integrated 
virus.  
 




Figure 5.3 - Schematic structure of the lentiviral transducing vector pHR’SIN.cPPT-SEW. This recombinant lentiviral 
vector encodes eGFP, which is flanked by the unique BamHI and NotI restriction sites. Expression is regulated from the 
SFFV promoter. WPRE helps stabilising the mRNA and cPPT facilitates the nuclear entry of the pre-integrated virus. Adapted 
from (Demaison, Parsley et al. 2002). 
 
5.2.1. Generating bi-cistronic constructs to be cloned in lentiviral vector 
Bi-cistronic vectors were chosen as the tool of choice to introduce wild-type or mutant ZAP-70 into 
primary T cells by lentivirus-mediated gene transfer. Such vectors allow the transfer and expression of 
two genes into the target cells. The first gene encodes for either wild-type ZAP-70, to reconstitute 
TCR signalling in SKG T cells, or mutant ZAP-70 to be used as an internal control. The second gene, 
downstream of an internal ribosomal entry site (IRES), encodes for a cell marker to assess the 
efficiency of the gene transfer at the single cell level and facilitate FACS-based cell sorting of 
transduced cells. Two alternatives were considered to act as cell marker. First, eGFP, which was 
previously successfully co-expressed in our laboratory with the TCRζ chain in T cells (Clark, Annenkov 
et al. 2004). Since the eGFP protein might be immunogenic and therefore inappropriate for long term 
in vivo experiments, a second reporter gene was considered: the murine homologue to the human 
low affinity Nerve Growth Factor Receptor (NFGR). To prevent interfering signalling, I used a non-
functional form of the NGFR which was truncated in its intracellular domain (ΔNGFR = dNGFR). This 
cell-surface marker is not expressed on the majority of haematopoietic cells (Bordignon, Bonini et al. 
1995), has been previously used to quantify gene transfer into lymphocytes (Bonini, Ferrari et al. 
1997) and has been shown to be a safe and inert reporter gene even in the presence of high 
concentrations of the ligand. Importantly this reporter gene is not thought to alter the function or 
survival of transduced T lymphocytes (Bonini, Grez et al. 2003). 
 
Finally, I also wanted to generate wild-type ZAP-70 and mutant SKG ZAP-70 V5-tagged constructs in 
order to distinguish between endogenous ZAP-70 and transduction-derived ZAP-70 protein and 
therefore confirm transduced gene expression. Consequently, eight distinct constructs (figure 5.4) 
had to be generated and inserted into the backbone of the lentiviral transducing vector pHR’SIN.cPPT-
SEW between BamHI and NotI restriction sites.  
 




Figure 5.4 – Bi-cistronic constructs. 8 different bi-cistronic constructs had to be produced to allow for the expression of 
either wild-type or SKG ZAP-70, with or without a V5-tag, and associated with one of two possible cell markers: eGFP or 
ΔNGFR.  
 
5.2.2. Cloning the genes of interest 
In order to clone wild-type ZAP-70 and SKG ZAP-70, I derived cDNA from wild-type and SKG 
splenocytes. Specific reverse primers were designed to add to the 3’ end of ZAP-70 either a BstBI 
restriction site to facilitate the V5-tagging or a SpeI restriction site for the untagged constructs. 
ΔNGFR was cloned from murine brain cDNA and truncated at amino acid 248 to remove the signal-
transducing intracellular tail. DNA of the genes of interest was amplified by PCR. All 5 PCR products 
were purified and run on a 1% agarose gels to verify the presence of the genes of interest (figure 5.5).  
 
  
Figure 5.5 - PCR products used for cloning. ZAP-70 was cloned from BALB/c and SKG splenocytes cDNA, with either a 
3’_BstBI or 3’_SpeI end to allow for tagging requirements. ΔNGFR was sourced from murine brain DNA. The primer pairs 
designed for ZAP-70 (1,876 bp product) and ΔNGFR (863 bp product) resulted in the predicted amplicons as shown by the bands 
on the agarose gel. 
 
The DNA of wild-type and SKG ZAP-70 were sequenced post-PCR to verify that no new mutations had 
been introduced and for the presence of the G-to-T substitution at nucleotide 489 in the SKG ZAP-70 
(figure 5.6) 
 




Figure 5.6 - Sequencing of ZAP-70 PCR products. The SKG G-to-T mutation was found in the clones produced from SKG 
cDNA (right panel) but not those produced from BALB/c cDNA (left panel). 
 
The purified PCR products were inserted into the lentiviral transducing vector pHR’SIN.cPPT-SEW via a 
multi-step cloning process (see figure 5.7 for the untagged constructs and figure 5.8 for the V5-tagged 
constructs) involving several intermediates which were all individually transformed into DH5α cells, 
selected, purified and DNA-sequenced, and resulting in the production of the eight previously 
described vectors.   
 






Figure 5.7 – Multi-step approach to clone wild-type and SKG ZAP-70 into lentiviral vector. Wild-type and SKG ZAP-70 









Figure 5.8 – Multi-step approach to clone V5-tagged wild-type and SKG ZAP-70 into lentiviral vector. Wild-type and 
SKG ZAP-70, tagged to a V5 sequence, were cloned in bi-cistronic vectors with either eGFP (pair 3) or NGFR (pair 4). Both 
genes were linked via an IRES sequence. 
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5.3. Transient expression of lentiviral constructs in HEK 293T cells 
 
Five cloned constructs were transfected into human embryonic kidney (HEK) 293T cells to verify the 
correct expression of the ZAP-70 protein since unmanipulated 293T cells do not express ZAP-70. Cell 
lysates were blotted with anti-ZAP-70 primary antibodies and ZAP-70 expression was detected as a 
result of the transfection of each vector. Lysates from the cells transfected with V5 tag-containing 
constructs were also blotted with anti-V5 antibodies to ensure that the ZAP-70 protein could be 
identified from its V5-tag (figure 5.9).   
 
 
Figure 5.9 - Western blot analysis of wild-type and SKG ZAP-70 expression. HEK 293T cells were 
transfected with lentiviral vectors cloned with either ZAP-70 or V5-tagged ZAP-70. Cell lysates were blotted 
with either anti-ZAP-70 (top panel) or anti-V5 (bottom panel). ZAP-70 expression was detected following 
transfection with bi-cistronic constructs (first five lanes). When transduced with a mono-cistronic construct 
that only contained eGFP, ZAP-70 was not detected in the cell lysate confirming that unmanipulated HEK 
293T cells do not express ZAP-70 (sixth lane).  
 
In summary, I designed and generated eight different bi-cistronic constructs to enable the virus-based 
transfer of the gene of interest (wild-type or mutant ZAP-70) as well as a reporter gene (eGFP or 
ΔNGFR) in the target cells. Expression of ZAP-70 was confirmed for all constructs tested in HEK 293T 
cells.   
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5.4. Optimising gene transduction protocols using a mono-cistronic lentiviral 
vector 
 
In order to optimise the gene transduction protocol required to transduce primary SKG T cells with a 
wild-type ZAP-70 gene, I first tested a mono-cistronic version pHR’SIN.cPPT-SEW which only 
contained eGFP.  
 
5.4.1. Evaluation of eGFP expression in HEK 293T cells 
To prepare for the optimisation experiments, large quantities of stocks of VSV-G-pseudo-typed 
lentiviral vectors were produced by co-transfecting HEK 293T cells with the self-inactivating 
transducing vector plasmid together with the packaging plasmid pCMVΔR8.2, and the VSV-G-
encoding plasmid pMD.G.  
 
Gene transfer efficiency of the newly prepared stocks and virus titrations were evaluated by 
transducing HEK 293T with 1:2 serial dilutions of the lentivirus stock and flow cytometric detection of 
eGFP expression at four days post-infection. The virus was efficient at transducing eGFP over a wide 
range of titers, with 99.47% of HEK 293T cells positive for the expression of the transgene when 
infected with a 1:100 virus dilution (figure 5.10).  
 
 
Figure 5.10 – Expression of eGFP in HEK 293T cells. Cells were infected with a mono-cistronic lentiviral vector, 
pHR’SIN.cPPT-SEW, encoding eGFP. The proportion of eGFP positive cells decreased with virus dilutions and reached 
99.47% at a 1:100 dilution. Data representative of four independent experiments. 
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Transduced HEK 293T cells were also analysed by microscopy to visualise transduced and expressed 
eGFP (figure 5.11) 
 
 
Figure 5.11 – Expression of eGFP in HEK 293T cells following lentiviral transduction. 48h after transduction 
HEK 293 T cells were visualised under a light microscope (panel A) and under a fluorescence microscope (panel B) 
as an indirect means to assess expression efficiency (40 x magnification). Arrows indicate a few representative cells 
expressing eGFP indicating successful transduction of the egfp gene into the target cell genome.  
 
5.4.2. Evaluation of eGFP expression in primary murine T cells 
Although lentiviruses are renowned for their ability to transduce non-dividing cells (Yang, Cohen et al. 
2008), the vast majority of wild type HIV are not able to efficiently infect mononuclear cells that are in 
a quiescent state (Zack, Arrigo et al. 1990). Accordingly, their ability to achieve efficient gene transfer 
in resting lymphocytes is limited (Unutmaz, Kewal Ramani et al. 1999; Dardalhon, Herpers et al. 
2001). Yet lentiviral vectors are able to transduce cells that are in early phases of the cell cycle and do 
not require mitosis for efficient nuclear transport (Swainson, Mongellaz et al. 2008).  
 
Therefore in order to optimise the gene transduction protocol, I first assessed the efficiency of the 
lentiviral virus to infect naïve, unfractionated BALB/c splenocytes under different conditions of 
stimulation of the target T cells.  
 
Splenocytes were harvested from wild-type BALB/c mice and stimulated with either anti-CD3/anti-
CD28 antibodies or with the lectin protein Concanavalin A (Con A). Transduction efficiency was then 
analysed by quantifying eGFP expression by flow cytometry (figure 5.12). When un-stimulated, only 
0.76% of CD4+ T cells expressed eGFP, whereas the transduction rate increased to 3.15% of CD4+ T 
lymphocytes upon activation with Con A and 2.14% following TCR activation with anti-CD3/anti-CD28 
monoclonal antibodies. Nevertheless, transduction rates were consistently low and below 4% with all 
protocols.  




Figure 5.12 – Effects of stimulating targets T cells at the time of transduction. Murine wild-type splenocytes 
were infected with eGFP-containing lentivirus and either not stimulated or activated with either ConA or a 
combination of anti-CD3 and anti-CD28. Although eGFP transduction rates improved with T cell stimulation, rates 
remained low at under 4% (n = 3).  
 
Since cationic polymers have been shown to enhance virus adsorption and transduction (Davis, 
Rosinski et al. 2004), I compared the effects of Con A stimulation at different concentrations in 
conjunction with either polybrene (hexadimethrine bromide) or diethylaminoethyl (DEAE)-Dextran. In 
all cases, the rates of CD4+ T cells expressing eGFP could not be improved satisfactorily and remained 
well below 2% (figure 5.13).  
 
 
Figure 5.13 – Effects of increasing doses of Con A on eGFP expression in conjunction with either polybrene or 
DEAE-Dextran. Polybrene and DEAE-Dextran are cationic polymers that can enhance virus adsorption and transduction. 
Primary cells were stimulated with varying concentrations of Con A in the presence of either polybrene (6 μg/ml) or DEAE-
Dextran (70 μg/ml). Although eGFP transduction improved with increasing concentration of Con A and was more efficient 
with polybrene, it remained low throughout and below 2% (n = 1).  
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Because the level of transgene expression can be significantly influenced by the use of different 
promoters (Swainson, Mongellaz et al. 2008), two other internal promoters were tested: the 
phosphoglycerate kinase (PGK) promoter and the elongation factor 1 alpha (EF1α) promoter 
(Zufferey, Nagy et al. 1997). Transduction with those two promoters was less efficient than with the 
SFFV promoter (data not shown). 
 
Although there is very little information available on efficient lentiviral vector-based gene transfer 
protocols into primary murine T lymphocytes, I attempted to adapt protocols that had proved 
successful with either lentivirus transduction in human T cells or with retrovirus transduction in 
murine T cells. For instance I pre-activated the splenocytes for 24h with either Con A or monoclonal 
anti-CD3/CD28 before viral transduction. Also I assessed the efficiency of seeding the pre-activated 
splenocytes on wells coated with Retronectin, a recombinant fibronectin molecule that has been 
shown to increase gene transfer in human T lymphocytes by co-localising virus particles and target 
cells on specific adhesion domains (Fehse, Schade et al. 1998).  
 
No improvement in the transduction rate of the transgene was observed following the use of 
Retronectin and the levels of transduction achieved in BALB/c cells after ex vivo pre-activation 
remained below 3% (figure 5.14). Expression levels of eGFP were severely reduced in SKG 
splenocytes. The level of CD4+ T cells expressing eGFP was reduced to 0.81% in SKG compared to 
2.82% in BALB/c, following anti-CD3/anti-CD28 stimulation. Even when pre-activated in a TCR-
independent manner with Con A, a similar drop was seen in transgene expression (from 2.78% in 









Figure 5.14 – Expression of eGFP in BALB/c and SKG splenocytes following pre-
activation and Retronectin treatment. Splenocytes were pre-activated for 24h with either 
Con A or anti-CD3 and anti-CD28 being viral transduction. Con A-activated cells were 
transduced in wells coated with Retronectin. Retronectin did not improve the transduction of 
eGFP in the target CD4+ T cells. Also, transduction rates were severely reduced in SKG 
splenocytes compared to wild-type counterparts (n = 2 for BALB/c, n = 1 for SKG).  
 
Interestingly, three days after transduction, expression of eGFP was visible by fluorescence 
microscopy in cultures of both wild-type and SKG splenocytes and at roughly similar levels (figure 
5.15), confirming that the virus stock is viable and that although some cells from both BALB/c and SKG 
spleens are transducible, it is the T lymphocyte subset that appears to be especially refractory to 









Figure 5.15 - BALB/c and SKG splenocytes transduced with eGFP. Splenocytes were visualised, 72h post-transduction, 
under a light microscope (panel A) and under a fluorescence microscope (panel B), as an indirect means to assess 
transduction efficiency (40 x magnification). Some BALB/c and SKG cells express eGFP (arrows) but they are not T cells as 
they are larger in size.  
 
Additional differential treatments were tested, such as 96h pre-activation of the splenocytes with 
either IL-2 (100 U/ml) or IL-7 (10 ng/ml) prior to infection, although no increase in transduction 
efficiency was observed. I also found that, although centrifugal inoculation enhances infection 
through virus binding (O'Doherty, Swiggard et al. 2000), spinning the cells post-infection for one hour 
at 1,200 g and at room temperature did not have a significant impact on the transduction rate. 
Different settings of spinning time, temperature and speed were also evaluated without influencing 
transduction rates. Finally, and rather than using a stock of purified and concentrated viral sediment, I 
co-cultured the splenocytes in direct contact with HEK 293T cells which 48h prior had been 
transfected with the three virus-forming plasmids and were consequently secreting fresh 
recombinant virus particles in the supernatant. Again, the transduction rates remained low and below 
1.5%.  
 
In summary, using a lentiviral-vector approach as well as different protocols to stimulate target T cells 
and enhance the co-localisation of virus particles with the target cells (summarised in table 5.1), I was 
not able to achieve transduction of the reporter transgene at a rate sufficient to enable further in 
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vitro functional analysis or in vivo experiments. Consequently, I switched to a retrovirus-based gene 
transfer approach.  
 
                     Parameter                                               Variables 
Internal promoters : SFFV, EF1α, PGK 
Target cell pre-activation :  
Antibody-based : Anti-CD3 
 Anti-CD3 + anti-CD28  
 Either soluble or plate-bound 
 Varying concentrations 
Mitogen-based : Con A 
 Varying concentrations 
Cytokine-based : IL-2 or IL-7  
 Duration (24h/48h/72h/96h) 
Cationic polymers : Polybrene 
 DEAE-Dextran 
 Varying concentrations 
Culture media : RPMI 
 DMEM 
Enhanced co-localisation of virus 
particles and target cells : 
Recombinant fibronectin molecule (Retronectin) 
 
Spinoculation by centrifugation (different speed, 
different temperatures, different time) 
 
Co-culture of target cells with virus-producing HEK 
293T cells 
              Table 5.1 – Strategies used to optimised lentiviral-based transduction in primary murine T cells 
 
5.4.3.   Evaluation of retroviral vector-based transduction protocols 
Establishing a gene-transduction protocol that produces sufficiently elevated transduction rates was 
of the utmost importance. Having fully explored the lentivirus-based approach, it was felt that no 
significant progress could be achieved by further optimisation of known protocols. Therefore, I 
explored a retrovirus-based approach using the Moloney murine leukaemia virus-derived vector MFG. 
The first step was to optimise the transduction protocol using a mono-cistronic MFG vector 
containing eGFP and kindly provided by Dr Alexander Annenkov (Bone and Joint Unit, Queen Mary’s 
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University London). Upon successful completion of that stage, the second step was to clone the bi-
cistronic constructs, previously sub-cloned into the lentiviral vector, into the retroviral vector MFG 
(Boggs, Patrene et al. 1995).  
 
The third step was to generate packaging cell lines, one for each of the eight bi-cistronic constructs, 
which could then be used to provide viral supernatants on an ad hoc basis. This process is further 
described in section 5.8.  
 
5.5. Initial assessment of eGFP expression using the mono-cistronic retroviral 
vector 
 
Because retroviral vectors are only able to integrate in cycling cells due to their inability to translocate 
the viral genome across the nuclear envelope (Miller, Adam et al. 1990; Roe, Reynolds et al. 1993), 
primary murine T cells had to be pre-activated for 24h before transduction. Cells were then allowed 
to expand and flow cytometry analysis of gene transduction efficiency was carried out four days post-
transduction (figure 5.16).  
 
 
Figure 5.16 – Protocol for retrovirus-based gene transduction. Primary murine cells are harvested from lymphoid organs 
and activated in vitro for 24h with anti-CD3 and anti-CD28 before transduction by spinoculation with viral supernatant 
supplemented with polybrene (8 μg/ml) and IL-2 (10 U/ml). Transduced cells were then cultured for four days before flow 
cytometry analysis to assess gene transduction efficacy. 
 
Using a mono-cistronic MFG vector encoding for eGFP, splenocytes were harvested from BALB/c mice 
and activated with monoclonal anti-CD3 and anti-CD28. To determine optimal cell density, 
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splenocytes were seeded at 1, 2.5, 5, 8 or 10 x 106 per well. From the first experiment with the mono-
cistronic retrovirus, eGFP expression achieved levels never previously observed when using the 
mono-cistronic lentivirus, with 25.5% of CD4+ T cells expressing eGFP, when seeded at 5 x 106 per well 
(figure 5.17).  
 
 
Figure 5.17 – Effects of cell density on eGFP expression. BALB/c splenocytes were seeded at a density of 1, 2, 5 8 or 10 
x 106 per well before retroviral transduction. The rate of eGFP expression in CD4+ T cells was assessed by flow cytometry 
and found to be optimal at a density of 5 x 106 per well (n = 2 for 1, 2.5 and 8 x 106; n = 3 for 5 and 10 x 106). 
 
EGFP expression in wild-type splenocytes was also easily visualised by microscopy following 










Figure 5.18 – Expression of eGFP in primary murine splenocytes following retroviral transduction. 72h after 
transduction wild-type splenocytes visualised under a light microscope (panel A) and under a fluorescence microscope (panel 
B) as an indirect means to assess expression efficiency (40 x magnification). eGFP expression is increased in the cell 
clusters which are indicative of T cells activation following TCR stimulation with anti-CD3/CD28 antibodies (green arrows).   
 
5.6. Optimisation of protocol with mono-cistronic retroviral vector 
 
Following initial MFG-based transduction of eGFP in around 25% of wild-type CD4+ T cells, several 
parameters in the protocol were modified and tested in order to increase the transduction rate as the 
higher the transduction rate, the easier to generate enough reconstituted T cells for in vivo 
experiments.  
 
For instance I observed that, although splenocytes provide an endogenous source of antigen-
presenting cells (APCs), whose FcRs can bind anti-CD3 and cross-link TCRs on T cells, coating the wells 
with anti-CD3 and anti-CD28 yielded better transduction (47.75%) than using soluble antibodies 
(17.97%) or a combination of both (25.44%). Of interest for future in vitro experiments, transduction 
of splenocytes from HNT-TCR BALB/c stimulated with HA peptide was successful and 33.75% CD4+ T 
cells from this population expressed eGFP (figure 5.19). 
 




Figure 5.19 – Effect of activation protocol on eGFP expression. BALB/c splenocytes were pre-activated for 
24h with either soluble or coated anti-CD3/anti-CD28 or a combination of both. eGFP expression in CD4+ T cells 
was optimal when splenocytes had been activated with coated anti-CD3/anti-CD28 for 24h before virus 
transduction (n = 2).     
 
Also spinoculation by centrifugation yielded better results when carried out at 24C rather than 30C, 
and using RPMI for transduction and cell culture was beneficial when compared to DMEM (data not 
shown).  
 
Once all optimised parameters were put together, the transduction rate of eGFP in wild-type 
splenocytes increased to 49.6% and 47.9% in wild-type lymph nodes (figure 5.20). Although SKG T cell 
activation and proliferation is defective compared to BALB/c T cells and although retroviral-based 
transduction relies on cell cycling, eGFP expression in CD4+ T cells sourced from SKG lymphoid organs 
was equally successful with 49.3% expression in CD4+ T cells from spleen and 58% in CD4+ T cells from 
lymph nodes (figure 5.20).   
 







Figure 5.20 – eGFP expression in BALB/c and SKG T cells with the optimised protocol for retroviral transduction. 
Panel A - Flow cytometry analysis showed that eGFP was expressed in around 50% of CD4+ T cells sourced from BALB/c 
lymph nodes and almost 60% of CD4+ T cells from SKG. Panel B – On average, eGFP expression was comparable in T 
cells from wild-type or SKG spleens, whereas it was slightly higher in SKG lymph nodes T cells compared to BALB/c 
counterparts (n = 2).  
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5.7. Transferring the bi-cistronic clones into the MFG vector 
 
5.7.1. Cloning strategy 
Since preliminary transduction results using a mono-cistronic MFG vector indicated that my approach 
for reconstituting ZAP-70 mutant T cells with wild-type ZAP-70 was realistic, a cloning strategy was 
designed with a view to exploiting the bi-cistronic constructs I had already produced, avoiding the 
need to re-PCR the gene of interest, a procedure which always carries a risk of introducing new 
mutations. The constructs, originally designed with a 5’_BamHI end and a 3’_NotI end to match the 
restriction sites in the lentiviral vector, had to be manipulated since they now had be cloned between 
NcoI and NotI restriction sites in the retrovirus vector backbone, MFG. Because of the difficulty of 
finding unique restriction sites in both the bi-cistronic construct (which contained nucleotide 
sequences for ZAP-70, V5, IRES and either eGFP or ΔNGFR) and the MFG vector, a multi-step 
approach was used.  
 
Briefly, two short oligonucleotide sequences were annealed and sub-cloned in MFG between 
NcoI/NotI to introduce the 5’ end of ZAP70 from the start codon to the BstBI site and inclusive of the 
AarI site, both AarI and BstBI sites are not found in MFG. A truncated version of ZAP-70 was then cut 
between AarI and BstBI in one of the previously generated lentiviral vectors and sub-cloned into the 
two unique restriction sites inserted with the oligonucleotides. Finally, any bi-cistronic construct with 
ZAP-70 could then be cloned in the resultant MFG vector between BsiWI (a unique site not found in 










Figure 5.21 – Multi-step approach to sub-clone bi-cistronic constructs from lentiviral vector into MFG, the retroviral 
vector.  
 
5.7.2. Transient expression of retroviral constructs in HEK 293T cells  
Following the multi-step approach described above, eight retroviral MFG vectors were generated 
each containing either wild-type or SKG ZAP-70, with or without V5 tag, as well an IRES sequence and 
one reporter gene: eGFP or ΔNGFR.  
 
Since ZAP-70 had been sub-cloned into MFG via three individual steps, expression of the ZAP-70 
protein from the eight reconstituted bi-cistronic vectors had to be verified. Therefore, the eight MFG 
constructs were transfected into HEK 293T cells. Cells were lysed 48h post-transfection, and lysates 
were blotted with anti-ZAP-70 antibodies and ZAP-70 expression was detected as a result of the 
transfection of each vector, although the protein detected from the SKG ZAP-70_V5/ΔNGFR construct 
seemed lower in molecular weight and/or slightly degraded (figure 5.22).  




Figure 5.22 - Western blot analysis of wild-type and SKG ZAP-70 expression. HEK 293T cells were transfected with 
MFG retroviral vectors cloned with either wild-type or SKG ZAP-70. A lentiviral construct, previously shown to correctly 
express ZAP-70, was used as a positive control. Cell lysates were blotted with anti-ZAP-70 and ZAP-70 expression was 
detected following individual transduction of each bi-cistronic construct. Cell lysate from mock transduction in 293T did not 
show ZAP-70.  
 
Cell lysates from the cells transfected with the V5 tag-containing constructs were also blotted with 
anti-V5 antibodies to ensure that the ZAP-70 protein could be identified from its V5-tag (figure 5.23).   
  
 
Figure 5.23 - Western blot analysis of V5-tagged ZAP-70 expression. HEK 293T cells 
were transfected with MFG retroviral vectors cloned with bi-cistronic constructs. Cell 
lysates were blotted with anti-V5 and V5-tagged ZAP-70 expression was detected from 
each construct. 
 
Finally, I verified the correct expression of the reporter genes. Although eGFP was detected in the 
lysates of the cells (figure 5.24), NGFR could not be detected in the appropriate cell lysates, 
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probably because of the poor specificity of the antibodies used since NGFR could not be detected 
either in the positive control of mouse brain extract (data not shown). 
 
  
Figure 5.24 - Western blot analysis of eGFP expression. HEK 293T cells were 
transfected with MFG retroviral vectors cloned with bi-cistronic constructs. Cell 
lysates were blotted with anti-eGFP and eGFP expression was detected from 
each construct. A mono-cistronic construct, containing eGFP only, was used as a 
positive control.  
 
5.8. Producing packaging cell lines for bi-cistronic vectors 
 
Current retroviral gene transfer technology is based on the coordinated design of retroviral vectors 
and packaging cell lines. Packaging cell lines package retroviral RNAs into infectious particles without 
the concomitant production of replication-competent virus, therefore enabling new levels of safety 
and control (Mann, Mulligan et al. 1983; Miller and Buttimore 1986). This is possible because the 
structural genes necessary for particle formation and replication, gag, pol and env, are integrated into 
cell lines without , the RNA packaging signal necessary for retrovirus particle formation. Subsequent 
introduction of a retroviral vector containing , transcription and processing elements, and the gene 
of interest produces infectious, replication-incompetent infectious virus that can infect and introduce 
a gene of interest into a wide variety of mammalian cell types in vitro or in vivo, but cannot replicate 
within these cells because they lack the viral structural genes (Morgenstern and Land 1990; Miller and 
Chen 1996).  
The PT67 packaging cell line is derived from a mouse fibroblast (NIH 3T3) cell line. Virus packaged 
from PT67 cells bear the dualtropic 10A1 viral envelope protein and can enter cells, including those of 
murine origin, via two different surface molecules: the amphotropic retrovirus receptor, RAM1, and 
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the GALV receptor, and thus exhibits a broader host range than virus packaged by other lines (Miller 
and Miller 1994; Miller 1996). 
 
Rather than transfecting the retroviral vector directly into PT67 cells, retroviral constructs can be 
generated by infecting the PT67 packaging cells with virus obtained from an ecotropic packaging cell 
line. This approach has, theoretically, several advantages: a high percentage of the cells acquire the 
construct, the copy number is more consistent and additionally, virus-producing clones derived from 
transduced, rather than transfected, cells are more stable. Since this method relies on the availability 
of previously transfected, virus-releasing ecotropic cells, I used Phoenix ecotropic (Phoenix-Eco) 
retrovirus producer lines which are highly transfectable HEK 293T cells, previously transformed to 
express viral proteins and package ecotropic retroviruses (Swift, Lorens et al. 2001).  
 
Consequently the strategy to generate stable PT67 packaging cell lines was sequential. First, the MFG 
vector was transfected into Phoenix-Eco cells, and the supernatant which contained MFG retroviral 
particles was collected. Second, the Phoenix-Eco–derived viral supernatant was used to infect PT67 
packaging cells lines. Once stably transduced, PT67 cells could be frozen to be re-used at a later stage 
and provide viral supernatants on an ad-hoc basis. Therefore, and using this two-step approach 
(figure 5.25), eight PT67 packaging cell lines were produced, each one able to produce retroviral 





Figure 5.25 – Two-step process to produce retrovirus-producing cell lines. A MFG retroviral vector containing the gene 
of interest, and the RNA packaging signal , was transiently expressed in Phoenix-Eco packaging cell lines. Ecotropic virus 
subsequently released was then used to stably integrate PT67 packaging cell lines. Both packaging cell lines provide the 
genes necessary for particle formation which have been deleted from the vector: gag, pol, and env. Viruses released from 
these cell lines contain the products of these genes, are infectious, but lack the genes themselves, thus preventing retroviral 
production from subsequently infected cell lines. 
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For simplicity and ease of reading, bi-cistronic retroviral particles will be subsequently referred to, in 
this document, with the following codenames: 
 
               Codename:  
 Mono-cistronic retrovirus containing: 
                      RV0                       eGFP                       n/a 
 Bi-cistronic retrovirus containing: 
                      RV1                  WT ZAP-70                 IRES_eGFP 
                      RV2                 SKG ZAP-70                 IRES_eGFP 
                      RV3             WT ZAP-70 + V5                 IRES_eGFP 
                      RV4             SKG ZAP-70 + V5                 IRES_eGFP 
  
                      RV5                 WT ZAP-70               IRES_NGFR 
                      RV6                SKG ZAP-70               IRES_NGFR 
                      RV7             WT ZAP-70 + V5               IRES_NGFR 
                      RV8             SKG ZAP-70 + V5               IRES_NGFR 
Table 5.2 – Codenames for mono- and bi-cistronic vector-containing retroviral particles 
 
5.9. ZAP-70 expression in primary murine splenocytes using bi-cistronic 
vectors  
 
Murine primary lymph node cells from BALB/c and SKG mice were transduced with eGFP-containing 
bi-cistronic retroviral particles produced by PT67 cells. The transduction was carried out following the 
protocol previously optimised with the eGFP-containing mono-cistronic construct.  
 
Although 37% of CD4+ T cells transduced with the mono-cistronic construct (RV0) expressed eGFP, 
less than 1% of cells expressed eGFP following transduction with one of the bi-cistronic constructs: 
RV1, RV2, RV3 or RV4 (figure 5.26). EGFP expression levels were low in both BALB/c and SKG lymph 
node T cells. NGFR–containing bi-cistronic retroviral particles were not used at that stage as they 
required a specific primary detection antibody, appropriate for flow cytometry, which had not yet 
been identified at this stage of my experimentation.  
 
 




Figure 5.26 – eGFP expression in BALB/c and SKG T cells following transduction of bi-cistronic constructs. Flow 
cytometry analysis showed that eGFP was expressed in 37% of CD4+ T cells sourced from BALB/c lymph nodes following 
retroviral transduction with mono-cistronic MFG vectors. On the other hand, when transduction of the target cells was carried 
out using bi-cistronic retroviruses, eGFP expression fell below the 1% mark for all constructs tested  (n = 2).  
 
These results demonstrated that although the cell activation and cell transduction protocols worked 
adequately with mono-cistronic RV0, the bi-cistronic retroviral particles were not able to replicate 
similar transduction rates and therefore a systematic approach was required to identify potential 
issues and corrective measures.  
 
5.10. Optimisation of protocol with bi-cistronic retroviral vectors 
 
Two main factors could contribute to the low transduction rates observed with the bi-cistronic 
retroviruses. Either the virus did not infect the cells or the virus infected the cells but somehow the 
expression of eGFP, the IRES-controlled secondary gene in the bi-cistronic construct, was defective 
and did not reflect the true transduction rate of ZAP-70, the primary gene in the bi-cistronic 
construct.  
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One possible reason to explain a lack of infection of the targets cells by the retrovirus would be low 
viral titer. Here the functional viral titer was assessed by the viral ability to infect NIH 3T3 cell lines, 
which are widely accepted as the standard target cells for titration of retrovirus because of the 
efficiency at which these cells become infected (Ausubel, Brent et al. 2004). Indeed, viral 
supernatants of mono-cistronic and bi-cistronic PT67 packaging cell lines were compared and, for 
instance when using a 1/8 serial dilution of viral supernatant, 96% of NIH 3T3 cells transduced with 
RV0 expressed eGFP, whereas this rate was reduced to less than 20% with bi-cistronic RV1, RV2, RV3 
or RV4 indicative of a lower virus titre (table 5.3).  
 
                                   eGFP expression in NIH 3T3 (%) 
             1/8 viral dilution             1/32 viral dilution 
                        RV0                     96.07                      66.08 
                        RV1                     19.40                       4.53 
                        RV2                     15.20                       3.76 
                        RV3                     15.28                       5.05 
                        RV4                     20.18                       8.10 
            Table 5.3 – Percentage of NIH 3T3 cells expressing eGFP following transduction with MFG retroviruses 
 
To remedy the low viral titer, several options were explored. First, multiple rounds of transduction of 
the PT67 packaging cells were carried out with ecotropic retroviral supernatants derived from 
transfected Phoenix-Eco cells. Second, CD4+ T cells were purified to enhance retroviral transduction 
efficiency. Third, packaging cells were selected to exclude those cells that had lost their ability to 
package infectious particles together. The results of these different approaches are shown in the next 
sections. 
 
As previously mentioned, another possible explanation for the low expression of eGFP with the bi-
cistronic retroviruses, might be that following virus entry into the cells, the IRES sequence is not 
recognised or processed properly in primary T cells as IRES- and cap-dependent translation are driven 
by different intracellular factors (Martinez-Salas 1999). Therefore cap-dependent ZAP-70 expression 
might be intact and similar in rate to the cap-dependent translation of eGFP from the mono-cistronic 
vector, whereas the defective IRES-dependent translation of the reporter gene might give an 
erroneous and undervalued assessment of the level of expression of the primary gene ZAP-70. This 
can be checked by attempting to quantify ZAP-70 expression with intra-cellular staining of the V5 tag 
and correlate its expression to that of eGFP, the reporter gene. If both genes are expressed at a 
similar level, this will demonstrate that IRES-dependent transcription is efficient and that eGFP 
expression can be used as a reliable indicator of ZAP-70 expression.  
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5.10.1. Increase of virus titer by multiple rounds of transduction of PT67 
packaging cells 
 
The two-step approach used to generate bi-cistronic retroviruses might be a reason for the lower 
virulence of the resulting viral stocks. One attempt to increase the viral titer was to subject PT67 
packaging cell lines to multiple rounds of transduction with the viral particles generated by 
transfected Phoenix-Eco cells. This meant that following initial infection with Phoenix-Eco cells 
retroviral supernatant, PT67 cells were allowed to grow and recover before being transduced again 
with another batch of viral supernatants from freshly transfected Phoenix-Eco (figure 5.27). For 
clarity, retroviral particles generated from two rounds of PT67 cell transduction will be noted RV1-2x, 





Figure 5.27 – Multiple rounds of transduction of PT67 packaging cell lines. In order to increase the viral titer of 
retroviruses particles packaged by PT67 cells, the PT67 packaging cell line was subjected to several rounds of viral 
transduction. Briefly, PT67 cells were transduced with retroviral supernatant from Phoenix-Eco cells newly transfected with 
one of the eight bi-cistronic MFG constructs (e.g. wild-type ZAP-70/eGFP). Subsequently, transduced PT67 cells would 
package retrovirus RV1. Those same PT67 cells would then be allowed to rest and grow before being transduced a second 
time with the supernatant of a new batch of Phoenix-Eco cells, again transfected with the same bi-cistronic MFG construct. 
The twice-transduced PT67 would then now generate retrovirus particles named RV1-2x. Further rounds of transduction 
could be applied to the same PT67 cells, as long as they remained healthy and viable.  
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Retrovirus generated following sequential double-transduction of PT67 cells with RV1 and RV2, and 
labelled RV1-2x and RV2-2x, were assayed in NIH 3T3 cells for viral transduction efficacy. At a 1/8 viral 
dilution, 50.74% of NIH 3T3 cells infected with RV1-2x expressed eGFP compared to only 19.40% 
when transduced with RV1. This demonstrated that the viral titer did indeed increase following an 
extra round of transduction of the PT67 packaging cell lines (table 5.4). A similar increase in viral 
efficiency was observed with RV2-2x when compared to RV2.  
 
                                   eGFP expression in NIH 3T3 (%) 
             1/8 viral dilution              1/8 viral dilution 
                      RV0                        96.07                        66.08 
                      RV1                        19.40                         4.53 
                      RV2                        15.20                         3.76 
                   RV1 2x                        50.74                        20.21 
                   RV2 2x                        54.15                        18.20 
             Table 5.4 – Assessment of transduction efficacy of retroviruses generated from double transduction  
             of PT67 packaging cells. 
 
The increased viral efficacy of RV1-2x and RV2-2x was also reflected in the increased percentage of 
eGFP expressing murine primary CD4+ T cells since on average eGFP expression with either RV1-2x 
and RV2-2x was about twice that of RV1 and RV2. Nevertheless, the transduction rate remained 
below 3% (figure 5.28). These results imply that there isn’t a simple correlation between the viral 
efficiency in NIH 3T3 cell lines and primary T cells since although the rate of transduction of RV1-2x in 
NIH 3T3 cells is half the rate achieved with RV0, when it comes to primary T cells the rate of 
transduction of RV1-2x is less than 10% the rate achieved with RV0. Therefore subjecting PT67 cells to 
multiple rounds of transduction, although helpful, might not be sufficient on its own to increase 
transduction efficacy of the bi-cistronic retroviruses to the level of the mono-cistronic one.   
 




Figure 5.28 – Comparison of the transduction efficacy of retroviruses generated from single or double transduction 
of PT67 packaging cell lines. EGFP expression if primary CD4+ T cells was increased with retrovirus particles generated 
from PT67 packaging cell lines transduced twice (RV1-2x and RV2-2x) compared to retrovirus RV1 and RV2 produced by 
PT67 cells transduced only once (n = 2 for RV1 and RV2, n = 1 for RV1-2x and RV2-2x).   
 
5.10.2. Transduction of purified CD4+ T cells 
Another avenue explored to increase the rate of transduction in the target T cells was to purify and 
transduce CD4+ T cells rather than transduce heterogeneous populations of cells from the lymph 
nodes. Therefore CD4+ T cells were purified from SKG lymph nodes and seeded at either 0.5, 1 or 2 x 
106 per well and infected with RV3-3x. The rates of eGFP expression in those CD4+ T cells remained 
below 1% and remained lower than the rate of eGFP expression obtained in CD4+ T cells following 
transduction of bulk cells from SKG lymph nodes with RV3-3x (figure 5.29).  




Figure 5.29 – Assessment of eGFP expression in purified CD4+ T cells versus bulk cells. CD4+ T cells  were purified 
from SKG lymph nodes, seeded at a density of 0.5, 1 or 2 x 106 cells per well, activated for 24h with plate-bound anti-CD3 
and anti-CD28. Following transduction with RV3-3x, eGFP expression remained below 1% and lower than in CD4+ T cells 
transduced as part of bulk lymph node population (n = 1).  
 
5.10.3. Re-selection of Phoenix-Eco and PT67 virus-packaging cell lines 
The percentage of Phoenix-Eco and PT67 cells capable of packaging retroviral vectors decreases 
slowly with continued passage of the packaging cell line, presumably due to loss of the viral genes 
used to construct the line, and therefore packaging cells should be re-selected on a regular basis. Re-
selection allows cells that are no longer able to package retroviral particles to be discarded and 
therefore should increase the virus titer at each step of the two-step process used to generate high-
titer retroviruses.  
 
Because Phoenix-Eco and PT67 cells contain different selectable markers, each cell line had to be re-
selected using different protocols. The PT67 cell line contains two different selectable markers for the 
separately transfected gag-pol and env constructs, and re-selection of the PT67 cells is performed in 
three stages. PT67 were first grown for five days in the presence of amethopterin (100 nM) before 
being grown for an extra 5 days in DMEM-HAT medium containing hypoxanthine (30 mM), 
amethopterin (1 mM) and thymidine (20 mM). Finally, the cells were cultured in DMEM-HT medium 
containing hypoxanthine (30 mM) and thymidine (20 mM). Phoenix-Eco cells were re-selected using a 
similar process. Cells were first selected for one week with both hygromycin B (300 μg/ml), to 
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increase gag-pol expression, and diptheria toxin (1 μg/ml) to increase envelope protein expression, 
before being grown in normal medium for another week.  
 
Re-selected PT67 cells were transduced a fifth time with retroviral supernatants from re-selected 
Phoenix-Eco cells to generate RV-5x, and retroviral efficiency of RV1-5x was compared against that of 
retrovirus from PT67 cells pre-selection. Although the viral titer continued to increase marginally with 
each new round of PT67 transduction (eGFP expression in SKG CD4+ T cells increased from 1.88% with 
RV1-2x to 6.21% with RV1-4x and 7.18% with RV1-5x), re-selection of the virus packaging cells did not 
improve the transduction rate significantly: 6.21% with RV1-4x pre-selection and 6.26% with RV1-4x 




Figure 5.30 – Effect of virus-packaging cells re-selection on transduction rates. Although each new round of PT67 
transduction slightly increased the transduction efficiency of resulting retroviruses in primary SKG CD4+ T cells (1.88% with 
RV1-2x, 6.21% with RV1-4x and 7.18% with RV1-5x), re-selection of the virus packaging cells did not improve the 
transduction rate significantly: 6.21% with RV1-4x pre-selection and 6.26% with RV1-4x post-selection (n = 2).   
 
Increasing transduction rate in NIH 3T3 cell lines, demonstrated that the virus titer actually increased 
with both multiple rounds of PT67 transduction and re-selection of packaging cell lines. In fact the 
transduction efficacy, in NIH 3T3, of RV1-5x was almost identical to the virus titer of the mono-
cistronic retrovirus RV0 (figure 5.31) although it remained several folds lower in murine primary T 
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cells. These results suggest that the virus titer alone is not responsible for the low transduction rates 
observed and that some intrinsic problems with the bi-cistronic vector might also play a role.   
 
 
Figure 5.31 – Increasing transduction efficiency in NIH 3T3 cells. Both additional rounds of PT67 transduction and re-
selection of virus packaging cells improved the rate of eGFP expression in NIH 3T3 cells which is reflective of the virus titer.  
 
5.10.4. Other approaches to improve transduction efficacy 
Other avenues were explored in an attempt to increase the transduction rates obtained with bi-
cistronic vectors.  
 
At the Phoenix-Eco cells levels, I first attempted to increase the viral titer of the Phoenix-Eco retroviral 
supernatant by transfecting the bi-cistronic construct with polyethylenimine (PEI) rather than 
calcium-phosphate. Although the transfection rate in Phoenix-Eco cells – as assessed by flow 
cytometric analysis of eGFP expression - was increased following PEI-based transfection, this 
technique also increased cell death and most importantly the titer of the resulting viral supernatant, 
when tested in NIH 3T3 cells, was actually lower than following calcium-phosphate-mediated 
transfection (data not shown).  
 
Another explored approach was to by-pass the PT67-step in the process to generate retrovirus and 
directly transduce the target T cells with the retroviral supernatant harvested from transfected 
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Phoenix-Eco cells and which normally was used to transduce PT67 and establish stable virus-
producers. The transduction rate from this approach did not improve over the rate achieved using 
PT67-derived retrovirus (figure 5.32) 
 
 
Figure 5.32 – Comparing transduction rates of Phoenix-Eco-derived and PT67-derived retroviral supernatants. 
Primary T cells were transduced with RV2 either packaged by PT67 cells, as in previous experiments, or by freshly 
transfected Phoenix-Eco cells. No significant differences were observed in terms of transduction efficiency between both 
retroviruses. Results presented as mean ± SEM of duplicate cultures. 
 
Amendments to the protocol were also attempted at the PT67 level. For instance, viral supernatant 
from PT67 cells was harvested 48h after transduction with Phoenix-Eco retrovirus, rather than the 
usual 24h, since it was thought that it might enable incremental packaging and accumulation of 
retroviral particles in the supernatant. The transduction rate in primary T cells of retrovirus RV1-5x 
collected after 48h was actually halved compared to RV1-5x collected after only 24h (figure 5.33). This 
is probably an indication that virus particles might not be stable for prolonged period of time in 
supernatants and need to be collected rapidly for optimal virus efficiency.  
 
Another method was to transfect the PT67 packaging cell line with the bi-cistronic MFG vector 
subsequent to previous transductions with Phoenix-derived retroviral supernatant. Again, this did not 
improve the transduction rate in primary T cells (figure 5.33). Similarly, 10x concentration of the 
PT67-derived viral supernatant did not improve the transduction rate in primary T cells (figure 5.33). 
Virus concentration was carried out using spin columns and the flow-through was also collected and 
tested to ascertain that the virus had been retained in the concentrate.   





Figure 5.33 – Variations in protocol at the PT67 level. Primary T cells were transduced with RV1-5x using the control 
protocol (n = 2). Alternatives to the protocol were investigated: harvest the PT67 viral supernatant 48h after transduction with 
Phoenix-Eco-derived virus (n = 2); direct transfection of PT67 packaging cell lines with MFG (n = 2); or 10x concentration of 
the PT67 viral supernatant (n = 1).  
 
Protocol amendments at the target T cell level were investigated and included: transduction of the 
target cells with RV1-5x after activating the T cells with monoclonal antibodies for 48h instead of the 
usual 24h; and double transduction of the target T cells with PT67-derived RV1-5x with a 24h-rest 
period between the two transductions. In both cases, the rate of eGFP expression in T cells was lower 
than when using the control protocol (figure 5.34). 
 




Figure 5.34 – Variations in protocol at the target T cells level. Primary T cells were transduced with RV1-5x using the 
control protocol. Alternatives to the protocol were investigated: pre-activate the target T cells with monoclonal antibodies for 
48h rather than 24h; transduce the target T cells twice with a 24h resting period in between. Results presented as mean ± 
SEM of duplicate cultures. 
 
5.10.5. Is the IRES sequence functional? 
Another possible explanation for the low expression rates of eGFP when using bi-cistronic vectors 
might have been that IRES-driven transcription in murine T cells was malfunctioning. Consequently 
expression levels of IRES-controlled eGFP could not reflect the true expression rate of ZAP-70, the 
primary gene in the bi-cistronic construct.  
 
First, I checked that ZAP-70 expression could be detected in transduced murine primary following 
transduction with the bi-cistronic vectors. In order to distinguish endogenous ZAP-70 present in 
murine primary T cells and ZAP-70 expressed from the retroviral constructs, I used retroviral vectors 
RV3 and RV4 which contained V5-tagged ZAP-70. Cell lysates of transduced cells were blotted for V5 
and expression of retroviral vector-derived ZAP-70 could be detected (figure 5.35). 
 




Figure 5.35 – Western blot analysis of whole-cell lysates of transduced peripheral CD4+ T cells. Primary T cells from 
BALB/c and SKG mice were transduced with either RV3, which contained wild-type ZAP-70-V5, or RV4 which contained SKG 
ZAP-70-V5. Immuno-blotting against V5 revealed that expression of ZAP-70 derived from the retroviral vectors could be 
detected in the cell lysates of transduced T cells. Lysates of non-transduced murine primary T cells did not show ZAP-70 
when blotted with V5, confirming specificity of the antibody used.  
 
Both BALB/c and SKG lymph nodes cells were infected with RV3. Following transduction, cells were 
surface-stained for CD4 and stained intra-cellularly for V5. Flow cytometric analysis of eGFP and V5 
showed that although a very small proportion of CD4+ T cells expressed ZAP-70_V5 and not eGFP 
(1.11% in BALB/c CD4+ T cells and 1.71% in SKG CD4+ T cells), overall the levels of expression of ZAP-
70_V5 correlated well with the expression of eGFP and 5.32% of BALB/c CD4+ T cells expressed both 
proteins versus 6.23%% in SKG CD4+ T cells (figure 5.36).  
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Figure 5.36 – Correlation of ZAP-70_V5 and eGFP expression in transduced CD4+ T cells. Lymph node cells from 
BALB/c mice (panel A) and SKG mice (panel B) were transduced with a bi-cistronic vector containing both ZAP-70_V5 and 
eGFP. Flow cytometric analysis showed that only a small proportion of CD4+ T cells expressed ZAP-70_V5 without 
expressing eGFP and most CD4+ T cells expressing ZAP-70_V5 also expressed eGFP (5.32% in BALB/c and 6.23% in SKG 
T cells). Data representative of two independent experiments. 
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This indicated that the IRES sequence cloned in the bi-cistronic vectors was functional, that IRES-
driven transcription of eGFP was similar in levels to that of ZAP-70 and that eGFP could confidently be 
used as a reliable indicator of retroviral vector-induced ZAP-70 transduction. This also meant that the 
low levels of eGFP expression observed following transduction with bi-cistronic retroviruses reflect 
low expression levels of ZAP-70 induced and that those levels were insufficient to enable meaningful 
reconstitution of TCR signalling in SKG T cells nor to permit further functional analysis of transduced T 




In this chapter I described my attempts to establish a system for the stable integration of the murine 
wild-type ZAP-70 into SKG mutant T cells, thereby restoring the integrity of TCR signalling within these 
cells. The chosen approach relied on establishing virus-mediated gene transfer protocols in order to 
compare the effects of reconstituted SKG T cells on the development of arthritis in a T cell-mediated 
adoptive transfer model and consequently investigate the contribution of defective TCR signals to 
development of the autoimmune arthritis.  
 
Viral vectors are useful vehicles for the delivery of foreign genetic material into target cells since they 
have the ability to integrate into the host cell genome and maintain gene expression (Mulligan 1993). 
Retroviral vectors are only able to integrate in cycling cells due to their inability to translocate the 
viral genome across the nuclear envelope (Miller, Adam et al. 1990; Roe, Reynolds et al. 1993). 
Lentiviruses, on the other hand, are a subclass of retroviruses that have evolved a mitosis-
independent nuclear import strategy allowing them to integrate into non-dividing cells (Unutmaz, 
Kewal Ramani et al. 1999). Other advantages of using lentiviral vectors include their capacity to 
shuttle large large amounts of genetic material and to maintain stable long-term transgene 
expression following integration into the host chromatin (Cockrell and Kafri 2007). In addition, 
lentiviruses have been shown to be very effective at transducing and enabling transgene expression in 
different cell types, including haematopoietic cells (Demaison, Parsley et al. 2002). Consequently my 
first approach was to use a lentiviral vector, more specifically a HIV-based vector since such vectors 
have been successfully used for in vitro and in vivo transduction of transgenes (Bartosch and Cosset 
2004).  
 
Chapter 5  Results 
181 
 
Although wild-type HIV-1 lentiviruses cannot infect quiescent T lymphocytes (Zack 1995), stable 
expression of a transgene has been achieved in human primary T cells following a short ex vivo 
transduction protocol when using a lentivirus modified to contain a central DNA flap (Dardalhon, 
Herpers et al. 2001). Using a similarly enhanced lentiviral vector and comparable protocols, I was not 
able to achieve high and consistent levels of transduction for the eGFP transgene into murine primary 
CD4+ T cells. Over 30 distinct experimental conditions were tested and eGFP expression was at best 
detected in only 4% of the transduced CD4+ T cells. Transduction following 24h activation of T cells 
with stimulatory monoclonal antibodies remained low and did not provide better transduction than 
those levels achieved with a mitogen such as Con A. Although co-localisation of virus particles and 
target cells on specific adhesion domains of Retronectin, a recombinant fibronectin molecule which 
has been shown to increase gene transfer in human T lymphocytes (Fehse, Schade et al. 1998), in 
murine T lymphocytes, I did not observe an equivalent increase of transduction rate and only 
achieved transgene expression in approximately 2% of cells. Pre-activation of the target cells with 
cytokines such as IL-2 or IL-7 for 96h did not yield gene transduction above 1% although such 
techniques have proved very successful in stably transducing resting human T cells (Unutmaz, Kewal 
Ramani et al. 1999). Neither transduction by centrifugation (spinoculation) nor the use of cationic 
polymers such as polybrene or DEAE-Dextran improved transduction significantly although both 
techniques have been shown previously to increase transduction efficiency (O'Doherty, Swiggard et 
al. 2000; Davis, Rosinski et al. 2004). Finally, it was also noted that the transduction rate in SKG 
splenocytes was dramatically reduced from the already low rates achieved with BALB/c cells.  
 
In view of these findings, I felt that the gene-transduction strategy needed to be substantially 
reviewed and amended. To this end, I switched to a retrovirus-based approach using the Moloney 
murine leukaemia virus (MLV)-derived vector MFG, which was originally constructed by P. Robbins 
and B. Guild in Richard Mulligan's laboratory at the Whitehead Institute (Cambridge, MA), and has 
been shown to be superior in conferring gene expression after transduction of a variety of target cells 
(Ohashi, Boggs et al. 1992; Byun, Kim et al. 1996; Krall, Skelton et al. 1996). However, it should be 
noted that in comparison to human T cells, efficient retroviral gene transfer and subsequent 
expansion of murine primary T cells is more difficult to achieve (Lee, Sadelain et al. 2009) although 
the molecular basis for this difference remains elusive (Riviere, Gallardo et al. 2000).  
 
One limitation of this new approach was that retroviral vector-based protocols require the target T 
cells to enter mitosis for efficient transduction (Miller, Adam et al. 1990; Roe, Reynolds et al. 1993), 
and owing to the SKG mutation there were concerns that the cells might not be able to be activated 
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to a sufficient level. Preliminary data using a mono-cistronic retroviral vector expressing eGFP showed 
that, although defective in TCR signalling, SKG CD4+ T cells could be activated, with monoclonal anti-
CD3 and anti-CD28, to a level which was sufficient for consistent retroviral transduction rates above 
40% to be achieved.  
 
Switching to a retrovirus-mediated approach had knock-on effects on two other aspects of the 
project. First, I needed to confirm that non-transduced SKG T cells stimulated with the activation 
protocol required for retrovirus transduction were still arthritogenic and could induce arthritis in the 
adoptive transfer model. This is because ex vivo activation of cells for an extended period of time has 
been shown to potentially change the functional capacity of T cells (Sauce, Tonnelier et al. 2002). The 
arthritogenicity of SKG CD4+ T cells stimulated ex vivo was successfully demonstrated and was 
described in Chapter 4, section 4.5.  
 
Second, I had to revise the cloning strategy and determine whether the constructs designed to be 
cloned in the lentivirus backbone could be re-used in the retrovirus backbone with minimal 
modifications. Initially, I cloned eight distinct bi-cistronic constructs, each coding for either a wild-type 
or SKG copy of the mouse ZAP-70 gene, followed by a second gene, downstream of an IRES sequence, 
coding for a cellular marker of transduction. In one subset of clones, the ZAP-70 gene was fused to a 
V5 tag. All clones were sequenced to verify that no mutations had been introduced during cloning and 
expression of ZAP-70 was confirmed with all the constructs when inserted in lentiviral vectors. 
Following the change of viral strategy, the constructs were successfully excised from the lentiviral 
vectors and re-inserted, via a multi-step cloning process, into MFG retroviral vectors. Again, 
expression of the genes of interest and the reporter genes was verified and both the target proteins 
and the reporter proteins could be detected by Western blotting in the cell lysates of transduced HEK 
293T cells as well as primary T cells.  
 
Successful infection by MLV-derived retroviral vectors requires that target cells proceed through 
mitosis (Miller, Adam et al. 1990; Roe, Reynolds et al. 1993) and express an appropriate retroviral 
receptor (Miller 1996). Since eGFP transduction rates over 40% were routinely achieved with the 
mono-cistronic virus, this would suggest that both the requirement for cell cycling and receptor 
expression were met by the SKG T cells, yet when switching to bi-cistronic retroviral vectors, and 
using the same optimised transduction protocol, eGFP was expressed in less than 2% of the target 
SKG CD4+ T cells. Therefore other factors had to be investigated to explain the low transduction 
efficacy achieved with the bi-cistronic vectors.  
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Since infection with the mono-cistronic virus was achieved at workable levels, I focused on two 
aspects which differed between the mono-cistronic and the bi-cistronic virus, namely the virus titer 
and the IRES sequence.  
 
The virus titre of the bi-cistronic virus initially produced by the PT67 packaging cell line, when 
assessed in NIH 3T3 cells, was considerably lower than that of the mono-cistronic virus. Therefore 
several techniques, including multiples rounds of transduction and re-selection of the Phoenix-Eco 
and PT67 packaging cell lines, were attempted. Although the virus titer eventually increased to a level 
which enabled almost identical eGFP expression rates in NIH 3T3 from the bi-cistronic and the mono-
cistronic virus in NIH 3T3, the viral transduction rate in primary T cells increased but remained much 
lower than that achieved with mono-cistronic virus (<6% and >40% respectively), suggesting that 
increasing the virus titre although helpful was not sufficient.  
 
Bi-cistronic vectors in which the first gene is translated in a cap-dependent manner and the second 
gene in an IRES-dependent (cap-independent) manner have been applied to a variety of experimental 
settings, from cultured cells to transgenic animals, and shown to be efficient tools to ensure 
transgene expression in primary murine T cells (Ouyang, Ranganath et al. 1998; Szabo, Kim et al. 
2000). IRES-containing expression cassettes are considered an improvement over dual promoter 
vectors which have been used to co-express two genes but which often led to transcriptional 
interference and/or dissociated gene expression (Martinez-Salas 1999). The rationale behind the 
choice of a IRES-based bi-cistronic vector was therefore sound and substantiated, especially since I 
used an IRES element derived from encephalomyocarditis virus, whose efficiency has been found to 
be higher than IRES elements derived from other types of virus (Borman, Le Mercier et al. 1997; 
Gallardo, Tan et al. 1997).  
 
However, IRES-driven expression has sometimes been shown to be lower than cap-dependent 
expression of the same reporter in the mono-cistronic version of the same vector (Wagstaff, Lilley et 
al. 1998), therefore I had to ensure that the IRES sequence cloned in my construct was functional. 
This was done by comparing the IRES-driven expression rate of eGFP with the cap-dependent 
expression level of V5-tagged ZAP-70 which was assessed by intra-cellular staining. I confirmed that 
the IRES sequence incorporated in the retroviral vector was functional in primary SKG T cells and that 
the detected expression of the reporter correlated well with the detected expression of ZAP-70-V5. 
Therefore, expression of eGFP could be used as an accurate and reliable indicator of the levels of 
expression of the primary gene, ZAP-70, in the transduced cells. However, the secondary structure of 
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the IRES element is complex since conserved motifs form stem-loops to facilitate RNA-RNA and RNA-
protein interactions and promote translation (Martinez-Salas 1999; Balvay, Soto Rifo et al. 2009). 
Therefore the finding that the IRES sequence is functional does not preclude the possibility that the 
introduction of the IRES sequence in the bi-cistronic vector may render the virus RNA more labile or 
that it might interact with other intra-cellular factors, including other parts of the vector, thereby 
compromising the virus ability to transduce effectively. Consequently, an approach worth exploring 
would be the generation of ZAP-70-encoding mono-cistronic vectors. The difficulty in that case would 
be to accurately assess the transgene transduction rate in the absence of a reporter gene in the viral 
vector. This could only be approximated by internal staining of a similar V5-ZAP-70 construct, but it 
would not be possible to ascertain that the rate of transduction of the V5-tagged transgene was 
necessarily an exact reflection of the untagged transgene. Still it would be possible to empirically 
evaluate transduction efficiency using assays that reflect TCR signalling reconstitution, such as 
proliferation assay for instance, before using those cells in in vivo experiments.  
 
The low rates of transduction I achieved seriously hampered the experimental options. The low 
absolute numbers of transduced CD4+ T cells made sorting difficult, since CD4+ T cells were only a 
subset of the starting heterogeneous population. Also the use of a non-sorted population, where only 
a residual fraction of SKG cells were transduced and whose TCR signalling was reconstituted, was 
unlikely to yield a notable effect especially at the whole-organism level in vivo. Only experiments 
easily quantifiable at the single-cell level could have been carried out, and even these would have 
been insufficient on their own to validate the hypothesis explored in this thesis. For instance 
differences have been observed in the F-actin localisation between BALB/c and SKG T cells when 
migrating on ICAM-1. In wild-type BALB/c T cells, the F-actin is polarised in the front of the migrating 
cells whereas in SKG T cells an F-actin ring remains distributed throughout the cells (Cope lab, 
unpublished data). Therefore one further experiment could have been to assess whether the 
introduction of wild-type ZAP-70 in reconstituted SKG T cells, helped localisation of F-actin as per the 
pattern observed in wild-type T cells.  
 
Although not realistically feasible within the time and resource constraints of this project, an 
alternative approach to study the effect of reconstituted ZAP-70 in arthritogenic SKG T cells would 
have been the generation of a transgenic mouse model. Saini and colleagues recently studied the 
regulation of ZAP-70 during thymic development by developing a ZAP-70-/- transgenic mouse that 
expressed a tetracycline-inducible gene encoding for ZAP-70 and a human CD2 reporter (Saini, Sinclair 
et al. 2010).  Such an experimental system means that expression of the target gene can be 
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temporally controlled by feeding the transgenic mice with food/water containing the inducing 
antibiotic (tetracycline) at any chosen time. In our case, the induction of wild-type ZAP-70 in SKG T 
cells would have been carried out post-thymic selection in order to ensure the existence of a 
repertoire of auto-reactive arthritogenic T cells. SKG T cells, following successful induction of wild-
type ZAP-70, could be identified and sorted by staining the human cell-surface CD2 protein or another 
reporter included in the construct. Those cells could then be used in the adoptive transfer model 
described in Chapter 4.  
 
In conclusion, despite trying both lentiviral and retroviral vector approaches, the efficiency of gene 
transduction into target murine primary T cells was insufficient for further in vitro functional analysis 
or for testing the arthritogenicity of transduced T cells in adoptive transfer experiments.  Therefore, 
and instead of reconstituting the signalling machinery, I turned to other options such as restoring 
functional defects of SKG T cells which will be described in Chapter 6.  
















Chapter 6 – Reconstitution of IL-2 signalling 
using exogenous recombinant IL-2 
    





In chapter 3 it was demonstrated that naïve BALB/c and ZAP-70 mutant SKG CD4+ T cells expressing a 
TCR transgene differentiate into distinct subsets of effector Th cells following stimulation with specific 
antigen in the absence of a polarising cytokine environment.  Specifically, newly activated SKG T cells 
were found to be relatively deficient in IL-2, IL-4 and IFNγ production during the early stages of Th 
differentiation, a crucial stage of T cell fate determination. Reduced production of IL-2, IL-4 and IFNγ 
during differentiation of SKG Th cells was associated with production of significantly higher amounts 
of IL-17 and lower amount amounts of IL-4 when compared to wild type BALB/c T cells.  
 
In the light of these findings, it was important to confirm that the defect in TCR signalling was 
responsible for the exaggerated Th17 responses and development of arthritis. Hence, in chapter 5, I 
attempted to investigate, using virus-mediated gene transfer, the effects of reconstituting SKG Th 
cells with wild type ZAP-70 on the development of arthritis in a T cell-mediated adoptive transfer 
model.  
 
The second approach, described in this chapter, involved testing the effects of reconstituting in vitro 
the defects in cytokine expression observed during differentiation of SKG T cells. Specifically, I 
investigated whether supplementation of differentiating SKG T cells with exogenous recombinant IL-
2, IL-4 or IFNγ inhibited the differentiation to IL-17 producing T cells and restored cytokine production 
towards a wild-type expression profile. 
 
In the following experiments I used the differentiation protocol adopted in chapter 3, with some 
modifications (figure 6.1). In brief, purified naïve CD4+ T cells were stimulated with HA peptide in the 
presence of low, intermediate or high levels of exogenous recombinant IL-2 or IL-4 or IFNγ. 
Exogenous cytokines were added to cultures a second time during the differentiation phase when T 
cells were expanded on day 3. Cell aliquots were harvested at the end of the differentiation period on 
day 6 for qPCR analysis of expression of lineage-specific transcription factors. Cells were re-stimulated 
with antigen on day 7 in the absence of exogenous cytokines. Supernatants were harvested on day 9 
and 11 for analysis of the cytokines secreted by the differentiated Th cells.  




Figure 6.1 – Assay of cytokine production using naïve CD4+ T cells from lymphoid organs. Naïve CD4+ T cells were 
purified from HNT-TCR BALB/c and SKG mice and then activated with HA peptide (2 µg/ml) on day 0 in the presence of IL-2 
(1, 10 or 100 U/ml), IL-4 (1, 10 or 50 ng/ml) or IFNγ (1, 10 or 50 ng/ml). Exogenous cytokine was also added on day 3 when 
cells were expanded. Cells were re-stimulated on day 7 with the same concentration of peptide in the presence of mitomycin-
C treated non-transgenic APCs. Cells were collected at the end of the differentiation period (day 6) and processed for qPCR 
analysis of lineage-specific transcription factors. Supernatants were collected on day 9 and day 11 for flow analysis of 
secreted cytokines using the CBA system.  
 
6.2. Effects of adding exogenous IL-4 during early differentiation  
 
Naïve T cells from BALB/c or SKG lymphoid organs were stimulated with HA peptide in the presence 
of 1, 10 or 50 ng/ml of exogenous recombinant murine IL-4. Exogenous IL-4 was again added on day 3 
at the same concentration as on day 0. At the end of the differentiation process, cells were re-
stimulated with antigenic peptide in the absence of any supplementary exogenous cytokine. 
Expression levels of IL-17 and IL-4 at day 9 and day 11 were then determined, since those were the 
two cytokines whose production levels were significantly different between wild-type and SKG 
effector Th cells which had differentiated in the absence of exogenous cytokines.  
 
Supplementing differentiating SKG T cells with a low amount of exogenous IL-4 (1 ng/ml) did not have 
an effect of the production of IL-17 by SKG differentiated T cells upon antigen recall which remained 
vastly higher, at 1,147 pg/ml, than the levels of IL-17 produced by BALB/c at 120 pg/ml (figure 6.2). 
When identical SKG cells were subjected to concentrations of exogenous IL-4 above 10 ng/ml – the 
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concentration required to polarise naive T cells to a Th2 phenotype - the production of IL-17 was 
severely repressed to 100 pg/ml.  
 
Exposure of differentiating SKG T cells to exogenous IL-4 led to a dose-dependent increase in 
production of IL-4 once the SKG cells became effector T cells. This result was expected since the 
presence of exogenous IL-4 at the time of initial TCR stimulation would initiate the differentiation of 
naïve SKG T cells into Th2 cells and amplify the Th2 differentiation in an autocrine loop (figure 6.2). 
Exogenous IL-4 also led to the inhibition of IFNγ in all three SKG groups.  
 
 
Figure 6.2 – Production of IL-17 and IL-4 by effector Th cells differentiated in the presence of exogenous IL-4. 
Purified naïve T cells were stimulated with HA peptide in the presence of 1, 10 or 50 ng/ml of exogenous recombinant 
murine IL-4. On day 7, differentiated effector Th cells were washed and re-stimulated with antigenic peptide in the 
absence of additional exogenous IL-4, and supernatants from day 11 were collected and analysed for the presence of 
IL-17 and IL-4. IL-4 promotes Th2 differentiation by SKG T cells. Also supplementation of differentiating SKG T cells 
with IL-4 at concentrations above 10 ng/ml severely repressed the production of IL-17 by SKG effector T cells. IFNγ 
production was markedly repressed in all SKG groups exposed to IL-4 during differentiation. Results presented as 
mean ± SEM of duplicate cultures (except IFNγ).  
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6.3. Effects of adding exogenous IFNγ during early differentiation  
 
Naïve T cells from BALB/c or SKG lymphoid organs were activated with HA peptide in the presence of 
1, 10 or 50 ng/ml of exogenous recombinant murine IFNγ. Cells were cultured according to the 
protocol previously described.  
 
When naïve SKG T cells were stimulated in the presence of either 10 or 50 ng/ml IFNγ, they 
differentiated into effector T cells whose production of IL-17 was reduced by more than 60% 
compared to SKG T cells not exposed to IFNγ whereas at the lower concentration of 1 ng/ml IFNγ, the 
effect on IL-17 effector production was only very slightly reduced from the levels produced by 
untreated SKG T cells (figure 6.3). 
 
The addition of exogenous IFNγ during differentiation had a profound suppressive effect on the 
production of IL-4 by SKG effector T cells as the production of IL-4 was completely abolished in the 
three groups of SKG differentiated T cells pre-treated with IFNγ.  
 
Overall these data confirmed that both IL-4 and IFNγ negatively regulate the T cell production  of IL-
17 in the effector phase (Harrington, Hatton et al. 2005; Park, Li et al. 2005) and that 
supplementation of differentiating SKG T cells with intermediate to high concentrations of either IL-4 
or IFNγ could reduce the SKG T cell production of IL-17 to wild-type levels. IL-4 was also able to 
restore IL-4 production by effector SKG cells which had been exposed to the highest concentration of 
IL-4 during the differentiation phase. In contrast, exposure top high concentrations of IFNγ blocked IL-










Figure 6.3 – Production of IL-17 and IL-4 by effector Th cells differentiated in the presence of exogenous 
IFNγ. Purified naïve T cells were stimulated with HA peptide in the presence of 1, 10 or 50 ng/ml of exogenous 
recombinant murine IFNγ. On day 7, differentiated effector Th cells were washed and re-stimulated with antigenic 
peptide in the absence of additional exogenous IFNγ, and supernatants from day 11 were harvested and analysed for 
the presence of IL-17 and IL-4. Presence of exogenous IFNγ, even at low concentration, during differentiation 
completely repressed the production of IL-4 by SKG effector T cells. Exposure of the differentiating SKG cells to IFNγ 
concentrations equal or above 10 ng/ml led to reduced IL-17 production by SKG effector T cells. Results are 
presented as mean ± SEM of duplicate cultures.  
 
6.4. Effects of adding exogenous IL-2 during early differentiation  
 
6.4.1. IL-17 production is reduced following early supplementation of 
exogenous IL-2  
Since SKG T cells are relatively deficient in IL-2 production following antigenic TCR stimulation, the 
effect of supplementing differentiating SKG T cells with exogenous IL-2 on their subsequent 
production of IL-4 and IL-17 was studied.    
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Naïve T cells were stimulated with antigenic peptide in the presence of 1, 10 or 100 U/ml of 
exogenous recombinant murine IL-2, and were then cultured according to the protocol previously 
described.  
 
Supplementing differentiating SKG T cells with 100 U/ml of exogenous IL-2 led to a consistent 
reduction in the production of IL-17 by SKG effector Th cells when compared to SKG T cells subjected 
to 1 U/ml exogenous IL-2, a low level of exogenous IL-2 supplementation required for all T cell 
cultures to survive. On day 9, SKG T cells differentiating in a high IL-2 cytokine environment produced 
215 pg/ml IL-17, a 80% reduction from the 1,001 pg/ml produced by SKG T cells differentiating in a 
low IL-2 cytokine environment. For comparison T cells from BALB/c mice produced 88 pg/ml of IL-17 
in a low IL-2 differentiating environment (figure 6.4, panel A). These data are representative of two 
independent experiments.  
 
The effect of IL-2 supplementation on IL-17 production was sustained on day 11 and caused a dose-
dependent reduction in IL-17 production (figure 6.4, panel A).  
 
The inhibitory effect of exogenous IL-2 on the production of IL-17 by effector Th cells was also 
decreased in BALB/c (figure 6.4, panel B), proving that the effect is not specific to SKG T cells and that 
even in the context of wild-type differentiating T cells the production of IL-17 can be regulated by 
exogenous IL-2, albeit from a lower baseline level.  
 
These results demonstrate a clear dose-dependent relationship between the amount of IL-2 present 
in the early stages of cell differentiation and the production of IL-17 by differentiated effector T cells. 
These data suggest that supplementation of differentiating SKG T cells with high doses of exogenous 
recombinant IL-2 inhibit differentiation to IL-17 high producer T cells and restore IL-17 synthesis to 
the levels seen in wild-type cells.  
 







Figure 6.4 – Production of IL-17 by effector Th cells differentiated in the presence of exogenous IL-2. Purified naïve T 
cells were stimulated with HA peptide in the presence of either 1, 10 or 100 U/ml of exogenous recombinant murine IL-2. On 
day 7, differentiated effector Th cells were washed and re-stimulated with antigenic peptide in the absence of any 
supplementary exogenous IL-2, and supernatants from day 9 and day 11 were harvested and analysed for the presence of 
IL-17. Panel A – Expression of IL-17 produced by differentiated SKG T cells on day 9 and day 11 are inversely proportional to 
the amount of exogenous IL-2 they were exposed to during the early stage of T cell differentiation. Panel B – A similar effect 
was observed in the production of IL-17 from BALB/c Th cells when subjected to early treatment with exogenous IL-2. Results 
presented as mean ± SEM of duplicate cultures and are representative of two independent experiments. 
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6.4.2. Variable effect on IL-4 production of supplementation of exog. IL-2 
 
In contrast to IL-17, exposure of differentiating SKG naïve T cells to the highest doses of exogenous IL-




Figure 6.5 – Production of IL-4 by effector Th cells differentiated in the presence of exogenous IL-2. Purified naïve T 
cells were stimulated with HA peptide in the presence of either 1, 10 or 100 U/ml of exogenous recombinant murine IL-2. On 
day 7, differentiated effector Th cells were washed and re-stimulated with antigenic peptide in the absence of any 
supplementary exogenous IL-2, and supernatants from day 9 and day 11 were harvested and analysed for the presence of 
IL-4. Differentiating T cells that had been exposed to the higher doses of exogenous IL-2 produced more IL-4 once 
differentiated. Results presented as mean ± SEM of duplicate cultures.  
 
More specifically, on day 9 differentiated SKG cells treated with 100 U/ml IL-2 produced 1,838 pg/ml 
of IL-4 which was similar to the levels produced by BALB/c T cells at 1,715 pg/ml. In contrast, SKG T 
cells that had been exposed to the lower level 1 U/ml of IL-2 during differentiation produced 
approximately one third of that amount of IL-4 at 513 pg/ml.  
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On day 11 a similar pattern was observed, although levels of IL-4 were reduced in all cell cultures in 
comparison to day 9, suggesting that IL-4 is produced rapidly following antigen recall and that then 
expression declines, or that it is consumed rapidly. This is in contrast to IL-17 whose levels were 
consistently higher in day 11 cultures suggesting that IL-17 is either produced later following antigen 
recall and/or is more stable once secreted and accumulates in the culture supernatants. 
 
However in a second experiment, the production of IL-4 was low for all groups of differentiated SKG 
cells irrespective of the dose of exogenous IL-2 they had been treated with during early 
differentiation (figure 6.6, panel B). Thus, in this experiment, IL-2 supplementation was unable to 
increase IL-4 production, although it was able to reduce IL-17 production (figure 6.6, panel A).  







Figure 6.6 – Repeat experiment for production of IL-17 or IL-4 by effector Th cells differentiated in the presence of 
exogenous IL-2. Purified naïve T cells were activated in the conditions previously described. Panel A – In agreement with 
previous observations, the amounts of IL-17 produced by differentiated SKG T cells on day 9 and day 11 is inversely 
proportional to the amount of exogenous IL-2 they were exposed to during the early stage of T cell differentiation. Panel B – 
The production of IL-4 by differentiated SKG T cells was low in all three SKG groups irrespective of the concentration of 
exogenous IL-2 they had been exposed to during differentiation. Results presented as mean ± SEM of duplicate cultures. 
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This suggests that the effect of IL-2 on Th2 differentiation was less consistent than that of Th17 
differentiation and therefore we could be in the presence of one of two scenarios when it comes to 
the effect of IL-2 on effector production of IL-17 and IL-4. The first option is that the presence of high 
concentration of IL-2 during differentiation pushes SKG T cells to differentiate away from Th17 and in 
a pattern similar to wild-type T cells resulting in the production by differentiated T cells of low levels 
of IL-17 and high levels of IL-4. This would be consistent with the first experiment. The second option 
is that the addition of IL-2 does not fully restore the wild-type cytokine profile but rather interferes 
with the IL-17 transcription machinery, leading to differentiated SKG T cells with a reduced ability to 
produce high levels of IL-17 but which are still producing low levels of IL-4, similar to those produced 
in the absence of exogenous IL-2, as was observed in the second experiment. This question was 
further investigated by looking into the expression of RORc and GATA3 following exogenous IL-2 
treatment.  
 
6.4.3. RORc expression is repressed and GATA3 expression is unchanged 
following early supplementation of exogenous IL-2 
Following antigen-driven TCR activation, naïve T cells undergo cell differentiation which is regulated 
by a combination of TCR- and cytokine-derived signals and is enforced by the induction of master 
transcriptional regulators such as T-bet, GATA3 and RORγt. Therefore in order to establish whether 
the changes in IL-17/IL-4 correlated with Th17/Th2 differentiation, I also assessed the levels of 
lineage-specific transcription factors expressed intracellularly by the end of the differentiation period 
on day 6, and to measure how their expression might have been affected by the presence of 
exogenous IL-2 in the culture environment.  
  
In two independent experiments, mRNA for RORc was down-regulated to wild-type levels in the 
presence of high dose of exogenous IL-2 (figure 6.7) when assessed on day 6 at the end of the 
differentiation period. Since RORc encodes RORγt, a key transcription factor which regulates IL-17 
gene expression, this is consistent with results from previous section.  
 
However, the concentration of IL-2 present in the cytokine environment during early differentiation 
did not influence the levels of GATA3 expressed in SKG T cells, since these remained lower than wild-
type levels (figure 6.7). This is in line with the data from the second experiment where the levels of 
secreted IL-4 were equally low in all three SKG groups, although the fold-difference between BALB/c 
and SKG groups is much lower at the mRNA level that at the protein levels. This may imply another 
level of regulation either via other transcription factors or post-translational modifications.    




Tbx21 encodes T-bet and is a transcriptional regulator of IFNγ. Levels of Tbx21 mRNA by day 6 were 
down-regulated with increasing concentrations of IL-2. This is in contrast to the up-regulation of IFNγ 
detected on day 9 and day 11 in the two SKG groups having received either 10 or 100 U/ml IL-2.  
 
 
Figure 6.7 – Day 6 expression levels of lineage-specific transcription factors following differential treatment with IL-2 
during early differentiation. Purified naïve T cells from SKG mice were stimulated with HA peptide in the presence of 1, 10 
or 100 U/ml of exogenous recombinant murine IL-2. At the end of the differentiation period on day 6, cells lysates were 
analysed for expression of Tbx21, RORc, and GATA3 mRNA by qPCR. Levels of RORc expression in SKG T cells decreased 
with increasing concentration of IL-2 during early differentiation. Tbx21 followed a similar dose-dependent pattern of down-
regulation as for RORc, although relative expression levels were lower. Levels of SKG GATA3 mRNA on day 6 did not seem 
to be influenced by the concentration of IL-2 and remained lower than wild-type levels. Data are normalised with expression 
amounts of the house-keeping gene hprt. mRNA levels from BALB/c T cells are set to 1 and expression levels in the SKG 
groups are relative to the expression in BALB/c for each individual gene. Results are representative of two independent 
experiments. 
 
6.4.4. The IL-17 inhibition is not due to IL-2-driven increase in IL-4  
Naïve SKG CD4+ T cells activated with antigen in the presence of exogenous IL-2 differentiated into 
effector T cells that produced reduced levels of IL-17. Although the increase in IL-4 production was 
not consistent in two independent experiments, and at day 6 post-activation no increase in GATA3 
mRNA levels was detected in SKG T cells treated with high concentrations of exogenous IL-2, I 
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addressed the question of whether the inhibition of IL-17 was not due to this elusive increase in IL-4, 
since as stated previously IL-4 can potently inhibit the production of IL-17 by effector T cells 
(Harrington, Hatton et al. 2005; Park, Li et al. 2005).  
 
Highly purified CD4+ T cells from BALB/c and SKG mice were activated with HA peptide in the 
presence of a low dose of IL-2 (1 U/ml) and neutralising anti-IL-4 antibody at 10 µg/ml. This 
concentration is routinely used in polarising experiments and had been shown to work in a 
neutralising capacity in my lab. An additional group of SKG naïve T cells was also treated with 
neutralising anti-IL-4 antibody (10 µg/ml) in the presence of a high dose of IL-2 (100 U/ml). Following 
antigen recall of differentiated T cells on day 7, supernatants was collected on day 11 and analysed 
for the presence of IL-17.   
 
Naïve SKG T cells exposed to low amounts of IL-2 differentiated into effector T cells that produced 
higher levels of IL-17 than BALB/c T cells exposed to the same differentiation conditions. When 
concurrently exposed to neutralising anti-IL-4 antibody, both BALB/c and SKG T cells produced slightly 
higher levels of IL-17, demonstrating that IL-4 generated during the differentiation of the cells was 
inhibitory to IL-17 production (figure 6.8). When naïve SKG cells were exposed to high doses of IL-2, 
they differentiated into Th cells whose IL-17 production was reduced to wild-type levels. This was also 
true in the presence of a neutralising anti-IL-4 antibody, demonstrating that the IL-17 inhibitory effect 
seen following treatment of differentiating SKG T cells with 100 U/ml IL-2 is not mediated indirectly 











Figure 6.8 – Production of IL-17 by effector Th cells differentiated in the presence of exogenous IL-2 and neutralising 
anti-IL-4 antibody. Purified naïve T cells were stimulated with HA peptide in the presence of either low (1 U/ml) or high 
concentration (100 U/ml) of exogenous recombinant murine IL-2, and in the presence of neutralising anti-IL-4 (10 µg/ml). 
Once differentiated, the effector Th cells were washed and re-stimulated on day 7 with HA peptide and without any 
exogenous cytokines or antibodies. Supernatants were harvested on day 11 and analysed for the presence of IL-17. In the 
absence of anti-IL-4, SKG T cells exposed to low dose of IL-2 differentiated into effector T cells that produced higher levels of 
IL-17 than wild-type having being exposed to the same differentiation conditions. In a high IL-2 environment, the reduced 
production of IL-17 by SKG effector T cells was similar with or without neutralising anti-IL-4 antibodies, being repressed back 
to wild-type levels under both conditions. Results are presented as mean ± SEM of duplicate cultures. 
 
6.5. Effects of exogenous IL-2 on the production of other cytokines  
 
Expression of cytokines IFNγ and TNFα was up-regulated in a dose-dependent manner following 
addition of exogenous IL-2 (figure 6.9). Since the levels of IFNγ and TNFα produced by wild-type and 
SKG cells treated with 1 U/ml IL-2 were similar on day 9 following antigen recall, providing SKG naïve 
T cells with additional IL-2 actually increased the production of IFNγ and TNFα to levels beyond those 
of BALB/c.  
 
IL-6 production by SKG differentiated T cells was not influenced by the presence of exogenous IL-2 in 
the culture medium, and levels of IL-6 in the three SKG groups remained similar to each other and 
overall slightly above wild-type levels (figure 6.9).  
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As previously observed, the production of IL-10 by SKG T cells differentiated in the presence of low 
levels of exogenous IL-2 (1 U/ml) was below that of BALB/c cells (7,322 pg/ml and 10,085  pg/ml 
respectively). When supplemented with increasing doses of IL-2, SKG T cells initially up-regulated the 
production of IL-10 to levels similar that of wild-type on day 9, but by day 11, IL-10 production 





Figure 6.9 - Production of IFNγ, TNFα, IL-6 and IL-10 by effector Th cells differentiated in the presence of exogenous 
IL-2. Purified naïve T cells were stimulated with HA peptide in the presence of 1, 10 or 100 U/ml of exogenous recombinant 
murine IL-2. On day 7, differentiated effector Th cells were washed and re-stimulated with antigenic peptide in the absence of 
any supplementary exogenous IL-2, and supernatants from day 9 and day 11 were collected and analysed for secreted 
cytokines. IFNγ and TNFα were up-regulated above wild-type levels when previously exposed to increasing concentrations of 
IL-2. SKG IL-10 levels were restored to that of wild-type on day 9 but decreased below wild-type levels subsequently. IL-6 did 
not fluctuate in SKG Th cell supernatants and remained slightly above wild-type levels. Results presented as mean ± SEM of 
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6.6. IL-2 treatment increases SKG CD25 expression to BALB/c levels  
 
IL-2 binds to specific cell-surface high-affinity IL-2 receptors made up of three proteins including the 
low-affinity α subunit CD25 which is undetectable on naïve T cells but whose expression is induced 
following their encounter with antigen (Kim, Imbert et al. 2006). Although CD25 has got a very short 
cytoplasmic tail and cannot induce intracellular signal transduction (Hatakeyama, Minamoto et al. 
1986), it is essential for the formation of the high-affinity ternary IL-2R complex without which T cells 
may not be able to respond to the low concentrations of IL-2 that are physiologically produced in vivo. 
 
The activation of naive T cells in vitro leads to very high levels of CD25 expression through a two-step 
process. First, moderate levels of CD25 are rapidly induced by TCR and co-stimulatory signals, in part 
by activation of NF-κB (Kang, Tran et al. 1992; Kontgen, Grumont et al. 1995; Himes, Coles et al. 
1996), NFAT (Ranger, Oukka et al. 1998; Peng, Gerth et al. 2001), AP-1 (Yang, Conze et al. 1998; 
Sabapathy, Kallunki et al. 2001), and CREB/AFT (Schuh, Twardzik et al. 1998; Yeh, Lecine et al. 2001). 
Concurrently, antigen-stimulation of naïve T cells also induces the expression and secretion of IL-2. 
Second, secreted IL-2 in turn amplifies and prolongs the expression of CD25, thus acting as a positive 
feedback regulator for the expression of its own high-affinity receptor (Bismuth, Leclercq et al. 1984; 
Bismuth, Moreau et al. 1985; Waldmann 1989; Lin and Leonard 1997). Such a mechanism, mediated 
via STAT5 (John, Vinkemeier et al. 1999; Rusterholz, Henrioud et al. 1999; Rameil, Lecine et al. 2000; 
Kim, Kelly et al. 2001), increases IL-2 binding and hence signalling by activated T cells through 
enhanced capture of IL-2 by CD25. Moreover CD25 can also regulate interactions in trans since when 
expressed on one cell, it can increase IL-2 signalling on adjacent cells that express the binary IL-2Rβ-γc 
complex but not CD25 (Eicher and Waldmann 1998). The subsequent IL-2/IL-2R interaction drives 
extensive clonal expansion and effector development and plays a major role in controlling the 
magnitude and duration of the T cell immune response. 
 
As expected highly purified CD4+CD62L+ naïve T cells from both BALB/c and SKG did not express CD25 
on their cell surface since CD25+ cells were excluded during the selection procedure (figure 6.10).  
 




Figure 6.10 – Naïve T cells from BALB/c and SKG do not express CD25. Naïve CD4+ T cells were purified from BALB/c 
and SKG lymphoid organs and stained with anti-CD4 and anti-CD25 antibodies. Flow cytometry analysis confirmed that, as 
expected, naïve T cells do not express CD25 on their cell surface. Figures representative of two independent experiments.    
 
The purified naïve CD4+ T cells were then stimulated with antigenic peptide in the presence of low or 
high concentrations of IL-2 and left to differentiate for 6 days. On day 6, cells were harvested and 
stained for cell surface expression of CD4 and CD25.  
 
When stimulated with 1 U/ml exogenous IL-2, 94.3% of BALB/c CD4+ T cells expressed CD25 
compared to 64.5% for SKG T cells. This means that under these conditions, there exists a sub-
population of SKG T cells which would be less likely to respond to IL-2 present in this micro-
environment (figure 6.11, left panel).  
 
When stimulated with 100 U/ml exogenous IL-2, CD25 expression in SKG T cells was up-regulated, and 
levels of cell-surface expression were comparable between SKG and BALB/c T cells, 96.2% and 97.3% 
respectively (figure 6.11, right panel).  
 





Figure 6.11 – High concentrations of exogenous IL-2 promotes expression of CD25 on SKG T cells. Naïve CD4+ T 
cells were activated with HA peptide in the presence of low or high concentrations of IL-2 and left to differentiate for 6 days. 
Cells were harvested and stained on day 6 with anti-CD4 and anti-CD25 antibodies. Flow cytometry analysis shows that with 
1 U/ml IL-2, differentiating SKG T cells express lower amounts of CD25 at their cell surface than wild-type cells, but this can 
be restored to wild-type levels with 100 U/ml exogenous IL-2.      
 
6.7. IL-2-driven STAT5 phosphorylation is not defective in SKG  
 
The formation of the quaternary IL-2/IL-2R complex leads to signal transduction through the tyrosine 
kinase JAK1 and JAK3 which respectively associate with IL-2Rβ and γc (Nelson, Lord et al. 1994; 
Nelson and Willerford 1998). Subsequent phosphorylation events lead to the recruitment and 
activation of STAT5 transcription factors which is an important outcome of productive IL-2R signalling 
(Malek and Castro 2010). Phosphorylated STAT5 dimers migrate to the nucleus where they bind to 
specific DNA consensus elements and activate the transcription of mitogenic and survival target genes 
(Horvath and Darnell 1997; Lord, McIntosh et al. 2000; Gaffen 2001). Up-regulation of CD25 is also 
controlled by this pathway (Moriggl, Topham et al. 1999).  
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Therefore the next step was to check whether the IL-2/STAT5 signalling axis was functional in SKG T 
cells and whether the deficient production of endogenous IL-2 in SKG led to basal differences 
between wild-type and SKG expression levels of the protein itself (i.e. total STAT5), and/or on the 
induction of its phosphorylated form (p-STAT5). If differences were found, it would also be important 
to establish whether impaired levels of STAT5 or p-STAT5 in SKG T cells could be restored with the 
supplementation of high concentrations of IL-2.  
 
These experiments were especially relevant because IL-2 mediated inhibition of IL-17 in T cells has 
been shown to be mediated via STAT5 (Laurence, Tato et al. 2007), and therefore it provides one 
mechanism by which IL-2 deficiency might cause excessive IL-17 production in SKG T cells.  
 
Naïve T cells that had been stimulated with peptide in the presence of low or high levels of IL-2 for 6 
days were washed and rested in cytokine-free medium overnight. On day 7, the cells were stimulated 
(from 15 to 120 minutes) with 100 U/ml IL-2 before being lysed and assayed for p-STAT5 and total 
STAT5 by Western blotting. 
 
The blots in figure 6.12 show that the amounts of STAT5 protein in whole-cell lysates of wild-type and 
SKG T cells are comparable. STAT5 phosphorylation could be detected in SKG T cells within 15 
minutes of IL-2 stimulation.  
 
The data might suggest that when the cells have been exposed to low levels of IL-2, the response to 
acute IL-2 is less robust and/or not sustained as well over time in SKG T cells as there are less p-STAT5 
in SKG whole-cell lysate at the 60 and 120 minutes time-points. I previously showed that, in the 
absence of high levels of exogenous IL-2, only about 65% of SKG CD4+ T cells expressed CD25 which 
may account for the seemingly lower levels of p-STAT5 in SKG at the later time-points.  
 
When the primary activation of the TCR was accompanied by high concentrations of IL-2, wild-type 
levels of p-STAT5 were down-regulated from the levels seen with low concentrations of IL-2, which 
might suggest desensitization following prolonged exposure to high levels of IL-2. This effect was not 
as marked for SKG T cells as no real differences was observed on the Western blots between SKG p-
STAT5 following treatment with 1 or 100 U/ml IL-2 (figure 6.12).  
 
Overall the data suggest that STAT5 is expressed at wild-type levels in SKG T cells, and that 
phosphorylation of STAT5 can be induced by IL-2-signalling in SKG T cells. 






Figure 6.12 – Western blot analysis of STAT5 and p-STAT5 expression in BALB/c and SKG whole-cell lysate. 
Naïve CD4+ T cells from BALB/c and SKG lymphoid organs were activated with HA peptide in the presence of low or 
high doses of IL-2 and left to differentiate for 6 days. On day 6, cells were harvested, washed and rested in fresh 
complete medium overnight, before acute stimulation with 100 U/ml IL-2 for 15, 30, 60 or 120 minutes. Whole cells 
were lysed and blotted for either total STAT5 or p-STAT5. Following acute IL-2 stimulation SKG STAT5 could be 
phosphorylated in either scenario. The phosphorylation of STAT5 in differentiating SKG T cells treated with 1 U/ml IL-
2, may be reduced and/or not sustained as well over time when compared to phosphorylation in BALB/c T cells. 
When naïve SKG T cells were activated with 100 U/ml IL-2, STAT5 was phosphorylated at levels at least equal to 
wild-type T cells.          
 
6.8. IL-2 pre-treatment does not increase FoxP3 expression in differentiating 
SKG CD4+ Th precursors  
 
IL-2 has been shown to be important for the development of thymic-derived natural (nTregs) Treg 
cells (Bayer, Yu et al. 2005) partly through the activation of STAT5 which directly binds the FoxP3 
promoter (Antov, Yang et al. 2003; Snow, Abraham et al. 2003; Zorn, Nelson et al. 2006; Yao, Kanno et 
al. 2007).  
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 Although other signals such as TCR recognition of self-antigen in the context of MHC class II and 
CD28-mediated co-stimulation also play a part (Salomon, Lenschow et al. 2000; Tang, Henriksen et al. 
2003; Tai, Cowan et al. 2005), IL-2 is an important cytokine to maintain homeostasis of Treg cells in 
the periphery (Fontenot, Rasmussen et al. 2005; Bayer, Yu et al. 2007). The up-regulation and 
maintenance of FoxP3, whose expression depend on IL-2R signalling, is essential for Treg cells as the 
main function of FoxP3 is to reinforce and maintain their suppressive function (Gavin, Rasmussen et 
al. 2007). Yet studies have shown that sub-optimal IL-2R signalling seems sufficient for relatively 
normal Treg cell homeostasis, although it increases the susceptibility to autoimmune diseases (Yu, 
Zhu et al. 2009).  
 
Data also indicate that peripheral conventional T cells can develop to become FoxP3+ induced Treg 
(iTregs) cells (Chen, Jin et al. 2003; Fantini, Becker et al. 2004; Zheng, Wang et al. 2004) and that this  
phenomenon occurs more often in mucosal tissues such as the gut and lungs (Izcue, Coombes et al. 
2009). IL-2, in conjunction with TGFβ, has been demonstrated to be an essential mediator of in vitro 
iTregs production (Davidson, DiPaolo et al. 2007; Zheng, Wang et al. 2007). As with nTregs, IL-2-driven 
STAT5 activation is essential to induce FoxP3 expression, although distinct conserved non-coding 
regions of FoxP3 are remodelled in iTreg versus nTreg cells (Zheng, Josefowicz et al. 2010), raising the 
possibility of a distinct contribution by IL-2R signalling in these lineage choices (Malek and Castro 
2010). Importantly once induced, the maintenance of FoxP3 expression and suppressive function can 
also be mediated by other IL-2-related γc cytokines such as IL-7 and IL-15 (Setoguchi, Hori et al. 2005; 
Yates, Rovis et al. 2007; Passerini, Allan et al. 2008; Wuest, Willette-Brown et al. 2008). 
 
Since IL-2-signalling, via the activation of STAT5, can both promote the development of iTregs but also 
inhibit Th17 cells (Laurence, Tato et al. 2007), the cell-fate choice between Th17 and iTregs seem 
reciprocally regulated and IL-2R signalling may contribute to this decision (Bettelli, Carrier et al. 2006; 
Veldhoen, Hocking et al. 2006; Gavin, Rasmussen et al. 2007; Malek 2008; Malek and Castro 2010). 
Therefore the lineage-commitment choice between Th17 and iTreg cells is probably particularly 
sensitive to amounts of IL-2 and therefore it became important to investigate whether induction of 
FoxP3 and generation of iTregs could be a mechanism to explain the inhibition of IL-17 production 
observed as a consequence of the addition of high concentrations of exogenous IL-2 during the 
differentiation of SKG naïve T cells in the experiments described in previous sections.  
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As previously described, 1.9% of the starting population of SKG naïve CD4+ T cells compared to 0.6% 
in naive BALB/c were of the CD4+CD25-FoxP3+ phenotype (figure 6.13).  
 
 
Figure 6.13 – Intra-cellular expression of FoxP3 in purified naive BALB/c and SKG T cells. Naive CD4+ T cells, purified 
from HNT-TCR BALB/c and SKG lymphoid organs, were stained with anti-CD4 and anti-FoxP3 monoclonal antibodies. On 
average there were 3 times less FoxP3+ cells in the wild-type naive CD4+ population when compared to SKG mice. Flow-
cytometry figures representative of two independent experiments. 
 
Following antigenic TCR activation in the presence of 1 or 100 U/ml exogenous IL-2, differentiating T 
cells were harvested and lysed on day 6 for qPCR analysis of mRNA levels of FoxP3. FoxP3 mRNA 
levels were higher in SKG T cells, though did not increase in a dose dependent fashion, when 
compared to levels in BALB/c T cells. Also the presence of higher concentrations of exogenous IL-2 did 









Figure 6.14 – Day 6 expression levels of FoxP3 following differential treatment with IL-2 during early differentiation. 
Purified naïve T cells from SKG mice were stimulated with HA peptide in the presence of 1, 10 or 100 U/ml of exogenous 
recombinant murine IL-2. At the end of the differentiation period on day 6, cells were lysed and content was analysed by 
qPCR for levels of FoxP3 mRNA. SKG T cells contained higher levels of mRNA for FoxP3, though not significantly, than wild-
type cells. SKG FoxP3 levels did not fluctuate significantly following differential IL-2 supplementation. Data are normalised 
with expression amounts of the house-keeping gene hprt. mRNA levels from BALB/c T cells are set to 1 and expression 
levels in the SKG groups are relative to the expression in BALB/c (n=2). 
 
When comparing the intracellular protein levels of FoxP3 in BALB/c and SKG T cells exposed to either 
low or high concentrations of IL-2, FoxP3 could not be detected in any of the four groups irrespective 
of strains or IL-2 treatment (figure 6.15).  
 




             
Figure 6.15 – FoxP3 expression is not increased in SKG T cells differentiated in the presence of high concentrations 
of IL-2. BALB/c and SKG naïve CD4+ T cells were activated with HA peptide in the presence of low or high doses of IL-2 and 
left to differentiate for 6 days. Cells were harvested and stained on day 6 with anti-CD4 and anti-FoxP3 antibodies. Although 
high concentrations of IL-2 during differentiation induced higher expression of CD25 in SKG T cells, they had no effect at 
promoting the intra-cellular expression of FoxP3 in neither BALB/c T cells not SKG T cells.  
 
6.9. Is the inhibition of IL-17 in differentiated SKG T cells sustained in the 
absence of exposure to exogenous IL-2? 
 
The inhibitory effect of high concentrations of exogenous IL-2 on the production of IL-17 had so far 
been observed in the first week following antigen recall of differentiated SKG effector T cells. The next 
step was to investigate whether this effect was the result of a transient repression of the IL-17 
transcription machinery which required continued presence of exogenous IL-2 in the micro-
environment to maintain its effect over a longer period of time, or whether the IL-17 inhibition was 
the result of IL-2-induced epigenetic modifications imprinted to the IL-17 gene locus of the 
differentiating SKG T cells. In the latter case, the repressive effect on IL-17 might be sustained over 
time even in the absence of high concentrations of IL-2 in the cytokine milieu.  
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To test the long-term effect of exogenous IL-2, naïve T cells were stimulated with antigenic peptide 




Figure 6.16 – Studying long-term effect of exogenous IL-2 during differentiation. Naïve CD4+ T cells were purified from 
HNT-TCR BALB/c and SKG mice and activated with HA peptide (2 µg/ml) on day 0 in the presence of either 1 or 100 U/ml IL-
2. Cells were re-stimulated on day 7 and day 14 with the same concentration of peptide and in the presence of mitomycin-C 
treated non-transgenic APCs and low or high concentrations of IL-2. Exogenous IL-2 was also added on day 3 and day 10 to 
maintain cell viability in culture. Supernatants were collected on day 11 and day 18.  
 
Cultures of SKG naïve T cells were divided into three groups (table 6.1). The first group was stimulated 
with HA on day 0 in the presence of 1 U/ml IL-2, which was also supplemented on day 3. The second 
group was subjected to the same antigenic peptide stimulation but in the presence of 100 U/ml IL-2. 
On day 7 the differentiated effector T cells from both groups were re-stimulated with HA peptide in 
the presence of 1 U/ml IL-2, and then stimulated with HA peptide a third time on day 14 in the 
absence of exogenous IL-2. Supernatants were collected four days after either the first antigen recall 
(day 11) or the second antigen recall (day 18). The third group of SKG naïve T cells was stimulated and 













 week  




(D7 / D10) 
Control Naive BALB/c CD4+ IL-2 @ 1 U/ml IL-2 @ 1 U/ml 
1 Naive SKG CD4+ IL-2 @ 1 U/ml IL-2 @ 1 U/ml 
2 Naive SKG CD4+ IL-2 @ 100 U/ml IL-2 @ 1 U/ml 
3 Naive SKG CD4+ IL-2 @ 100 U/ml IL-2 @ 100 U/ml 
                     Table 6.1 – Dosing regimen of exogenous IL-2  
 
Upon antigen recall in the presence of exogenous IL-2 on day 11, SKG Th cells from group 1 produced 
higher levels of IL-17 compared to wild-type Th cells, and the production of IL-17 was suppressed in 
groups 2 and 3 where the SKG naïve T cells had been stimulated in the presence of high 
concentrations of exogenous IL-2 (figure 6.17). When IL-17 production was assessed after the second 
antigen recall on day 18, the production of IL-17 remained high in the first group (1 U/ml exogenous 
IL-2 throughout) and was maintained low in the third group (100 U/ml exogenous IL-2 throughout). In 
group 2, where the SKG T cells were subjected to high concentrations of IL-2 in the first week and 
then low concentrations of IL-2 in the second week, the production of IL-17 was intermediate 
between group 1 and group 3. This suggests that in vitro reconstitution of IL-2 leads to a transient, 
rather than imprinted, inhibitory effect of IL-17 production and that continuous supplementation of 
high concentrations of exogenous IL-2 is required to maintain the repressive effect. However, IL-17 
expression was also high in wild-type T cells on day 18, presumably because of the lower 
concentrations of IL-2 used in these cultures, indicating the emergence of a population of IL-17 










Figure 6.17 – IL-2-induced inhibition of IL-17 might not be sustained over time. Naïve CD4+ T cells purified from 
HNT-TCR BALB/c and SKG and activated with HA peptide (2 µg/ml) on day 0 in the presence of either 1 or 100 U/ml 
IL-2. Cells were re-stimulated on day 7 and day 14 with the same concentration of peptide with low or high 
concentrations of IL-2. Exogenous IL-2 was also added on day 3 and day 10 to maintain cell viability in culture. On 
day 11, levels of IL-17 were high from SKG T cells that had differentiated in the presence of 1 U/ml IL-2, but were 
suppressed when SKG T cells had differentiated in the presence of 100 U/ml. On day 18, the levels of IL-17 remained 
low only in SKG cell cultures exposed to high concentrations of IL-2 throughout the experiment, whereas they remain 
high in the SKG group exposed to low concentration throughout. Levels of IL-17 from SKG T cells first exposed to 
high concentrations and then to low concentrations were intermediate, demonstrating that unless a high 
concentration of IL-2 is present in the cytokine milieu, the inhibition of IL-17 production by SKG T cells is not 
maintained. Results presented as mean ± SEM of duplicate cultures. 
 
Following the first antigen recall in the presence of IL-2, production of IL-4 remained low, below 200 
pg/ml, for the SKG groups 1 and 2 and there were no differences between both groups although they 
had received different concentrations of IL-2 during differentiation (figure 6.18). SKG T cells from 
group 3, exposed to high levels of IL-2 both during differentiation and during the first antigen recall, 
produced much higher levels of IL-4 at 2,700 pg/ml, a third of the levels produced by wild-type T cells. 
This implies that high concentrations of IL-2 might be able to increase the production of IL-4 in a very 
transient fashion, as illustrated by the levels of IL-4 produced by group 3 following the second antigen 
recall when exogenous IL-2 was not provided and the levels returned to the levels produced by the 
other SKG groups to around 500 pg/ml.  





Figure 6.18 – IL-4 production is not affected by IL-2 treatment. Naïve CD4+ T cells purified from HNT-TCR 
BALB/c and SKG and activated with HA peptide (2 µg/ml) on day 0 in the presence of either 1 or 100 U/ml IL-2. Cells 
were re-stimulated on day 7 and day 14 with the same concentration of peptide with low or high concentrations of IL-
2. Exogenous IL-2 was also added on day 3 and day 10 to maintain cell viability in culture. On day 11, the production 
of IL-4 was elevated in the group exposed to high levels of IL-2, effect which was not sustained over time since on 
day 18, levels of IL-4 were low in the three SKG groups irrespective of the doses of IL-2 they had been previously 
exposed to during differentiation and the first antigen recall. Results presented as mean ± SEM of duplicate cultures. 
 
Long-term addition of different concentrations of exogenous IL-2 did not lead to the emergence of 
any discernable patterns for the production of IL-6 and TNFα (figure 6.19). IL-10 was initially up-
regulated on day 11 and then down-regulated on day 18 both in a dose-dependent manner. These 
data confirm that the IL-2 effect is very specific to IL-17. They also demonstrate that the reduced 
production of IL-17 by SKG T cells from group 3 is not the result of increased cell mortality due to 
prolonged exposure to high concentrations of IL-2 since the production of IL-6 and TNFα for instance 
by group 3 was not systematically the lowest.  
 




Figure 6.19 – IL-6, IL-10 and TNFα production following long-term exposure to exogenous IL-2. Naïve CD4+ T 
cells purified from HNT-TCR BALB/c and SKG and activated with HA peptide (2 µg/ml) on day 0 in the presence of 
either 1 or 100 U/ml IL-2. Cells were re-stimulated on day 7 and day 14 with the same concentration of peptide with 
low or high concentrations of IL-2. Exogenous IL-2 was also added on day 3 and day 10 to maintain cell viability in 
culture. The production of IL-6 and TNFα did not seem to be influence in the dose-dependent manner by the 
presence of exogenous IL-2. IL-10 was up-regulated at first and then down-regulated implying no real effect of 
exogenous IL-2. Results presented as mean ± SEM of duplicate cultures. 
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6.10. Does the in vitro inhibition of IL-17 translate in vivo? 
 
Collectively, the data so far have shown the following: 
 
 Un-manipulated naive SKG T cells differentiate toward a Th17 phenotype 
 Addition of exogenous IL-2 upon initial TCR activation of naive T cells reduces IL-17 production by 
differentiated effector T cells in a dose-dependent manner 
 The IL-2 effect is very selective to IL-17 production 
 Exogenous IL-2 does not promote differentiation to iTregs from naïve precursor T cells in this 
assay 
 The data suggest that the IL-2 effect might not be sustained over time unless SKG T cells are 
continuously exposed to high doses of exogenous IL-2 (100 U/ml) 
 The data suggest that the in vitro supplementation of exogenous IL-2 in this experimental setting 
does not profoundly change the differentiation of SKG naive T cells to a different phenotype (Th2 
or iTreg) but rather reduce their IL-17 production in a transient fashion 
 
Therefore the next step was to investigate whether in vitro treatment with exogenous IL-2 could 
convert SKG arthritogenic cells to non-arthritogenic cells in the adoptive transfer model. Using this 
approach the repertoire of auto-reactive cells remain unchanged since the IL-2 treatment is carried 
post-thymic selection. 
 
To test this, a new adoptive transfer experiment was designed to include four groups of recipient 
SCID mice (table 6.2). Each SCID mouse received 50,000 naïve CD4+CD62L+ T cells, harvested from 
pooled lymph nodes. These cells were stimulated with anti-CD3 (10 µg/ml) and anti-CD28 (1 µg/ml) 
and differentiated in vitro for 7 days in the presence of different concentrations of exogenous IL-2. 
Mice from the first group, functioning as a negative control, received BALB/c naïve T cells treated with 
high doses of IL-2. Mice from group 2 received naïve SKG T cells treated with low doses of IL-2. The 
production of IL-17 of those cells should therefore not be dampened and they should keep their 
arthritogenic and pro-inflammatory potential. Consequently this group served as the positive control 
for the experiment. Cells injected into SCID mice in group 3 and group 4 were naive SKG T cells 
treated with high doses of exogenous IL-2. In addition, animals from group 4 received daily i.p. 
(intraperitoneal) injection of recombinant human IL-2 (Proleukin - 25,000 U per i.p. injection) for 5 
days from the outset of the experiment, then 3 times per week until the end-point. 
 







IL-2 in vitro 
(7 days) 
IL-2 in vivo Comments 
Group 1 
(n = 10) 




(n = 10) 
SKG 1 U/ml - Positive control 
Group 3 
(n = 10) 
SKG 100 U/ml -  
Group 4 
(n = 6) 
SKG 100 U/ml 
25,000 U/i.p. 
5x daily from outset 
Then 3x /week 
 
                   Table 6.2 – Protocol for adoptive transfer to assess in vivo effect of IL-2  
 
Consistent with previous adoptive transfer experiments undertaken to verify the arthritogenicity of T 
cells activated in vitro  (see section 4.5), the onset of disease was earlier, first documented on week 4 
for the three groups that received activated SKG T cells, and thus irrespective of the in vitro pre-
treatment or further i.p. injections with Proleukin (figure 20, panel A). The effects of the different 
treatments on disease progression were noticeable and quantifiable by week 8, and statistically 
significant by week 9.   
 
Group 2 developed the most severe form of disease (based on mean arthritic scores when compared 
to the control group, p < 0.001) characterised by erythema and swollen joints as well as alopecia 
around the snout and eyes. Some mice also developed inflammation of the ears. In this group arthritis 
constantly evolved and worsened during the course of the experiment and by week 13 all mice were 
affected (figure 6.20, panel B).  
 
Group 3, which received SKG cells pre-treated with high doses of exogenous IL-2, developed a severe 
form of arthritis (very significant mean arthritic score compared to control group, p < 0.01) also 
characterised by swollen joints and alopecia. Mice in this group also developed a severe skin affliction 
mainly localised to the paws, eyes and tails. The disease seemed to peak at week 11 and to be slightly 
reduced or plateaued from that point. By the end-point of the experiment, 9 out of 10 recipient mice 
had developed the disease.  
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Group 4 received the exact same SKG cells as group 3 but in addition received in vivo treatment with 
recombinant human IL-2 during the duration of the experiment. The progression of disease was 
slower for this group and the severity was reduced. In the first few weeks of the experiment the mice 
in this group gained only half the weight that mice from the other groups gained (data not shown), 
possibly because the injections of IL-2 induced systemic effects. For instance reduced appetite and 
nausea are known side-effects in human patients receiving IL-2 treatment. The discrepancy in weight-
gain eventually flattened out. Two of the six mice contained in this group died on week 8. One mouse 
was found dead for no apparent reasons. The second mouse was seriously wounded on its tail, which 
got infected and required culling. At the time of death none of the two mice showed any signs of 
inflammation or joint swelling. It is likely that these mice died as a result of some unrelated event. 
From week 9, the disease progression increased in this group, although the mean arthritic score 
remained below that of group 2 and group 3. Mice from group 1, which received activated BALB/c T 
cells, did not develop arthritis.  







Figure 6.20 – Effect of exogenous IL-2 on SKG cell-mediated arthritic disease in SCID mice recipients. SCID mice 
received either BALB/c or SKG purified T cells pre-activated with anti-TCR antibodies and differentiated in vitro for 7 days in 
the presence of varying concentrations of exogenous IL-2. Mice from group 4 received regular i.p. injections of human 
recombinant IL-2. In this experiment, the progression (panel A) and the severity and incidence (panel B) of arthritis was 
reduced with in vitro IL-2 pre-treatment, and even more with further when the mice were treated with i.p. injections of IL-2. N = 
10 for groups 1, 2 and 3, n = 4 for group 4 (*** = p < 0.001; ** = p < 0.01; * = p < 0.05). 





In this chapter I investigated whether reconstituting in vitro the cytokine deficiencies observed during 
differentiation of naïve SKG T cells would affect the SKG T cell fate determination and more 
specifically inhibit the generation of IL-17 high-producer T cells and restore the wild-type cytokine 
production profile.  
 
Differentiating SKG T cells were supplemented with exogenous recombinant murine IL-2 at one of 
three possible concentrations: low (1 U/ml), intermediate (10 U/ml) and high (100 U/ml). Levels of 
lineage-specific transcription factors were assessed six days after the initial TCR peptide stimulation. 
Differentiating T cells were then re-stimulated with antigenic peptide and secreted cytokines were 
analysed. Results are summarised in table 6.3. 
 
 SKG BALB/c  
Exogenous IL-2: 1 U/ml 10 U/ml 100 U/ml 1 U/ml 
IL-17 +++ ++ + + 
RORc +++ ++ + + 
IL-4
1
 + + + +++ 
GATA3 + + + +++ 
IFNγ + + ++ + 
Tbx21 ++ + + ++ 
TNFα ++ ++ +++ + 
IL-6 ++ ++ + + 
IL-10 ++ ++/+++ ++/+++ +++ 
          Table 6.3 – dose effect of exogenous IL-2 during differentiation on cytokine production by effector Th cells  
 
The amounts of IL-17 produced by effector SKG T cells upon peptide re-stimulation, were inversely 
proportional to the amount of exogenous IL-2 they were exposed to during the early stage of T cell 
differentiation, showing a clear dose-dependent relationship between the presence of IL-2 in the 
early stage of Th fate determination and the bias toward IL-17-producing differentiated T cells. 
Following exposure to the highest concentrations of 100 U/ml exogenous IL-2, SKG differentiated T 
cells produced IL-17 at levels similar to wild-type T cells. Such a relationship was also demonstrated in 
wild-type naïve T cells when differentiated in the same supplementing conditions, highlighting that 
the mechanism whereby presence of IL-2 in the micro-environment regulates IL-17 overproduction is 
                                                          
1
 As representative of the second experiment 
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not specific to SKG mutant ZAP-70 and that IL-2 is a relevant regulator of Th17 differentiation even in 
normal mice. 
 
This association was confirmed at the mRNA level since levels of RORc expression in SKG 
differentiating T cells decreased with exposure to increasing concentrations of IL-2 during early 
differentiation. These data imply that IL-2 signalling interferes, directly or indirectly, with the 
expression of RORc and therefore the expression of RORγt and subsequent expression of IL-17.  
 
In order to determine whether the reduction of IL-17 following exogenous IL-2 treatment was the 
result of long-term chromatin changes at the cytokine locus or of transient repression of the RORc 
and/or IL-17 transcription machinery, naïve T cells were treated with successive rounds of TCR 
stimulation in the presence of differential IL-2 dosing. Naïve T cells exposed to high concentrations of 
IL-2 over two rounds, carried on expressing reduced levels of IL-17 following a third antigen recall. On 
the other hand, similar T cells exposed to low concentrations throughout remained high producers of 
IL-17. Naïve T cells first exposed to high and then low concentrations, eventually produced 
intermediate levels of IL-17. This suggests that the effect of IL-2 is not imprinted at the genomic level 
via either chromatin remodelling and/or epigenetic modifications, but rather might be controlled via 
the activation or up-regulation of repressors which interfere in a transient and dose-dependent 
manner with transcription, a repressive mechanism which requires a constant source of IL-2 to be 
maintained functional.   
 
Unlike the effect seen on IL-17 production, pre-treatment of naïve T cells with high concentrations of 
exogenous IL-2 did not return production of other cytokines to wild-type cytokine levels. In fact both 
TNFα and IFNγ levels were increased in a dose-dependent manner following pre-treatment with 
exogenous IL-2 and ended up at levels much higher than wild-type production. IL-10 and IL-6 levels on 
the other hand did not fluctuate with exogenous IL-2 treatment and remained unchanged.  
 
Conflicting results were obtained concerning the effects of IL-2 supplementation on IL-4 production. 
In a first experiment, IL-4 levels were increased in a dose-dependent fashion and naïve SKG T cells 
treated with 100 U/ml IL-2 differentiated into effector T cells that produced as much IL-4 as BALB/c 
effector T cells. The second experiment though did not reproduce those results and levels of IL-4 
produced by SKG T cells remained as low as the levels produced by IL-2-untreated SKG T cells, and 
irrespective of the concentration of exogenous IL-2 they were treated with. Such discrepancies might 
be due to different rates of IL-4 production or consumption between the two experiments. Yet GATA3 
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mRNA levels were also unchanged by differential treatment with exogenous IL-2 and remained below 
that of wild-type T cells, suggesting that the IL-4 cytokine assessment from the second experiment is 
probably a more accurate reflection of the situation in vitro, and that IL-4 production was not 
influenced by exogenous IL-2 at least in this experimental setting. Also, and since IL-4 had been 
shown to inhibit IL-17 production (Harrington, Hatton et al. 2005; Park, Li et al. 2005) and although 
the increase in IL-4 was irregular following treatment with high concentrations of IL-2, I verified that 
the repression of IL-17 was not due to excessive IL-4 production. When combining exogenous IL-2 and 
neutralising anti-IL-4 antibodies, the inhibitory effect on IL-17 production was still seen, 
demonstrating that the inhibition of IL-17 by exogenous IL-2 is not an indirect effect modulated by IL-
4.  
 
Therefore it seems that the addition of exogenous IL-2 during differentiation of SKG T cells to offset 
their intrinsic deficiency to produce that cytokine following TCR activation does not per se restore the 
wild-type cytokine profile by re-directing the fate determination of SKG CD4+ T cells away from the 
Th17 phenotype and toward Th2 lineage – similar to the way that BALB/c T cells differentiate in this 
assay – but rather interferes with the transcription of RORc and consequently prevents the generation 
of SKG T cell clones with a reduced ability to produce excessive amounts of the pro-inflammatory 
cytokine IL-17 when compared to wild-type counterparts. These data also suggest that the IL-2-driven 
repressive mechanism is transient, rather than imprinted through epigenetic marks, and requires 
sustained exposure to IL-2 for the repressive effect to be maintained over time. If high concentrations 
of exogenous IL-2 are interrupted, differentiated SKG T cells seem to revert to a phenotype of IL-17 
high-producers. This suggests that the propensity of SKG T cells to differentiate towards Th17 may be 
the results of many subtle changes in TCR signalling pathways. The mutant ZAP-70 may influence the 
TCR threshold effect and lead to a pro-inflammatory signature via several mechanisms, of which the 
impaired IL-2 production is only one.  
 
The effects of supplementing differentiating SKG T cells with exogenous recombinant murine IL-4 or 
IFNγ were also studied by using one of three possible concentrations: low (1 ng/ml), intermediate (10 
ng/ml) and high (50 ng/ml). The intermediate concentration of IFNγ or IL-4 is the concentration used 
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 SKG BALB/c  
Exogenous IL-4: 1 ng/ml 10 ng/ml 50 ng/ml None 
IL-17 +++ + + + 
IL-4  + ++ +++ +++ 
Exogenous IFNγ:  1 ng/ml 10 ng/ml 100 ng/ml None 
IL-17 +++ ++ ++ + 
IL-4  + + + +++ 
  Table 6.4 – dose effect of exogenous IL-4 or IFNγ during differentiation on cytokine production by effector Th cells 
 
From 10 ng/ml and above, IFNγ and IL-4 inhibited each other production in line with the well-
established reciprocal regulatory effect of those two cytokines in Th1 and Th2 development (Maggi, 
Parronchi et al. 1992; Ferber, Lee et al. 1999). The inhibition of IL-4 production by exogenous IFNγ 
was especially strong and is probably due to IFNγ-driven chromatin modifications of the IL-4 gene 
locus to inhibit its transcription and is consistent with the well-documented inhibitory effect of IFNγ 
on the generation of IL-4-producing Th2 subset (Maggi, Parronchi et al. 1992; Parronchi, De Carli et al. 
1992). 
 
In a pattern consistent with previous findings (Harrington, Hatton et al. 2005; Park, Li et al. 2005), IL-
17 production was also drastically repressed from T cells differentiated with exogenous IL-4, and to a 
lesser extent with exogenous IFNγ. Presence of exogenous IL-4 further amplified the production of 
endogenous IL-4 in an autocrine loop.  
 
Although these preliminary data suggest that naïve SKG T cells are responsive to the presence of 
exogenous IL-4 and IFNγ, with the time and resource constraints inherent to my studies, I decided to 
focus my attention on further exploring the IL-2/IL-2R axis and how its partial or defective activation 
in differentiating SKG T cells might be playing a role in favouring the development of pro-
inflammatory IL-17 high producers cells. This decision was supported by several facts: 1- exogenous 
IL-4 completely shut down the production of IFNγ by effector SKG T cells and vice-versa, and 
therefore neither exogenous IL-4 or IFNγ could be said to be restoring the wild-type cytokine profile; 
2- it had previously been shown that neither IL-4 nor IFNγ were key players in mediating SKG arthritis, 
and that there was no significant alteration of the disease course in IL-4- or IFNγ-deficient SKG mice 
(Hata, Sakaguchi et al. 2004); 3- the effects of IL-4 and IFNγ were already well characterised 
(Harrington, Hatton et al. 2005; Park, Li et al. 2005) and less novel than the effect of IL-2 on IL-17 
production.  
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As previously described the IL-2/IL-2R axis regulates and influence many critical functions in T cell 
biology and although IL-2- or IL-2R-deficient mice can develop some immunity, IL-2 dysfunctions have 
often been associated with the development of autoimmunity (Sadlack, Lohler et al. 1995; Sakaguchi, 
Sakaguchi et al. 1995; Suzuki, Kundig et al. 1995; DiSanto, Guy-Grand et al. 1996).  
 
One interesting aspect of IL-2 signalling is its preventive effect on the development of Th17 cells in 
vitro and within the tumour micro-environment in vivo (Kryczek, Wei et al. 2007; Laurence, Tato et al. 
2007). Laurence and colleagues showed that T cells stimulated through TCR and co-stimulatory 
signals, in the presence of TGF-β and IL-6, could be polarised to a Th17 phenotype although this 
phenomenon was inhibited by IL-2 through activation of STAT5. Conversely, the deletion of STAT5 in 
order to block IL-2R signalling increased differentiation of Th17 cells (Laurence, Tato et al. 2007). 
Although the IL-2  inhibitory mechanism is STAT5-dependent, it remains unclear whether STAT5 
directly inhibits IL-17 or IL-17 associated genes, or indirectly via the induction of FoxP3 which has 
been shown to physically interact with RORγt and inhibit its binding to the IL-17 promoter (Ichiyama, 
Yoshida et al. 2008; Zhou, Lopes et al. 2008).  
 
In the context of my experiments, and in contrast to Laurence, I investigated the differentiation 
process of SKG T cells in the absence of polarising conditions to highlight any intrinsic features of the 
SKG T cells or their TCR activation process that might pre-dispose them to spontaneously develop into 
IL-17 high-producers following lineage differentiation, and I demonstrated that such differentiation 
bias can be inhibited with the supplementation of exogenous IL-2 in the early stage of differentiation. 
This establishes a clear link within SKG CD4+ T cells between the mutant ZAP-70-driven early 
deficiency in IL-2 production and the T cell fate determination towards a pro-inflammatory 
phenotype.  
 
As previously described, IL-2 inhibition of IL-17 is driven via STAT5. IL-2 is a potent activator of STAT5 
transcription factors through up-regulation of CD25 and binding to its cognate ternary high-affinity 
receptors. Subsequent receptor dimerisation leads to activation of JAK3 and phosphorylation of the 
receptor cytoplasmic tail thereby enabling docking and phosphorylation of src-homology-2 (SH2)-
domain containing STAT5 (Lin and Leonard 1997; Levy and Darnell 2002; Boulay, O'Shea et al. 2003). 
My data showed that although CD25 expression in SKG T cells was impaired, it could be up-regulated 
to wild-type levels with exogenous IL-2 and that SKG STAT5 could be induced by phosphorylation 
following acute IL-2 stimulation.  
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Although only semi-quantitative analysis can be made from the Western blots, the results suggest 
that following chronic exposure to high concentrations of IL-2, levels of phosphorylation of STAT5 in 
SKG T cells are equivalent to those of BALB/c T cells. Taken together these data suggest there are no 
intrinsic defects in the IL-2R/STAT5 pathway in SKG T cells. These results suggest that the mutant ZAP-
70 and subsequent deficient production of IL-2 upon activation in naïve SKG T cells has indeed 
consequences, since the cytokine levels expressed are not sufficient to generate the levels of 
expression of CD25 seen in wild-type cells, therefore impeding further signalling cascades. This might 
mean that during both clonal activation and differentiation, SKG T cells will probably incur lower 
levels of signalling events induced by IL-2/IL-2R interactions with far-reaching consequences on the 
effector development of the differentiating cells over time. 
 
These results suggest that the lack of endogenous IL-2 produced is likely to prevent IL-2-induced 
repression of IL-17 production in vitro. Although the mechanism is unclear at that stage, STAT5 has 
been shown to be able to directly bind to IL-17 gene (Laurence, Tato et al. 2007) and may act as a 
direct repressor of IL-17. My data showed that RORc was equally repressed following differentiation 
in the presence of IL-2, suggesting that STAT5 may also constrain Th17 polarisation indirectly via 
interactions at the RORc locus. Alternatively other regulators may also be recruited downstream of 
STAT5 to contribute to the inhibitory effect.  
 
In addition, IL-2 has also a role in Treg lineage determination and Treg fitness (Fontenot, Rasmussen 
et al. 2005) and in vitro experiments show that TGF-β-induced expression of FoxP3 is strictly 
dependent on IL-2  and that therefore IL-2 is an essential mediator of iTreg cells production 
(Davidson, DiPaolo et al. 2007; Zheng, Wang et al. 2007). Therefore the cell-fate choice between Th17 
and iTregs is linked and particularly sensitive to amounts of IL-2 and other inflammatory cytokines 
present in the micro-environment which will influence activated T cells and dictate whether they 
adopt an effector or regulatory phenotype (Bettelli, Carrier et al. 2006; Veldhoen, Hocking et al. 2006; 
Gavin, Rasmussen et al. 2007; Malek 2008; Malek and Castro 2010).  
 
Consequently, another mechanism whereby exogenous IL-2 might have mediated IL-17 production in 
SKG differentiated T cells was via increased conversion of naïve T cells to Treg lineage. This hypothesis 
was not supported by my data since no increases in FoxP3 mRNA or intracellular FoxP3 were 
observed following supplementation of the differentiating medium with exogenous IL-2. That is not to 
say that such a phenomenon could not happen in vivo, but it is possible that the in vitro micro-
environment produced by the starting population was not conducive to iTreg generation. For instance 
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the high quantities of IL-6 in the in vitro system might have played a part since IL-6 can repress FoxP3 
in a STAT3-dependent manner (Bettelli, Carrier et al. 2006; Yao, Kanno et al. 2007). Another 
alternative is that there was not enough TGF-β to support additional FoxP3 expression and de novo 
generation iTregs since only high concentrations of TGF-β repress IL-23R expression and enhance 
FoxP3 expression whereas at low concentrations, TGF-β synergises with IL-6 and IL-21 to promote IL-
23R expression (Korn, Bettelli et al. 2007; Nurieva, Yang et al. 2007; Zhou, Ivanov et al. 2007; Zhou, 
Lopes et al. 2008).  
 
Although I demonstrated that in a controlled in vitro micro-environment, IL-2 deficiency led to a bias 
towards Th17 differentiation, the next step was to investigate whether such a phenomenon could be 
replicated systemically in vivo in a whole animal.  Therefore I used the adoptive transfer model 
previously optimised (chapter 4) to compare the arthritogenicity of naïve SKG CD4+ T cells when 
activated in vitro for 6 days with either low or high concentrations of exogenous IL-2.   
 
Since recombinant human IL-2 had been previously used in animal models and shown to exert a 
repressive effect on disease progression (Grinberg-Bleyer, Baeyens et al. 2010), and since IL-17 
suppression in vitro required sustain addition of exogenous IL-2, I explored whether continuous 
supplementation of exogenous IL-2, via i.p. injections, would further reduce the arthritogenicity of 
the SKG cells.  
 
Activated SKG cells pre-treated in vitro with low amounts of exogenous IL-2 were arthritogenic and by 
the experiment end-point on week 13, 100% of SCID mice recipients developed inflammatory arthritis 
with an average arthritic score of 4.15. In contrast, in the group that received SKG T cells pre-treated 
with high concentration of exogenous IL-2, both the incidence (90% of recipients) and the severity 
(average arthritic score = 3.15) were lower.  This was even further reduced when the adoptive 
transfer of T cells pre-treated with high concentration of exogenous IL-2 was complemented with 
regular i.p. injections of exogenous rhIL-2 (incidence = 75%, severity = 2.25).  
 
Although the differences in arthritic scores between groups showed clear trends, they were not 
statistically significant different, which might be due to the very small number of mice left in group 4 
(n = 4 from week 9 onwards). Yet, since all SCID groups received the same number of cells from the 
same donor SKG mice, any difference in arthritis score can be reasonably linked to the different 
treatments the cells and/or recipient mice were subjected to. Therefore these data suggest that 
exogenous IL-2 may reduced the incidence and severity of arthritis, incurred by SKG CD4+ T cells, in 
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the adoptive transfer model and that IL-2 deficiency in SKG T cells is an important mechanism leading 
to preferential Th17 differentiation and arthritogenicity. However, further studies are required to 
confirm this effect. 
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RA is a chronic inflammatory systemic disorder whose exact aetiology remains unresolved. The 
disease is characterised by aberrant immune responses leading to autoimmunity, although there is no 
consensus on the autoantigen(s) involved or the environmental factors that trigger the autoimmune 
process. 
 
There is accumulating evidence from GWAS and mouse models that defective TCR signalling, through 
both spontaneous and engineered mutations in genes encoding important TCR transduction signal 
molecules, predispose the host to autoimmunity through effects on T cell selection in the thymus as 
well as T cell differentiation and function in the periphery (Zikherman and Weiss 2009). For instance 
mutations in TCR proximal signalling molecules such as ZAP-70 or LAT in mice have been shown to 
lead to autoimmunity and severe inflammation (Aguado, Richelme et al. 2002; Sakaguchi, Takahashi 
et al. 2003; Sommers, Lee et al. 2005). In humans, a mutation in PTPN22 that leads to decreased TCR 
signalling has been significantly associated with type 1 diabetes, RA and systemic lupus 
erythematosus (Begovich, Carlton et al. 2004; Bottini, Musumeci et al. 2004; Kyogoku, Langefeld et al. 
2004; Criswell, Pfeiffer et al. 2005). 
 
Normal TCR signalling pathways lead to both immunogenic outcomes (positive selection, effector T 
cell differentiation and activation) and tolerogenic signals (negative selection, anergy induction and 
FoxP3+ Treg cells commitment and activation), and the balance between the two processes ensures 
immunological tolerance while still allowing immunogenic responses to occur when required (Liston, 
Enders et al. 2008). Studies using allelic variants of ZAP-70 with step-wise decreases in TCR signalling, 
have demonstrated that quantitative variations in TCR signalling can result in immune dysregulation 
ranging from immunodeficiencies to autoimmunity (Siggs, Miosge et al. 2007). Although the precise 
mechanisms whereby inherited defects in TCR signalling result into such diverging outcomes are not 
elucidated, the proposed mechanisms include impaired negative selection – and thereby disruption of 
central tolerance – as well as defects in Treg cells commitment and peripheral activation and 
therefore defective peripheral tolerance.  
 
SKG mice carry a point-mutation in the carboxyl-terminal SH2 domain of the protein tyrosine kinase 
ZAP-70 with attenuated TCR signalling and T cell activation. Consequently SKG mice are genetically 
prone to develop CD4+ T cell-mediated autoimmune inflammatory arthritis which resembles human 
RA (Sakaguchi, Takahashi et al. 2003).  
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Since understanding the relationship between genetic variants that affect TCR signalling and 
autoimmune diseases remains a major challenge, the SKG mouse model provides a unique 
opportunity to study in vivo the effects of TCR signalling thresholds on disease progression and more 
specifically to determine whether manipulating T cell functions by modifying TCR signalling could be a 
viable therapeutic approach to restoring immune homeostasis in an arthritis prone individual.  
 
In this study, I aimed to investigate, in the context of the SKG mouse model, how sub-optimal TCR 
signalling results in loss of immune homeostasis and the development of arthritis, and whether 
reconstitution of TCR signalling in mature, peripheral,  arthritogenic SKG T cells can restore immune 
homeostasis which in turn suppresses the disease process. More specifically I set out to explore the 
mechanisms whereby SKG T cells promote disease, focusing on pathways of T cell activation and 
differentiation. 
 
I first demonstrated that naïve BALB/c and ZAP-70 mutant SKG CD4+ T cells, expressing a TCR 
transgene, differentiate into distinct subsets of effector CD4+ T cells when stimulated with specific 
antigen in a neutral cytokine environment. Significantly, SKG effector T cells were deficient in IL-2 
production during early differentiation and became IL-17 high-producers upon antigen-recall, when 
compared to wild type BALB/c T cells. Thus, the mechanisms through which defective TCR signalling in 
SKG T cells favours the generation of arthritogenic T cells and contributes to disease were 
investigated using two complimentary approaches.  
 
The first approach sought to establish a system, using virus-mediated gene transfer protocols, for the 
stable integration of the murine wild-type ZAP-70 into SKG mutant T cells thereby restoring the 
integrity of TCR signalling within these cells to compare the effects of reconstituting SKG T cells with 
wild type or mutant ZAP-70 on the development of arthritis in a T cell-mediated adoptive transfer 
model. The second approach consisted of comparing the Th differentiation pathways between BALB/c 
and SKG naïve CD4+ T cells, and more specifically to highlight any differences in patterns of cytokines 
produced by wild-type BALB/c and SKG T cells during differentiation which might directly or indirectly 
be due to the ZAP-70 variant and explain the preferential bias towards Th17 differentiated phenotype 
in SKG animals.  
 
Reconstituting TCR signalling using a virus-based approach 
Despite using both lentiviral and retroviral vectors, the efficiency of gene transduction into the target 
murine primary T cells remained insufficient for in vitro functional analysis or for testing the 
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arthritogenicity of transduced T cells in adoptive transfer experiments.  Alternative approaches to 
remedy this issue and reconstitute the signalling machinery were described in Chapter 5, of which the 
generation of a conditional knock-in mouse model seems the most promising. 
 
If such a system could be developed in future to reconstitute TCR signalling in SKG T cells, and since 
SKG arthritis is linked to the ZAP-70 mutation, it is unlikely that the adoptive transfer of reconstituted 
SKG T cells would result in no change in phenotype. Two likely outcomes would be either more 
arthritis due, for instance, to the restoration of full TCR signalling in arthritogenic effector T cells or to 
less successful reconstitution of WT ZAP-70 into regulatory T cells; or less arthritis if the reconstituted 
T cells offer protection against the disease for instance by enhancing AICD of effectors, or by 
enhancing regulatory T cell function. 
 
In either case, it would be essential to carry out in vitro functional assays, using the HNT-TCR system, 
to investigate further the consequences of gene transfer and compare results between WT BALB/c T 
cells, unmanipulated SKG T cells as well as reconstituted SKG T cells. This would clarify the 
mechanisms by which altered signalling thresholds in reconstituted T cells may have an impact on the 
development of autoimmune arthritis. Aspects of special interest would be cell proliferation and 
survival, cell differentiation, cell migration, and immune regulation by dissecting the individual 
contributions of defective TCR signalling in effector versus regulatory T cells to autoimmune arthritis 
in vivo, as well as comparing efficiency of gene transfer in each subset. In the context of this study 
though, and instead of reconstituting the full signalling machinery, I turned to other options such as 
exploring the effects of restoring the IL-2 signalling pathway in defective differentiating SKG T cell.  
 
Reconstituting the IL-2 signalling pathway 
I then tested the effects of reconstituting in vitro the defects in cytokine expression observed during 
differentiation of SKG T cells, in an attempt to restore the wild-type phenotype.  
 
I showed that SKG T cells proliferated poorly and produced very low levels of IL-2, compared to 
control T cells. Also that differentiation of naïve SKG T cells in vitro led to the preferential generation 
of cells in which IL-17 was up-regulated, IL-4 production was substantially reduced while levels of 
TNFα, IFNγ, IL-6 and IL-10 were not significantly altered. Consistently, levels of T-bet in differentiating 
SKG T cells were unchanged, expression of GATA3 was reduced and that of RORγt was substantially 
up-regulated, when compared to HNT-TCR single transgenic mice. These data support the view that 
the distinct cytokine production profiles of BALB/c and SKG differentiated effector T cells reflect how, 
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from the outset, downstream TCR signalling pathways in naïve SKG T cells are modulated by the 
defective function of the ZAP-70 variant, leading to differential tuning of the molecular transcription 
machinery by intra-cellular events.  In other words, the genetic attenuation of TCR signalling at a TCR-
proximal step differentially influences, during the early differentiation process, the expression of 
distinct lineage-specific transcription factors and other intra-cellular events, resulting in the impaired 
expression of selected cytokines which in turn translate into distinct effector Th subtypes.  
Notably, in vitro restoration of IL-2 production, by supplementing differentiating SKG T cells with 
exogenous recombinant IL-2, led to suppression of IL-17 secretion and downregulation of RORc mRNA 
expression, whilst also restoring CD25 expression on SKG T cells to wild-type levels. Still when IL-2 
supplementation was restricted to early differentiation, SKG T cells eventually up-regulated their 
production of IL-17. This suggests that IL-2 does not exert its effect on IL-17 production via imprinting 
stable epigenetic changes with long-term efficacy, but rather through means which are temporal and 
spatial in nature and only suppressive as long as the cytokine is present in the micro-environment.  
 
 The effects of IL-2 supplementation were also tested in vivo in the adoptive transfer model. When 
pre-treated in vitro with low amounts of exogenous IL-2, activated SKG CD4+ T cells were arthritogenic 
and induced disease in all recipient SCID mice. In contrast, the incidence and severity of disease were 
lower in the group that received SKG T cells pre-treated with high concentration of exogenous IL-2. 
The decrease in severity and incidence of disease was even more exacerbated when the adoptive 
transfer of T cells was followed up with regular i.p. injections of exogenous rhIL-2.  
 
Collectively these data indicate that a state of relative IL-2 deficiency is characteristic of effector T 
cells with impaired antigen TCR signalling and that the ensuing lack of IL-2 promotes differentiation of 
Th17 cells, at the expense of Th2 cells, possibly through failure to down-regulate expression of the 
Th17 master transcription factor, RORγt. Also in vitro pre-treatment with and in vivo supplementation 
of exogenous IL-2 reduced the incidence and severity of arthritis, incurred by SKG CD4+ T cells, in the 
adoptive transfer model. These results show that IL-2-induced TCR threshold effects contribute to the 
skew towards Th17 for SKG T cells, and that such inherited effects may be reinforced by inflammatory 
factors and the production of cytokines to maintain the pro-inflammatory phenotype. Therefore IL-2 
deficiency in SKG T cells is an important mechanism leading to preferential Th17 differentiation and 
arthritogenicity.  
 
These results are also consistent with the established view that the major immunological phenotype 
in IL-2- (Schorle, Holtschke et al. 1991) and IL-2Rα- (Willerford, Chen et al. 1995) deficient mice is 
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autoimmunity resulting from defects in self-tolerance and T cell homeostasis. Dysfunctional 
CD4+CD25+ FoxP3+Treg cells also play a critical role in the autoimmunity that arise from IL-2 defects as 
this cell population can no longer suppress potentially autoreactive peripheral T cells that escaped 
thymic negative selection (Sakaguchi 2004).  
 
In the context of the SKG mouse model, the ZAP-70 mutation has been shown to impair the in vivo 
and in vitro suppressive function of natural Treg cells (Tanaka, Maeda et al. 2010). Therefore, and 
although not specifically explored in this study, IL-2 deficiency in the SKG model is likely to contribute 
to disease development via deleterious effects on Treg development and homeostasis.  This would be 
consistent with the known fact that there is an IL-2-dependent step during the development of nTreg 
cells which is due to direct regulation of FoxP3 and CD25 expression through STAT5 binding to 
respective enhancer elements of these genes (Zorn, Nelson et al. 2006; Yao, Kanno et al. 2007). IL-2 is 
also a major cytokine contributing to the homeostasis of peripheral Treg cells (Fontenot, Rasmussen 
et al. 2005; Bayer, Yu et al. 2007) and mice that harbour mutant IL-2Rs with impaired, but not absent, 
STAT5 activation exhibit symptoms of organ-specific autoimmunity as they age (Yu, Zhu et al. 2009). 
This is also in line with the known reciprocal relationship between Th17 and Treg cell fates, and 
therefore defective IL-2 production in SKG is likely to favour Th17 phenotype to the detriment of 
regulatory functions. Consequently it would be important to clarify the contribution that impaired IL-
2 signalling make to the defective suppressive function of SKG Treg cells. 
 
Future experiments 
The data presented in this thesis demonstrate that graded TCR signalling thresholds can lead to 
aberrant IL-2 dependent immune responses through effects on cytokine production and Th cell 
differentiation. I propose that in addition to the cytokine milieu, IL-2 signalling is, at least in part, an 
important pathway to maintain peripheral tolerance and control the generation of IL-17 high 
producers T cells and therefore the production of pro-inflammatory cytokines which can then activate 
other downstream pathways leading to hallmark features of chronic inflammatory arthritis 
(autoimmunity, synovitis and joint destruction). Therefore IL-2 signalling defects may promote 
autoimmunity at least partly via defective restriction of the IL-17-producing cells. These data are also 
in line with the recent finding that, at least in humans, the strength of T cell activation influences the 
skewing of CD4+ T cell responses towards a Th17 phenotype, and more specifically that low potency 
of TCR signal favours Th17 differentiation possibly through effects of reduced calcium signalling 
(Purvis, Stoop et al. 2010).  
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These results are especially important as SNPs linked to IL-2, CD25 and CD122 have been associated in 
human GWAS with RA (The Wellcome Trust Case Control Consortium 2007; Gregersen and Olsson 
2009) further highlighting the importance of the IL-2/IL-2R pathway in autoimmune susceptibility. 
 
Although Laurence established that IL-2 inhibition of IL-17 is STAT5-dependent (Laurence, Tato et al. 
2007), no precise molecular mechanism has been described. It would therefore be essential now to 
establish more specifically how IL-2 influences immunogenic and tolerogenic responses and whether, 
for instance, STAT5 down-regulates IL-17 expression through direct interactions with IL-17 or 
indirectly via RORc or other regulatory genes.   
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